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The objectives of this thesis are to ascertain how long it takes for patients with 
a mild traumatic brain injury to return to work or other usual activities; to 
identify the short-term effects on neurocognition and symptoms in patients 
with a mild traumatic brain injury; to determine the proportion of patients, 
out of all that attend the Emergency Department with a seizure, that attend as 
a consequence of traumatic brain injury; and to assess the value of the 
biomarkers S100B and copeptin in predicting outcomes in patients that attend 
the Emergency Department following a seizure. 
Methods 
This thesis comprises three studies in which I investigated the short and long-
term effects of mild traumatic brain injury (TBI) and prognostication in 
seizure. In study one, I undertook a systematic review and meta-analysis to 
determine return to work times for adults with mild TBI. A narrative synthesis 
and a random-effects meta-analysis was performed. The second study was a 
prospective observational cohort study of adults with mild TBI and non-head 
injured controls. The outcomes of interest were neurocognitive function and 
concussion symptom severity at baseline and 72 hours. The third study was a 
prospective observational cohort study of adults attending the Emergency 
Department with seizure. The proportion of patients that attended with 
seizure as a consequence of TBI was recorded. The biomarkers S100B and 




copeptin were measured to predict a composite primary outcome of seizure 
recurrence, death, hospitalisation, rehospitalisation or re-attendance at 
Emergency Department by seven days. 
Results 
In the systematic review and meta-analysis, the pooled proportion of people 
returned to work at one month was 56%, at six months 83%, and at 12 months 
89%. 
In the study of short-term effects of mild TBI, I enrolled 240 patients. Patients 
with TBI had marked cognitive impairment which persisted at 72 hours, and 
persistently high numbers of symptoms and high symptom severity. Patients 
with TBI had worse neurocognitive function, higher overall symptom severity, 
and a higher total number of symptoms compared with controls. 
In the third study of patients with seizures, 97 patients were recruited. No 
patients attended with a seizure as a consequence of TBI. 52% met the primary 
endpoint. S100B and copeptin were significantly higher in patients with 
compared to without the composite primary endpoint, but the biomarkers had 
poor prognostic value for predicting the primary outcome. 
Conclusions 
In this body of work, I have shown that mild TBI results in a neurocognitive 
deficit and a significant symptom burden, which persists for several days. 
Furthermore, although most patients have returned to usual activities, 
including work, by three months after injury, some are still unable to work a 




year after injury. A third of patients that have a seizure for any reason go on to 
have another seizure within a week. S100B and copeptin do not add value in 
predicting which patients have recurrence of seizure and very few patients 
attend the Emergency Department with seizure secondary to TBI.  






Traumatic brain injury (TBI) is common, affecting up to 600/100,000 people. 
Mild TBI accounts for up to 90% of all TBI. The Emergency Department 
attendance rate for head injuries is as high as 1800/100,000 population, and 
15-20% of those attendances result in hospital admission. Mild TBI causes 
symptoms such as headaches, dizziness, disordered balance, cognitive 
dysfunction and depression which in turn impact on quality of life. Accurate 
risk assessment and prognostication of patients with acute neurological 
conditions in the Emergency Department is essential. This PhD consists of a 
systematic review that examines the hard outcome of ‘return to work’ following 
a mild TBI; a prospective observational cohort study that reports the difference 
in neurocognitive function and symptoms that patients experience at baseline 
and three days after mild TBI; and a prospective observational cohort study 
that reports the number of patients that attend the Emergency Department 
with seizure secondary to TBI, and the value of two biomarkers in predicting 
the recurrence of seizures in patients that attend the Emergency Department 
having had a seizure. 
Methods 
This thesis comprises three studies in which I investigated the short and long-
term effects of mild traumatic brain injury (TBI) and prognostication in 
seizure. In study one, I undertook a systematic review and meta-analysis to 




determine return to work times for adults with mild TBI. The primary 
objective was to determine the time taken to return to work following a mild 
TBI. Articles were included if they reported on adults with mild TBI and 
recorded the outcome return to work. Six electronic databases and eight 
clinical trial registries were searched. A narrative synthesis and a random-
effects meta-analysis was performed. Bias was assessed using a modified 
version of the Newcastle Ottawa quality assessment tool. 
The second study was a prospective observational cohort study of adults with 
mild TBI and a comparison group of Emergency Department patients without 
brain injury. The primary outcomes were neurocognitive function and 
concussion symptom severity at baseline and 72 hours. Adult patients with 
mild TBI within the last 24 hours were included in the mild TBI group, and 
adults that attended the Emergency Department with trauma beneath the 
clavicle, or with a non-neurological medical condition, were included in the 
comparison group. Outcomes were measured on the Standardized Assessment 
of Concussion (SCA) and the Concussion Symptom Inventory (CSI) at baseline 
in the Emergency Department and at follow up at 72 hours. Comparisons were 
made between baseline and follow up, and between groups at single time 
points. 
The third study was a prospective observational cohort study designed to 
assess the prognostic value of the biomarkers S100B and copeptin in patients 
with seizure. Adult patients attending the Emergency Department with seizure 
of any cause were included. The primary outcome was a composite of seizure 
recurrence, death, hospitalisation, rehospitalisation or re-attendance at the 
Emergency Department at seven days. S100B and copeptin were measured in 




the Emergency Department. Statistical comparison of the two groups was 
performed, optimum thresholds of the biomarkers for diagnosing the endpoint 
were derived, diagnostic test characteristics were calculated, and logistic 
regression modelling was performed to identify variables most closely 
associated with the outcome. The aetiology of the seizure was identified and 
the proportion that had a seizure secondary to TBI was recorded. 
Results 
In the systematic review and meta-analysis, 14 studies were included. Three 
reported the average time taken to return to work, and 12 reported the 
proportion of patients that have returned to work by a pre-specified time point. 
The pooled proportion of people returned to work at one, three, six and 12 
months was 56%, 75%, 83%, and 89% respectively. 
In the study of short-term effects of mild TBI, 240 patients were included, of 
which 189 had mild TBI and 51 comprised the non-brain injured comparison 
group. Patients with mild TBI had marked neurocognitive impairment (SAC at 
baseline 25 [23-27], difference in SAC score between brain injured and non-
brain injured 1, p=0.02, [95% confidence interval [CI] -1.4 to -2.4]), worse 
symptom severity (CSI at baseline 9 [4-21], difference in CSI between brain 
injured and non-brain injured 9, p<0.001 [95% CI 8.4 to 13.7]), and high 
numbers of symptoms (number of symptoms at baseline 4 [2-8], difference 
between brain injured and non-brain injured 4, p<0.001 [95% CI 2.6 to 4.4]), 
all of which persisted at 72 hours. 




In the study of patients with seizures, 97 patients were recruited, of which 52% 
met the composite primary endpoint. No patients attended with a seizure as a 
consequence of TBI. S100B and copeptin were significantly higher in patients 
with compared to without the composite primary endpoint: 0.22 µg/L (95% CI 
0.14 to 0.31) vs 0.11 µg/L (95% CI 0.08 to 0.14) (difference 0.02 µg/L, p = 0.01, 
95% CI 0.02 to 0.2) for S100B; and 77.0 pmol/L (95% CI 44.3 to 109.7) vs 27.0 
(95% CI 18.2 to 35.9) (difference 50 pmol/L, p = 0.004, 95% CI 16.2 to 83.8) 
for copeptin. Thresholds of 0.088 µg/L and 6.26 pmol/L were identified for 
S100B and copeptin respectively. At those thresholds, S100B sensitivity and 
specificity was 58% (95% CI 43-72) and 60% (95% CI 44-74); and copeptin 
sensitivity and specificity was 80% (95% CI 66-90) and 21% (95% CI 11-36). 
Epilepsy, complex partial seizure, provoked/acute symptomatic seizure, and 
pyrexia were identified as factors independently associated with the primary 
outcome but there was no additional value when the biomarkers were included 
in the model. 
Conclusions 
In this body of work, I have shown that patients with mild traumatic brain 
injury have impaired neurocognitive function and a significant symptom 
burden that persists for several days, and in some patients is likely to persist 
for many months. Although most patients return to normal activities, 
including working, by three months after a mild traumatic brain injury, up to 
a tenth of patients are still unable to return to work at one year after the injury. 
Around half of patients that attend an Emergency Department with a seizure 
go on to be admitted or have another seizure by one week, but the biomarkers 




S100B and copeptin add no extra value to current prediction tools in 
identifying who will have a recurrent seizure, and few patients have a seizure 
secondary to TBI. 
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Chapter 1 Introduction 
Acquired brain injury 
A brain injury can occur because of a physical or traumatic mechanical force 
applied to a person’s head, or as a product of an electrophysiological, 
metabolic, hypoxic, or other pathological insult. The consequences of an 
acquired brain injury range from very transient symptoms to full dependence 
and death. Acquired brain injury is one of the most common reasons for 
patients to attend Emergency Departments and has a rate of admission into 
hospital of 566/100,000 people.1 Traumatic brain injury (TBI) is grouped into 
mild, moderate and severe categories based on the first measured Glasgow 
Coma Scale (GCS).2 Traumatic brain injury is termed mild, moderate or severe 
if the initial GCS is 13-15, 9-12, or 3-8 respectively.3,4 However, mild TBI is 
conceptually a condition that results from some form of physical trauma to the 
head and which may involve loss of consciousness and memory dysfunction 
around the time of the injury and be followed by symptoms including headache 
and difficulty thinking. Since there are rarely abnormalities seen on routine 
imaging studies, mild TBI is primarily a functional condition.5 Mild TBI can 
be thought of as possessing features occurring at the time of injury, specifically 
the presence of loss of consciousness or amnesia, and features occurring after 
the injury. There are many features that may follow, and these may occur 
immediately after the injury, or within minutes, hours or sometimes days 
(Table 1.1 and Figure 1.1). There are four definitions of mild TBI frequently 
described in the medical literature; those developed by the American Congress 
of Rehabilitation Medicine, the Centers for Disease Control and Prevention, 




the World Health Organisation collaborating Centre for Neurotrauma Task 
Force on mild TBI, and the European Federation of Neurological Societies 
























No complaints 49% 16% --- --- 37% --- 
Headache 25% 79% 22% 26% 42% 70% 
Memory problems 8% 59% 22% 16% 28% 57% 
Anxiety 19% --- --- 14% --- 27% 
Sleep disturbance 15% --- 23% 23% 22% 60% 
Dizziness 15% --- 14% 8% 29% 60% 
Irritability 9% --- 18% 24% 26% 51% 
Fatigue 9% --- 26% 37% 28% 65% 
Loss of concentration 8% --- 19% 14% 28% 57% 
Taking longer to think --- --- 20% --- 29% --- 
Frustration/Impatience --- --- 21% --- 27% 24% 
Depression 6% --- 14% 16% 22% --- 
Hyperacusis --- --- 9% --- 21% 51% 
Light sensitivity --- --- 9% 5% 17% --- 
Nausea --- --- 7% 3% 16% 30% 
 
Table 1.1 Proportions of patients with symptoms after mild TBI 





Figure 1.1 Proportions of patients with symptoms after mild TBI 
 
When reporting in the scientific literature, symptoms of mild TBI are recorded 
in checklists. Two of the commonest are the Rivermead Post Concussion 
Symptoms Questionnaire and the Concussion Symptom Inventory (Appendix 
2), which contain 16 and 12 symptoms respectively (Table 1.4).15,16 Mild TBI 
and concussion are terms that are often used interchangeably, and the 
difference between the two conditions is not well defined.5 It is unknown 
whether concussion is part of a TBI spectrum with less structural change than 
seen in more severe grades of TBI, or whether the functional brain injury 
associated with concussion is simply the result of reversible physiological 
changes. The term concussion is used commonly in sports and the most 
comprehensive definition of concussion is derived from sports related 




concussion. Sports related concussion is defined as a TBI induced by 
biomechanical forces, with several common features that may be present 
including transient impairment of neurological function, functional acute 
clinical signs and symptoms (no abnormalities on commonly utilised scans) 
and involving a range of clinical signs and symptoms that may or may not 
involve loss of consciousness.5 Despite symptoms of mild TBI routinely being 
measured on scores with the word ‘concussion’ in their title, a comparison of 
the most recent definition of concussion with the most commonly used 
definitions of mild TBI shows that the symptoms and signs used to describe 
mild TBI are more severe than those used to describe concussion (Table 1.2). 

















Traumatically induced An injury to the head 
as a result of blunt 
trauma or acceleration 
or deceleration forces 
Mechanical energy to 







rotation force to the 
head 
Biomechanical forces; 
direct blow to the 
head, face, neck or 
elsewhere on the body 
with an impulsive force 
transmitted 
to the head 
Brain injury description Disruption of brain 
function 
Not included Acute brain injury Cat. 0: Head injury with 
no TBI 
Cat. 1-3: Not explicit 
Traumatic brain injury 
GCS incorporated Yes No Yes Yes No 
GCS details GCS 13-15 after 30 min --- GCS 13-15 after 30 
min, or later upon 
presentation for 
healthcare. 
Cat. 0-2: GCS 15 
Cat. 3: GCS 13-14 
--- 
LOC incorporated Yes Yes Yes Cat. 0,1,3: Yes 
Cat. 2: No 
Yes - states may or 
may not be present 
Duration LOC <30 min <30 min <30 min Cat. 0: 0 min 
Cat. 1,3: <30 min 
Cat. 2: not specified 
Not defined 
Amnesia incorporated Yes Yes Yes Cat. 0,1,3: Yes 
Cat. 2: No 
No 
Amnesia type Immediately before or 
after injury 
Immediately before, 
during, or after the 
injury 
PTA Cat. 0,1,3: PTA 
Cat: not specified 
--- 
Amnesia duration PTA <24 hrs PTA <24 hrs PTA <24 hrs No PTA --- 




Altered mental state 
incorporated 
Yes Yes Yes No Yes 
Which altered mental 
state symptoms/signs 








--- Rapid onset (can be 






Yes Yes Yes Cat. 0,1: No 
Cat. 2,3: Yes 
No 
Duration of focal 
neurological deficit 
May or may not be 
transient 
Not specified Transient Cat. 0,1: No 
Cat. 2,3: Not specified 
--- 
Seizures incorporated Not specified Yes Yes Cat. 0,1: No 
Cat. 2,3: Yes 
No 





poor concentration, if 
assoc. with LOC or 
altered consciousness 
(adults/older children) 
Intracranial lesion not 
requiring surgery 
Cat. 0,1: No risk factors 
present 




Table 1.2 Comparison of definitions of mild TBI. 
ACRM, American Congress of Rehabilitation Medicine; CDC, Centers for Disease Control and Prevention; WHO, World Health Organisation 
collaborating task force; EFNS, European Federation of Neurological Societies; CISG, Concussion in Sports Group; GCS, Glasgow Coma Scale; 
Cat, EFNS category of mild TBI; LOC, loss of consciousness; PTA, post-traumatic amnesia; RGA, retrograde amnesia. Risk factors used in EFNS 
definition: unclear or ambiguous history, continued PTA, RGA > 30 min, trauma above the clavicles, signs of base of or depressed skull fracture, 
severe headache, vomiting, focal neurological deficit, seizure, age < 2, age > 60, coagulation disorders, high-energy accident, intoxication with 
alcohol/drugs 




An epileptic seizure is defined as a transient occurrence of signs and/or 
symptoms due to abnormal excessive or synchronous neuronal activity in the 
brain.17 Seizures are a rare consequence of mild TBI but a common reason for 
patients to attend the Emergency Department. Seizures account for 1% of all 
Emergency Department attendances in the US, and 1.4% of all medical 
admissions into hospital in the UK.18,19 Although 11% of the population will 
have a seizure in their lifetime, most are not due to epilepsy.20 Furthermore, 
seizures in patients that present to the Emergency Department are usually 
acute symptomatic, that is, secondary to another diagnosis, and not caused by 
epilepsy.18 The most frequently associated diagnoses in adults are alcohol-
related.18,21 In Emergency Department patients that present with a seizure and 
are investigated with neuroimaging, head injury is the second most common 
reason for scan, after alcohol-related seizure.22 The potential consequences of 
a seizure include physical injury, time off from working, degeneration into 
status epilepticus, hypoxic brain damage and death.23-25 In one study, 1.2% of 
Emergency Department attendances for seizure resulted in death, and injury 
or death was associated with 15% of seizure attendances.26 By far the most 
common injury was a head injury at 67%, followed by fractures, dislocations 
and sprains (14%). In a study of patients with epilepsy, which is a smaller 
group than patients that attend the Emergency Department with seizures, 
12.5% were unable to work due to epilepsy.23 Estimates of numbers of patients 
with status epilepticus vary from 6 - 7% with an associated mortality rate of up 
to 26% in adults.27-29 This can partly be explained by the diagnoses associated 
with status epilepticus. Hypoxia and anoxia carry the highest mortality rates, 
followed by stroke, tumour, metabolic derangement, drug overdose and 




traumatic brain injury.25 The ability therefore to identify patients likely to have 
a poor outcome or recurrent seizure is important. 
The risk of recurrence following a first unprovoked seizure is high with 
estimates ranging from 23% to 71% at two years.30 For patients treated with an 
anti-epileptic drug as soon as possible after a seizure, the recurrence rate was 
37% at two years, and the number of seizures prior to starting the drug, an 
abnormal EEG, and the presence of a neurological disorder were associated 
with increased risk of recurrence.31,32 The overall likelihood of seizure 
recurrence at one year is 43% but was 48% for unprovoked first seizures and 
29% for provoked first seizures, with the lower rate of recurrence in provoked 
first seizures because the provoking cause is subsequently treated.33 
  





Traumatic brain injuries can result in significant morbidity and mortality, and 
consequently create a burden carried by patients, the healthcare system and 
society. To understand the burden, it is essential to understand the size of the 
problem. Patients may experience a head injury. A head injury is distinct from 
a brain injury, because it is possible to sustain a head injury without a brain 
injury. Although rare, it is also possible to sustain a TBI without a head injury. 
The mechanism for this is a rapid acceleration-deceleration injury without a 
strike to the head, for instance during a motor vehicle collision. Patients or 
their associates may choose to attend an Emergency Department because they 
sustained a head injury. Within the Emergency Department they may be 
diagnosed with a brain injury. They may be admitted into the hospital or they 
may be discharged home. Epidemiological studies report all these rates, i.e. 
Emergency Department attendance rate, hospital admission rate, head injury 
rate and brain injury rate (Table 1.3). In the UK, a common source of data 
reported in epidemiological studies is Hospital Episode Statistics.34 Hospital 
Episode Statistics is a database containing details of all admissions and 
Emergency Department attendances at NHS hospitals in England. Each 
Hospital Episode Statistics record contains clinical information including 
diagnoses, operations, and patient, geographic and administrative 
information. The key studies from the UK that describe head or brain injury, 
report Emergency Department or hospital episodes from 1974, 1986 and 2001-
2003.35 Several more reports from Europe and the USA utilise equivalent 
national databases or local hospital records as data sources. The majority of 




studies use definitions of brain injury from the International Classification of 
Diseases systems (Table 6.1).36 
United Kingdom 
Traumatic brain injury represents an ongoing epidemic. Evidence on head and 
brain injuries has been collected in different regions in the UK since the 1970s. 
In a landmark study, information was abstracted from national, hospital 
admission and Emergency Department attendance data sets for the years 1971-
1976.35 Head injuries accounted for 9/100,000 deaths overall (less than 1%) 
but 15% of all deaths in the 15-24 years age group and up to 49% of all deaths 
were associated with motor vehicle collisions. This study, which describes data 
from 1974, reported hospital admission rates of 270/100,000 patients for head 
injuries. This rate was based on analysis of International Classification of 
Diseases codes assigned to patients in a four-week period. There was an overall 
Emergency Department attendance rate of 1778/100,000 attendances with 
higher attendance rates in younger age ranges and in males compared with 
females. 
In 1986, the north west of England was home to four million people. At that 
time, the hospital admission rate, distinct from Emergency Department 
attendance rate, for head injuries was 297/100,000.37 There was significant 
variation in rates across the region, from 88 to 886/100,000. In a nationwide 
analysis of Hospital Episode Statistics from 2001-3, compared with 1974, there 
was a reduction of 229/100,000 and an absolute number of admissions in 
England of 112,718 patients.38 The variation between local districts was seen 
again, from 91 to 419/100,000. The admission rate in the 0-15 and 75+ age 
ranges was much higher than in the 16-74 age group. A regression analysis 




performed on this data found that unemployment, long term sickness and lone 
parent families increased the hospital admission rate. In contrast, the use of 
public transport to get to work reduced the hospital admission rate. 
In Scotland, an analysis of the Scottish Morbidity Record data set, which 
includes all in-patient episodes, from 1998 to 2009, identified a rate of 
admission for TBI in males of 446/100,00 and females of 195/100,000.39 Over 
the 11 years of the study, the authors noted two periods at which the trend in 
admission rate reduced. This was in 2002 and 2005 for men, and 2001 and 
2004 for women. This decrease in admissions was seen chiefly in the younger 
age group, while there was an increase in admission trends in 2004 in older 
women, which was caused primarily by falls. This is seen again in a simple 
analysis of numbers of patients admitted for TBI in England from 1998 to 
2010.40 This study showed a near doubling in absolute admissions, from 
13,800 admitted in 1998 to 25,200 in 2010. When grouped by age, there was 
a small decrease in admissions in children, and a large increase in admissions 
in over 60s, from 3350 in 1998 to 12,800 in 2010. 
Emergency Department attendance rates for head injury are higher than 
hospital admission rates as many head injuries do not result in a brain injury 
significant enough to warrant admission. An analysis of the database of a UK 
Emergency Department treating rural and urban populations and covering 
1997 to 2003, found that head injuries accounted for 3.4% of all Emergency 
Department attendances with an attendance rate of 453/100,000.41 Urban 
rates were almost four times as high as rural and 10.9% of attendances were 
moderate or severe. 





Evidence of head injury rates in Europe comes from a range of geographic 
locations including urban and very rural regions. Because the populations are 
so distinct, and the type of rate reported (head injury, brain injury, Emergency 
Department attendance, hospital admission) are different, it is difficult to 
generalise or make assumptions about one population based on reports from 
another. In central Norway from 1979 to 1980, the incidence of head injury 
due to motor vehicle collision and requiring admission to hospital was 
89/100,000.42 In north Norway the rate for all cause TBI was estimated at 
229/100,000.43 The primary cause was falls (62%) followed by motor vehicle 
collisions (21%) and assault (7%). The two rates are different (head injury and 
TBI), and the head injury rate, reported in north Norway, is due to motor 
vehicle collision only. To compare central with north Norway, the rate of TBI 
due to motor vehicle collision must be calculated from the all cause rate, i.e. 
21% of 229/100,000, which is 48/100,000. Therefore, the rate of TBI due to 
motor vehicle collision in central Norway is almost half the rate of head injury 
due to motor vehicle collision in norther Norway.  
An analysis of nationally collected data in Norway, Sweden, Denmark and 
Finland between 1987 and 2001 found that the death rate from TBI was around 
10% in the former three countries and just over 20% for Finland, with males 
three times more likely to die than females in all four countries.44 The higher 
mortality rate in Finland was thought to be associated with alcohol 
consumption patterns, suicide and homicide. In Denmark, TBI-related 
Emergency Department attendances and hospital admissions both increased 
from 1998 to 2012.45 In patients aged ≥65, TBI related attendances rose 




substantially more than age <65 by 9% vs 3% per year. TBI related admissions 
also rose in the older group from 17% to 28% of all TBI related admissions. As 
a mechanism of injury, falls rose, and motor vehicle collisions reduced over 
the study period. In Hanover and Munster, Germany, all Emergency 
Department attendances for head injury with either symptoms of TBI or an 
ICD-10 code for TBI were analysed (Appendix 3). The incidence of Emergency 
Department attendance for TBI was 332/100,000, and 73% were admitted 
into hospital. The proportion of mild TBI was 90.2%, moderate 3.9%, and 
severe 5.2%.46 There was a 1% mortality rate, and the primary cause was falls 
(52.5%), followed by motor vehicle collisions (26.3%). 
USA 
Prior to the 1990s in the USA, data on TBI incidence were reported based 
primarily on hospital discharge codes and at hospital, city or county level. 
Emergency Department attendance rates were rarely reported, and the data 
sources were often small (Table 1.3). This began to change in the 1990s, with 
an analysis of the 1991 National Health Interview Survey. This US-wide survey 
collected data on mild or moderate TBI only, which were defined as head 
injuries resulting in loss of consciousness but not death or long-term disability. 
The authors reported that there was a TBI rate of 618/100,000, which is higher 
than other reports, but includes patients that did not receive any medical care, 
or that received primary care only. Among this group, 25% did not receive 
medical care, 14% were treated as out-patients, 35% attended Emergency 
Departments and were discharged, and 25% were admitted to hospital.47 
The National Hospital Ambulatory Medical Care Survey is a large database in 
the US designed to estimate utilisation and provision of Emergency 




Department and outpatient care. An analysis of the 1992-1994 dataset was 
performed to describe the characteristics of patients with TBI that present to 
the Emergency Department.48 There were an estimated 1,144,807 new 
Emergency Department attendances with TBI per year, with an Emergency 
Department attendance rate of 444/100,000, accounting for 1.3% of all 
Emergency Department visits. The greatest attendance rate was amongst the 
less than five age group at 1,091/100,000, followed by the greater than 85 age 
group at 1,026/100,000. The male to female ratio was 1.6 and female 
attendances were only greater than male attendances in the over 65 age 
groups. The primary cause was falls (39%) followed by motor vehicle collisions 
(23%) and assault (23%). 
The National Hospital Ambulatory Medical Care Survey dataset was also used 
to identify Emergency Department attendances for mild TBI during the years 
1998-2000.49 The authors found that for mild TBI there were 1.4 million 
Emergency Department attendances per year, which represented an 
Emergency Department attendance rate of 503/100,000. The highest 
attendance rates were in males (781/100,000) and in children under five 
(1115/100,000). The most common mechanism varied with age, with falls 
being most common in the extremes of age, and motor vehicle collisions in the 
middle age groups. When this data was analysed for isolated mild TBI, i.e. mild 
TBI with no other concomitant Emergency Department diagnosis, the 
Emergency Department attendance rate was 56/100,000, which equated to 
153,300 Emergency Department attendances annually.50 A further analysis of 
the National Hospital Ambulatory Medical Care Survey for Emergency 
Department visits, along with National Hospital Discharge Survey for in-




patient episodes, and the National Center for Health Statistics for mortality 
data, was performed for 2003.51 This study reported 1.6 million TBIs, which 
was made up of 1.2 million Emergency Department attendances, 290,000 
hospital admissions, and 51,000 deaths. The highest Emergency Department 
attendance rate was seen in the youngest age group, and the highest hospital 
admission rate was seen in the oldest age group. The most common 
mechanism was falls (32%), followed by motor vehicle collision (19%), struck 
by/against (18%) and assault (10%). 
The US Department of Health and Human Services, Centers for Disease 
Control and Prevention published a landmark study in 2010, which observed 
and calculated TBI rates from 2002 to 2006.52 This study also utilised data 
from the National Hospital Ambulatory Medical Care Survey and National 
Center for Health Statistics. The annual incidence of TBI in the US was 1.7 
million, of which 1.4 million (80%) attended the Emergency Department and 
were discharged, 275,000 (16%) were admitted into hospital, and 52,000 (3%) 
patients died. The age groups with highest rates of TBI-related Emergency 
Department visits were 0-4, and 15-19 years, although patients aged greater 
than 75 had the highest rates of admission and death. Males had a higher 
incidence than females in all age groups. Falls were the leading cause of TBI, 
and motor vehicle collisions were the most common cause of TBI-related 
death. Emergency Department attendances rose from 14.4% to 19.5% over the 
five years. Injuries comprised 30% of all Emergency Department attendances 
and 5% of all admissions, and TBI comprised 1.4% of all attendances (5% of all 
injuries), 0.7% of all admissions and 2% of all deaths.  




In North Carolina in 2010-2011, there were more than 140,000 Emergency 
Department attendances with TBI, equating to 7.3 Emergency Department 
visits per 1000 person-years.53 Emergency Department attendance rates were 
highest in the 0-4, 15-19 and >75 years age groups. The primary cause of TBI 
was falls (39.0%), followed by being struck by an object (17.6%) or motor 
vehicle collisions (14.1%). 
In addition to Emergency Department and in-patient healthcare usage, 
patients with head injuries also attend primary care and clinic-based services. 
In the US, over the five years from 2005 to 2009, for mild TBI, there were 3.8 
million primary care attendances, 380,000 outpatient attendances, and six 
million Emergency Department attendances with mild TBI (data also from the 
National Hospital Ambulatory Medical Care Survey and the National Center 
for Health Statistics).54 
These findings are consistent with estimates of 1.6 million, 1.7 million and 2.1 
million Emergency Department attendances for TBI in 2006, 2007, and 2008 
respectively.55 Around 15% were patients aged greater than 65 years, and of 
those, 61% were female and the older group also had higher acuity levels 
(represented as being assigned higher priority codes). A further US study, 
using the same methodology, and looking at US Emergency Department 
attendances in 2009 and 2010, estimated TBI diagnosed in the Emergency 
Department at 2.5 million cases a year.56 Falls (49%), followed by motor 
vehicle collisions (20%), struck by/against (11%), and assault (8%) were the 
commonest mechanisms. Using a different methodology, the Centers for 
Disease Control and Prevention published a national estimate for TBI related 
Emergency Department attendance, hospitalisation and death for 2007 and 




2013.57 They found that attendances were rising, from 1.6 million in 2007 to 
2.5 million 2013. This rise was chiefly accounted for by patients aged 0-4, 15-
24 and ≥75 years. Admissions into hospital also rose, and this was accounted 
for by the older age group. Overall, the most common mechanisms of injury 
were falls, followed by struck by/against an object and motor vehicles 
collisions. However, when stratified by age, in the older and youngest groups, 
falls accounted for most of the injury mechanisms, whereas in other age groups 
other mechanisms were more common. The methodology used in national 
studies in the US of Emergency Department attendances per year results in 
estimates from survey data. From these there is a clear rise in attendances per 
year (Figure 1.2). 
In Ontario, Canada in 2001, the incidence of mild TBI, calculated from 
Emergency Department and Family Physician health records, was 
426/100,000.58 Further data from Ontario, from 2002 to 2009, showed that 
Emergency Department attendance rates remained broadly stable at around 
1000/100,000 and similar patterns of sex, age and mechanism were seen.59 In 
British Columbia, Canada the rate of hospital admission for head injury in 
2000 was 255/100,000, and of those admissions, concussion accounted for 
34.9% of diagnoses.60 Across all of Canada the rate of concussion was 
estimated at 110/100,000.61 





Figure 1.2 US Emergency Department attendances with head injury 
Methodology used in each paper: Sosin, National Health Interview Survey; 
Jager, National Hospital Ambulatory Medical Care Survey (NHAMCS); 
Rutland-Brow, NHAMCS; Faul, NHAMCS; Pearson National Hospital 
Ambulatory Medical Care Survey Emergency Department (NHAMCS-ED); 
Korley, NHAMCS; Taylor, Healthcare Cost and Utilization Project, Nationwide 

































Jennet35 1974 England, Scotland, 
Wales 
HES equivalent England, 
Scotland, Wales 
--- 1778 270 --- --- ICD-9 
Klauber62 1978 San Diego County, 
California 
Hospital discharge data --- --- --- 295 --- ICD-A 
Jagger63 1978 North central 
Virginia 
Hospital admission data --- --- 208 --- --- --- 
Fife64 1979 Rhode Island Hospital discharge data   --- --- --- ICD-9-CM 




--- --- 89 ---- --- N/A 
Whitman65 1980 Chicago, Illinois Hospital discharge data --- --- 403 --- --- ICD-9-CM 
Cooper66 1980 The Bronx, New 
York City 
ED attendance data 
Hospital admission data 
Hospital discharge data 
--- --- 249 --- --- ICD-9-CM 
Kraus67 1981 San Diego County, 
California 
ED records, coroners’ 
cases, death 
certificates, and nursing 
home records 
--- --- --- --- 180 ICD 
Servadei68 1981-1982 San Marino ED and hospital records --- 694 468 --- --- NA 
Tennant37 1986 North West 
England 
HES NWRHA --- --- 297 --- --- ICD-9 




system and manual 
case examination 






Tate70 1988 North Coast Health 
Region, New South 
Wales, Australia 
Hospital discharge data 
& manual case 
examination 
--- --- 106 --- --- ICD 




Sosin47* 1991 USA NHIS 935,000 --- 158 --- 618 ICD 
Phillips60 1991-2001 British Columbia, 
Canada 
CIHI & Health Insurance 
Records (in patients 
only) 
--- --- 255 (1991) 
128 (2000) 
--- --- ICD-9 
Jager48 1992-1994 USA NHAMCS 1,144,807 444 --- --- --- ICD-9-CM 




--- --- --- 229 --- N/A 
Gordon61 1996-1997 Canada NPHS --- --- --- --- 110* N/A 
Yates41 1997-2003 Single ED in Devon, 
UK 














--- --- ICD-9 
Shivaji39 1998-2009 Scotland SMR01 --- --- Male 446 
Female 195 
--- --- ICD-10 
Van den 
Brand45 
1998-2012 Denmark Dutch Injury 
Surveillance System 




--- --- ICD-9-CM 
Rickels46 2000-2001 Hanover and 
Münster, Germany 
ED and hospital records 6783 332 242 --- --- ICD-10 
Ryu58 2001 Ontario, Canada ED and GP records --- --- --- --- 426 ICD-9 
Tennant38 2001-2003 England HES --- --- 229 --- --- ICD-9 
Fu59 2002-2010 Ontario, Canada NACRS --- 1014 (2002) 
979 (2009) 
--- --- --- ICD-10 
Faul52 2002-2006 USA NHAMCS 1.4m 468 94 --- --- ICD-9-CM 






2003 USA NHAMCS (for ED 
attendance) 
NHDS (for in-patient 
episodes) 




420 99 --- --- ICD-9-CM 
Pearson55 2006-2008 USA NHAMCS-ED 1.6m (2006) 
1.7m (2007) 
2.1m (2008) 
--- --- --- --- ICD-9-CM 
Taylor57 2007 & 
2013 
USA HCUP NEDS, HCUP NIS 
& NVSS 










Korley56 2009-2010 USA NHAMCS 2.5m --- --- --- --- ICD-9-CM 
 
Table 1.3 Emergency department attendance and hospital admission rates for head and traumatic brain injury 
ED, Emergency Department; HES, Hospital Episode Statistics; ICD-9, International Classification of Diseases, 9th Revision; ICD-A, 
International Classification of Diseases Adapted; REPR, Rochester Epidemiology 
Project Records; NWRHA, North West Regional Health Authority; NHS, National Health Service; NHIS, National Health Interview 
Survey; SMR01, Scottish Morbidity Record; ICD-10, International Classification of Diseases, 10th Revision; NHAMCS, National 
Hospital Ambulatory Medical Care Survey; NHAMCS-ED, National Hospital Ambulatory Medical Care Survey– Emergency 
Department; ICD-9-CM, International Classification of Diseases, 9th Revision Clinical Modification; NHDS, National Hospital 
Discharge Survey; NCHS, National Center for Health Statistics; NACRS, National Ambulatory Care Resource System; HCUP, 
Healthcare Cost and Utilization Project; NEDS, Nationwide Emergency Department Sample; NIS, National Inpatient Sample; NVSS, 
National Vital Statistics System; CIHI, Canadian Institute of Health Information; NPHS, National Population Health Survey. * mild 
and moderate TBI only




Outcomes following head injury 
Mild TBI results in a constellation of symptoms including headaches, cognitive 
dysfunction and emotional lability (Table 1.4). Although there are many 
validated tools available to measure such symptoms, application of the tools can 
sometimes only be performed by a neuropsychologist and may take several days 
to complete. Interpretation of the results may also only be done by a specialist, 
making the results difficult to utilise by wider healthcare professionals. Patient 
centred outcomes represent a more practical measure and are easy to 
understand for patients and physicians. 
CSI RPQ Common to both 
Headache Headaches  Yes 
Nausea Nausea  Yes 
Balance problems/Dizziness Feelings of dizziness  Yes 
Fatigue Fatigue  Yes 
Drowsiness  No 
Feeling like “in a fog”  No 
Difficulty concentrating  Poor concentration  Yes 
Difficulty remembering Forgetfulness  Yes 
Sensitivity to light Light sensitivity  Yes 
Sensitivity to noise Noise sensitivity  Yes 
Blurred vision Blurred vision  Yes 
Feeling slowed down Taking longer to think  Yes  
Being irritable  No  
Double vision No  
Feeling depressed  No  
Feeling frustrated  No  
Restlessness  No  
Sleep disturbance  No 
 
Table 1.4 Comparison of two commonly used checklists of symptoms 
of mild TBI 
CSI, Concussions Symptom Inventory; RPQ, Rivermead Post-Concussions 
Questionnaire. 
  




Return to work 
Return to work is a key outcome measure following mild TBI. Being unable to 
work impacts negatively on an individual’s wellbeing and on the greater 
economy.72 Mild traumatic brain injury has a significant impact on when and 
whether patients return to work. Some researchers estimate a third of patients 
with mild TBI that were previously employed were unemployed at three months 
follow up.3 On top of sustaining mild TBI, if the patient sustains further extra-
cranial injuries, they are at risk of increased limitation in function and resume 
work less frequently than those without extra-cranial injuries.73 The main 
barriers to returning to work following mild TBI are headaches, visual deficits, 
pain syndromes, dizziness, and postural instability, but return to work is also 
affected by age, multiple injuries, intracranial haemorrhage, and fatigue 
ratings.74,75 The indirect costs, i.e. cost of resources lost owing to illness, 
associated with TBI in Europe is estimated at around €20 billion a year.76 
Return to work is a pragmatic real-world outcome with direct relevance to 
patients and quality of life, and thus a clear understanding of the numbers of 
patients that return to work is essential.77-79 As an outcome it has some 
limitations, including variation in how it is defined. For instance, when a patient 
returns to work after mild TBI, they may not return full time or to the same 
physical or mental activities that they performed prior to the injury. 
Furthermore, in its purest sense, that is, when defined in terms of employed 
work, it only applies to people that were in employed work prior to injury. 
However, the definition is often extended to include studying, and extended 
further to include usual daily activities. The extension of the definition has 
worth in that it includes more patients, but at the expense of precision, as 
definitions of usual activities or activities whilst studying are not possible to 




apply consistently. Nevertheless, as an indicator of improvement, return to work 
is a valuable outcome measure following mild TBI. 
Mortality 
Although trauma is the leading cause of death in males below the age of 65, mild 
TBI rarely results in death. Deaths attributable to head injury are ascertained 
from International Classification of Diseases codes, although there are inherent 
problems with this classification system, such as the large number of codes that 
cover head injury or TBI. They are not mutually exclusive and provide no clinical 
data and no data on injury severity. Deaths attributable to injury vary widely 
between countries. In the mid-1980s, France had the greatest death rate due to 
injury out of eight developed countries at 7% and England the lowest at 2%.80 
From 1979 to 1992, an average of 52,000 US residents died each year due to TBI, 
although the rate declined over this period from 25 to 19/100,000 population 
over this time.81 The mechanism of injury also changed over this period with an 
increase of 13% in firearm related injuries and a decrease of 25% in motor 
vehicle related injury. Of almost 3000 patients admitted to hospital with TBI in 
Glasgow, 90% had mild TBI. At one year follow up, increased severity of injury 
at admission was associated with increased rate of death and vegetative state, 
and decreased rate of good outcome.82 However, initial TBI classification was 
not associated with rates of severe or moderate disability which, when combined 
was similar in each group (47% in mild TBI, 45% in moderate TBI, 48% in severe 
TBI). These results are striking in that they imply that at one year after injury, 
patients that had even a mild TBI still had high rates of disability, comparable 
to patients with moderate or severe TBI. This is in contrast to the results of a 
systematic review in which significant neurological outcomes such as 




unprovoked seizures, Parkinson’s disease, and dementia were associated with 
moderate and severe TBI but not with mild TBI.83 The finding that seizures are 
rarely associated with mild TBI was reproduced in a study of 2005 patients with 
mild TBI, of which only two patients (0.1%) developed seizures.84 
  




Pathophysiology of mild traumatic brain injury 
Biomechanics 
When the head sustains an impact, it rapidly accelerates then decelerates. There 
is relative motion between the brain and the skull which causes tension and 
pressure gradients within brain tissue. If limits of toleration are exceeded, injury 
can occur. In human cadaveric heads to which concussive impacts were 
administered, there can be a brain-skull displacement of up to 7 mm.85,86 Two 
types of accelerations, linear and rotational, are thought to be related to brain 
injury. Furthermore, they are thought to result in different injuries.87 Linear 
acceleration is thought to result in pressure gradient changes and focal injuries, 
whilst rotational acceleration causes shear forces at the skull-brain interface and 
results in more diffuse injury.88 In reality, both linear and rotational forces are 
applied to individuals as they suffer a head injury, and both types of force will 
contribute to mild TBI.89 The point on the head on which the impact is sustained 
is also important. Lateral and rear impacts create rotational accelerations that 
are up to 30% higher than frontal impacts.90 Lateral impacts cause high strain 
in the corpus callosum, whereas frontal impacts of the same energy results in 
high strain in the midbrain.90 In addition to whether the impact creates linear 
or rotational movement, the duration of the acceleration-deceleration, and 
whether the direction in which the head moves is coronal or sagittal is also 
critical.91,92 Sustained acceleration-deceleration causes displacement of the 
cytoplasm leading to intra-axonal damage to the neurofilament subunits, failure 
of the axonal cystoskeleton, and diffuse axonal injury.93 Current understanding 
of biomechanical thresholds for injury comes from sports in which athletes wear 
helmets with impact measurement devices such as the Riddell Head Impact 




Telemetry System sensor device or the six-degree-of-freedom system are the 
two most commonly used research systems.94 A mean peak linear acceleration 
of 100g, and rotational acceleration of 5776 rad/s2 have been identified as 
theoretical thresholds for injury.95,96 However, a definitive concussion threshold 
is probably not possible to determine as levels of acceleration greater than 200g 
have been recorded in elite athletes with no reported concussion.97 
Cellular changes 
A mild TBI is the result of energy, in the form of a physical strike, imparted 
either directly to the head, described as contact forces, or to another part of the 
body, with the energy transmitted through the body to the brain, described as 
inertial forces.98 There are multiple mechanisms occurring at a cellular level that 
result in altered neuronal function (Figure 1.3). Damage to deep white matter 
tracts, which result in diffuse axonal injury, are a consequence of rotational 
forces around a fixed fulcrum, thought to be the brainstem.92 The energy 
transmitted through the brain causes damage to the axolemma, the plasma 
membrane of the axon, resulting in microscopic pores which in turn alter the 
permeability of the axolemma.99-101 Unchecked ionic fluxes and a simultaneous 
indiscriminate release of neurotransmitters occurs.102 Potassium then moves 
extracellularly, and calcium and sodium intracellularly.103 During this early 
period (up to about 20 minutes after injury), extracellular potassium levels 
continue to increase.104 Under normal circumstances, the potassium would be 
absorbed by surrounding glial cells, but in the context of TBI this does not 
happen.105 Simultaneously, non-specific depolarisation results in glutamate (an 
excitatory amino acid) release which in turn increases the potassium efflux from 
the cells by activating multiple neurotransmitter receptors.104 In the acute 




phase, in response to altered membrane potential as a consequence of the ion 
shifts, axolemmal energy-dependent voltage and ligand gated ion channels, 
such as sodium-potassium pumps, increase work, thereby increasing the 
demand for adenosine triphosphate, with consequent increased glycolysis.106 
This hypermetabolic state lasts about half an hour after mild injury and up to 
four hours following severe injury.107 
Energy applied to the brain during the instant of impact results in damage to 
microstructural components of the brain, including axons, dendrites, dendritic 
connections, and astrocytic processes.107 The elevated intra-axonal calcium 
concentration results in neurofilament phosphorylation and collapse of axonal 
structure.100 Points on the axonal cell membrane at which intracellular 
microtubules anchor are mediated by integrins and other proteins, and may be 
a specific point of molecular damage following injury.108,109 These physical, 
neurotransmitter and neurometabolic changes lead to axonal dysfunction, 
disconnection and death.99 In addition, an inflammatory response occurs after 
mild TBI as a result of upregulation of inflammatory and cytokine genes, leading 
to oxidative stress and potentially to cellular injury, described as 
‘immunoexcitotoxicity’.110 
These pathophysiological changes have been postulated to be correlated with 
clinical symptoms. Migraines, headaches, photophobia and phonophobia are 
thought to be associated with ionic flux; axonal injury and altered 
neurotransmission with impaired cognition and slowing of reaction times; and 
altered cytoskeletal proteins and cell death with chronic or persistent 
impairments.107





Figure 1.3 Neurometabolic changes in traumatic brain injury 





Traumatic brain injury affects cerebral vascular autoregulation. Cerebral 
autoregulation is often described in the form of the cerebral autoregulation 
index. This is a function of cerebral vascular resistance and mean arterial blood 
pressure. Cerebral vascular resistance is in turn a function of middle cerebral 
artery flow velocity and is usually measured using transcranial Doppler 
ultrasound. The cerebral autoregulation index ranges from one (perfect 
autoregulation) to zero (absent autoregulation).111 Cerebral autoregulation was 
profoundly affected in a patient that was hit by a car and suffered a brief 
concussion.111 Six days after the injury, during elective anaesthesia for a knee 
operation, there was no change middle cerebral artery flow velocity in response 
to inducing a rise in mean arterial blood pressure by infusing phenylephrine. A 
normal response would have been to see maintenance of constant middle 
cerebral artery flow velocity but in this case, there was a rise in flow velocity 
which matched the rise in mean arterial blood pressure, and a calculated 
cerebral autoregulation index of zero, indicating absent cerebral autoregulation. 
In 29 patients with mild TBI and 29 age matched controls, transcranial Doppler 
ultrasonography of the middle cerebral arteries was performed within 48 hours 
injury.112 A blood pressure cuff on each leg was inflated to levels higher than 
systolic pressure, then rapidly deflated, triggering a sudden drop in systemic BP. 
The normal response to this would be to reduce overall cerebrovascular 
resistance which would in turn restore cerebral blood flow to normal resting 
level. The changes in blood pressure and cerebral blood flow in the proximal 
middle cerebral arteries immediately before and after the cuff release were used 
to calculate the cerebral autoregulation index. Eight of the 29 patients with mild 




TBI (but none of the 29 controls) had poorly functioning or absent cerebral 
autoregulation. Poor autoregulation was correlated with low blood pressure but 
not with any peri- or post-injury factors. Furthermore, disrupted cerebral 
autoregulation has been described in concussed athletes 72 hours after injury.113 
In this group reduced cerebral autoregulation also appeared to be associated 
with symptoms. The theory that altered cerebral autoregulation is associated 
with symptoms is supported by the finding that in adolescents with mild TBI, 
cerebral autoregulation was initially reduced and gradually improved as 
symptoms resolved, such that autoregulation was normal and symptoms 
completely resolved by 12 weeks.114 Cerebral autoregulation abnormalities also 
may persist beyond perceptible clinical recovery. In 18 athletes that sustained a 
concussion, there was impaired autoregulation that persisted at 14 days but had 
resolved by a month, and in whom all were cleared to return to play by 14 days.115 
However not all patients with mild TBI have reduced middle cerebral artery flow 
velocity. In a small study of six adolescent patients with sports related TBI, flow 
velocity was measured and a change in mean arterial blood pressure was 
triggered by a change in position from supine to upright.116 Middle cerebral 
artery flow velocity was reduced in three patients, elevated in two patients.  
  




Abnormalities detectable on magnetic resonance imaging 
Magnetic resonance imaging techniques 
Diffusion tensor imaging (DTI), also known as diffusion weighted magnetic 
resonance imaging (MRI), is an MRI technique in which multi-directional 
magnetic field gradients are used to describe the movement of water molecules 
in tissue. In cerebrospinal fluid water molecule movement is essentially 
unrestricted, since it can occur in any direction. This is termed isotropic 
diffusion. In axonal tracts, because the cell membrane and myelin sheath 
represent a relatively impermeable barrier to water, movement is restricted to 
the direction of the tract. This ‘unequal’ movement is termed anisotropic. As 
water moves along the directions of the magnetic field gradients, the MR signal 
of diffusing hydrogen protons is attenuated in proportion to the movement 
along the gradient. Diffusion can then be modelled in three dimensions in an 
ellipsoid (also known as a tensor).117,118 There are several metrics used to 
describe anisotropy. Fractional anisotropy is a quantification of the degree of 
anisotropy, that is, the degree to which water molecules travel along the main 
axis of the ellipsoid. Fractional anisotropy ranges from zero to one, with one 
meaning movement in a single direction (along the axis of the ellipsoid), and 
zero meaning wholly isotropic movement, i.e. movement in any direction in a 
perfect sphere. Other commonly used DTI variables include mean diffusivity 
(average amount of diffusion irrespective of direction), axial diffusivity 
(diffusion along the main axis of the ellipsoid), radial diffusivity (average of 
diffusion in the two other axes), and the apparent diffusion coefficient, which is 
a measure of the impedance of water molecule diffusion. Fractional anisotropy 
is a commonly reported measure in mild TBI but is limited by the requirement 
that fractional anisotropy measurements are extracted from pre-defined white 




matter tracts or anatomical regions of interest. If a lesion exists outside of the 
region of interest it will not be apparent in the fractional anisotropy analysis.118 
To circumvent this limitation, the entire brain volume can be assessed using a 
voxel-by-voxel (also known as voxelwise) approach. A voxel is a pixel volume in 
the three-dimensional space of the MR image. A limitation to the voxelwise 
approach is that it requires standard registration algorithms for analysis. This 
method does not easily allow alignment of multiple subjects’ fractional 
anisotropy images in a way that allows valid conclusions to be drawn from the 
subsequent voxelwise analysis. A solution to this is a technique called Tract 
Based Spatial Statistics, which aims to improve the sensitivity, objectivity and 
interpretability of analysis of multi-subject diffusion imaging studies.119 
Graphical model based multivariate analysis is sometimes used as a 
complement to the tract based spatial statistics approach of identifying neuronal 
tract abnormalities. Graphical model based multivariate analysis is a Bayesian 
multivariate technique that can identify voxels that are predictive of group, for 
instance mild TBI or control, at an individual patient level rather than at a group 
level.120-122 
Different white or grey matter tracts have different normal fractional anisotropy 
ranges. An abnormal fractional anisotropy can be higher or lower than the 
normal range. An elevated fractional anisotropy, that is, more unidirectional 
water movement than would be expected, might reflect inflammatory changes 
such as axonal swelling or cytotoxic oedema.123,124 A lower than normal 
fractional anisotropy, representing more multi-directional water movement, 
might reflect axonal degradation, axonal discontinuity, or increased water in the 
interstitial space.125 




Susceptibility weighted imaging is an MR technique that is especially sensitive 
to changes in the local magnetic field. This makes it particularly useful in 
detecting microhaemorrhages in mild TBI. 
Arterial spin labelling is an MR technique that provides a measure of blood flow 
without using intravenous contrast. To obtain the measure of cerebral blood 
flow, a conventional MR sequence is first performed. Following conventional 
imaging, blood water protons, which are outside of the region of interest that is 
being imaged, are saturated or have their magnetisation inverted. This gives 
them a magnetic label. Images are then acquired after enough time has passed 
to allow the labelled protons within blood water to flow into the region that is 
being imaged. When the two images are subtracted, cerebral perfusion can be 
demonstrated, which in turn can be associated with cerebral blood flow.118 
Neuronal tract abnormalities 
A PubMed search using the terms ((((tract abnormality[Title/Abstract]) OR 
diffusion tensor imag*[Title/Abstract]) OR dti[Title])) AND 
((((mtbi[Title/Abstract]) OR mild tbi[Title/Abstract]) OR mild traumatic brain 
injury[Title/Abstract]) OR concussion[Title/Abstract]) identified 361 articles, 
of which 23 were identified as relevant to describing neuronal tract 
abnormalities in mild TBI (Table 1.5). All studies included a comparator group 
acting as a control, some of which were healthy volunteers and some of which 
were patients with musculoskeletal injuries, often described as orthopaedic 
controls. The number of patients with mild TBI enrolled in each study ranged 
from eight to 102, with a median of 33 patients included. More recently 
published studies tended to include more patients. Two studies reported the 
results of MRI performed on the day of injury, eight within a week of injury, five 




within one and two weeks of injury, four within two and four weeks of injury, 
one within one and six months of injury, one more than a year after injury and 
two did not specify when the scan was done (Figure 1.4). 
 
Figure 1.4 Number of studies by time of MRI 
 
Eighteen of the 23 studies reported changes in fractional anisotropy. Nine of 
those 18 reported increased fractional anisotropy. The specific white matter 
tracts affected that displayed increased fractional anisotropy were frequently in 
the corpus callosum and particularly in the genu and splenium of the corpus 
callosum, the corona radiatae bilaterally, uncinate fasciculus, the frontal lobes, 
and the middle cerebellar peduncles and pontine crossing tract (Figure 1.5 and 
Figure 1.6).126-133 Twelve of the 17 studies reported decreased fractional 
anisotropy. As in studies that described increased fractional anisotropy, 




decreased fractional anisotropy was also noted in the corpus callosum, corona 
radiatae bilaterally, the uncinate fasciculus, and the frontal lobes. In addition, 
decreased fractional anisotropy was also noted in the left superior temporal 
gyrus, internal and external capsules, and the inferior longitudinal and inferior 
fronto-occipital fasciculi.125-128,134-141 Three studies reported both increased and 
decreased fractional anisotropy in different regions of the brain.126-128 
 
Figure 1.5 Sagittal view of brain showing fasciculi 
 
Two studies reported increased mean diffusivity, and this was noted in the right 
uncinate fasciculus, posterior limb of the internal capsule, optic radiation & 
splenium (Figure 1.6 and Figure 1.7).139,142 One study reported decreased mean 
diffusivity, and this was in the frontal lobe.125 Three studies reported increased 
radial diffusivity, and this was in the corpus callosum, the corona radiatae, and 
the internal external capsules.136,141,143 In one of these studies an increase in 
radial diffusivity was only seen in complex mild TBI compared with controls.141 
One study reported reduced radial diffusivity, and this was seen in the genu, left 
corona radiata & left uncinate fasciculus.131 





Figure 1.6. Coronal section through basal ganglia 
 
 
Figure 1.7. Sagittal section through midline 
  




Although there is little consistency in whether the measures of diffusion are 
increased or decreased, there is some consistency in the region of the brain 
affected, with the corpus callosum most frequently affected (Figure 1.6). 
Furthermore, any change in diffusivity indicates injury, with an increase in 
diffusivity potentially indicating oedema and a decrease potentially indicating 
tract disruption or axonal discontinuity. This suggests that in mild TBI the 
corpus callosum is most frequently affected and this could either be by 
developing oedema after injury, or by individual neurones becoming disrupted. 
That this deep structure of the brain is commonly affected is consistent with 
biomechanical models of brain injury, in which deep structures such as the 
corpus callosum are subject to the highest strain forces as a result of lateral 
impacts.90 In contrast, in a study that included moderate as well as mild TBI, 
lower fractional anisotropy was noted in the corpus callosum, particularly in the 
more severely injured patients.135 This was explained by the falx being elongated 
at the posterior portion of the corpus callosum, limiting posterior movement of 
the corpus callosum and consequently making it more susceptible to strain. The 
reduction in fractional anisotropy noted in this study, indicating increased 
multidirectional water movement, may be a consequence of callosal oedema. 
Eight studies reported correlations or associations between neuronal tract 
abnormalities and neurocognitive test results. In 20 patients with mild TBI, 
executive function was inversely related to lower fractional anisotropy in the 
frontal lobes, whilst in 22 patients with mild TBI, elevated fractional anisotropy 
in the right hemisphere was positively associated with attentional deficits.125,131 
In this last study, there were no structural lesions identified on conventional 
MRI sequences. The elevated fractional anisotropy was postulated to be due to 




cytotoxic oedema or changes in water content within the myelin sheath. This 
implies that subtle white matter tract lesions, in the absence of structural 
abnormalities seen on conventional imaging, account for persistent symptoms 
and signs observed in patients with mild TBI. The authors repeated their study 
and found only elevated fractional anisotropy in the genu to be consistently 
replicated.130 When assessed at four months, there was recovery of several 
lesions, which correlated with a reduction in self-reported symptoms. Increased 
fractional anisotropy in white matter was also negatively correlated with 
cognitive function in 11 patients with mild TBI compared with controls, and with 
DTI lesion load in nine patients with mild TBI.126,128 Lower fractional anisotropy 
in several regions including the corona radiata, superior longitudinal fasciculus 
and corpus callosum was positively correlated with deficits in attention, whilst 
lesions in the optic radiation were associated with deficits in spatial 
awareness.139 Lower fractional anisotropy in the internal capsule was also 
associated with reduced cognitive processing speed in 33 patients with mild 
TBI.140  





Reference Number/condition MRI technique & regions of interest scanned Timing of MRI Findings (change 
compared with 
control) 




20 (mild TBI) 
20 (Control) 
T1, T2 & voxelwise DTI  
None prespecified*  
< 2 weeks after 
injury 
FA reduced  
MD reduced  
15 regions, 5 in frontal lobe  
 
Mild TBI patients had poorer neurocognitive 
test results than controls. 










T1, T2 & DTI 
Bilateral genu, splenium, and body of the 
corpus callosum, superior longitudinal 
fasciculus, corona radiata, superior corona 
radiata, uncinate fasciculus, internal capsule 







Normalisation at 3 
months follow up of 
DTI measures. 
FA increased in genu, left superior corona 
radiata, left corona radiata, & left uncinate 
fasciculus. 
RD reduced in genu, left corona radiata & left 
uncinate fasciculus. 
FA levels in the right hemisphere predicted 
variance in attentional deficits (positive 




20 (mild to 
moderate TBI) 
27 matched control 
T1, T2 & DTI 
genu, stem, and splenium of the corpus 
callosum, corona radiata, anterior & posterior 
limbs of internal capsule, frontal & occipital 
white matter 
Median 3.5 
days after injury 
FA reduced Reduced FA values in the genu, stem and 
splenium of the corpus callosum. 





29 (mild TBI) 
29 (control) 
T1, T2 & DTI 
Voxelwise analyses 
Bilateral genu, splenium, and body of the 
corpus callosum, superior longitudinal 
fasciculus, corona radiata, superior corona 
radiata, uncinate fasciculus, internal capsule 
Mean 16 days 
after injury 
FA increased Genu of corpus callosum 
Rao137 
2012 
14 (mild TBI) Voxelwise  
31 areas of the brain 
< 1 month after 
injury 
FA reduced Left superior temporal gyrus. 
Lower baseline FA in the superior and middle 
temporal gyri were predictive 
of depression over time. 
Higher MD scores in the right superior 
longitudinal fasciculus, inferior frontal & 
superior temporal white matter were 
predictive of depression over time. 








T1, GRE, FLAIR & DTI 
Multiple ROI 
MRI performed 
4 times for each 
patient within 8 
days after injury 
FA increased Not specified 
Impaired memory correlated with white 









62 ± 46 months FA increased & 
decreased  
Increased FA in grey matter  
Reduced FA in white matter 
Significant negative correlation between the 
digit symbol test (indicator of neurological 
dysfunction) & both FA severity & FA load. 
 
High PCS scores correlated with DTI findings 
Kou128 
2013 
9 (mild TBI) T1, T2, GRE, FLAIR, SWI, DTI, fMRI 
Voxelwise 
In ED FA increased & 
decreased  
Multiple regions. 
SAC scores were found to be inversely 




51 (mild TBI) 
51 (control) 
T1, T2, DTI, SWI 
Examined 12 frontotemporal cortical (grey 
matter) regions, & 2 white matter regions 
(thalami and hippocampi). 
Voxelwise 
Mean 14 days 
after injury 
FA increased  Bilateral superior frontal cortices on 
voxelwise but no difference in ROI analyses. 
TBI patients had increased cognitive, 
somatic, & emotional complaints but there 











ROI: corpus callosum, right and left uncinate 
fasciculi, and right and left frontal lobes 
<4 days for 
28/38 of 
participants 
FA reduced  
ADC increased 
FA reduced in corpus callosum & right 
uncinate fasciculus, and ADC increased in 
right uncinate fasciculus. 
SNTF serum biomarker. 




75 (mild TBI) 
40 (ankle injury 
controls) 
T1, T2, FLAIR, SWI, DTI 
Voxelwise 
<14 days (mean 
5.8) 
No differences No association between MRI findings and 




39 (mild TBI) 
28 (control) 
DTI, TBSS, GAMMA < 7 days  GAMMA detected abnormalities in the right 




    







76 (mild TBI) 
32 (CT+ mild TBI) 
44 (CT- mild TBI) 
50 (control) 
T1, T2, DTI 
Voxelwise & ROI 
11.2 ± 3.3 days FA reduced 
RD increased 
Mild TBI: right internal and external capsules, 
genu of the corpus callosum, and uncinate 
fasciculi and anterior corona radiata 
bilaterally. 
Complex mild TBI: genu and body of the 
corpus callosum, the external capsules, 
uncinate fasciculi, and anterior corona 
radiata bilaterally, the right internal capsule, 
and the right inferior longitudinal and 
inferior fronto-occipital fasciculi. 











T1, T2, DTI 
TBSS & ROI 
Not described FA reduced Depression: right nucleus accumbens, 
anterior limb of the internal capsule, and 
superior longitudinal fasciculus. 




72 (mild TBI) 
36 (trauma control) 
DTI 
TBSS & multiple ROI 
6-8 weeks after 
injury 
RD Increased in 
PCS+ patients 
Increased RD in genu, body, & splenium of 
the corpus callosum; bilateral anterior, 
superior, & posterior corona radiata; 
bilateral superior longitudinal fasciculus; 
bilateral cingulum; bilateral posterior 
thalamic radiations; bilateral anterior limb of 
the internal capsule; & bilateral external 
capsule.  
Increased MD in genu & body of the corpus 
callosum, bilateral superior corona radiata, 
right anterior corona radiata, right anterior & 
posterior limb of the internal capsule, & the 
right superior longitudinal fasciculus. 
Three groups – PCS+ mild TBI, PCS- mild TBI, 
& control.  
No difference in neurocognitive test results 
across groups. No difference in DTI measures 
between the two mild TBI groups. 











TBSS & ROI 
Mean 10 hours 





FA reduced in splenium. 
MD increased in posterior limb of internal 
capsule, optic radiation & splenium in mild 
TBI compared to control. 
FA on day of injury in corona radiata, 
superior longitudinal fasciculus & genu 
negatively correlated with attention and 
language, RD in corona radiata & superior 
longitudinal fasciculus positively correlated 
with attention, optic radiation negatively 






40 (mild TBI with 
headache) 
24 (mild TBI 
without headache) 
DTI Not described FA increased & 
decreased 
Mild TBI and post-traumatic headache: 
reduced FA in splenium and increased FA in 




47 (mild TBI) 
37 (control) 
DTI 
TBSS & ROI designed to identify cerebellar 
white matter tract injury 
GAMMA 
< 7 days after 
injury 
FA increased  TBSS analysis: higher FA in the middle 
cerebellar peduncle. 
ROI-based analysis: FA higher in middle 
cerebellar peduncle & pontine crossing tract. 
GAMMA analysis: abnormalities in middle 
cerebellar peduncle, pontine crossing tract, 









ROI including bilateral right uncinate fasciculi, 
bilateral inferior frontal 
occipital fasciculi, & the genu of the corpus 
callosum. 
Mean 25.9 
hours & 3 
months after 
injury follow up 
MD increased Left uncinate fasciculus, right inferior frontal 
occipital fasciculus, and genu. 
MD higher in LOC+ than LOC- TBI patients in 
right uncinate fasciculus. 
No differences at 3 months, and orthopaedic 
controls improved, indicating resolution of 








Mean 21 days FA reduced 
RD increased 
Not specified 







20 (mild TBI) 
16 (control) 
DTI 
TBSS & ROIs including the splenium, body and 
genu of the corpus callosum, bilateral posterior 
limbs of the internal capsule, uncinate 
fasciculus, corona radiata & corticospinal tract. 
<72 hours and 
7-10 days follow 
up 




32 (mild TBI) 
21 (controls) 
DTI 
TBSS & compartment specific WMTI** metrics 
Mean 17 days Reduced intra-
axonal diffusivity 




33 (mild TBI) 
31 (control) 
DTI 
TBSS & ROI 
<7 days and 1-3 
months follow 
up 
Reduced FA Left anterior limb of the internal capsule and 
the right inferior fronto-occipital fasciculus, 
which improved by follow up. 
Test of cognitive information processing 
speed at baseline predicted recovery of 
structural integrity of left anterior limb of 
internal capsule & right inferior fronto-
occipital fasciculus at follow up. 
 
Table 1.5. Studies of neuronal tract abnormalities in mild TBI 
MRI, magnetic resonance imaging; TBI, traumatic brain injury; Control, control; ASL, arterial spin labelling; CBF, cerebral blood 
flow; DTI, diffusion tensor imaging; FA, fractional anisotropy; MD, mean diffusivity; GRE, gradient recalled echo; FLAIR fluid 
attenuated inversion recovery; ROI, regions of interest; PCS, post-concussion symptoms; SWI, susceptibility weighted imaging; SAC, 
Standardised Assessment of Concussion; SNTF, calpain-cleaved αII-spectrin N-terminal fragment; ADC, apparent diffusion 
coefficient; TBSS, Tract-Based Spatial Statistics; GAMMA, Graphical-model-based Multivariate Analysis; LOC+, loss of 
consciousness at time of injury; LOC-, no loss of consciousness at time of injury; WMTI, white matter tract integrity. 
*Voxelwise analysis allows identification of abnormal regions without pre-specifying the region. 
**Compartment specific white matter tract integrity metrics include measures of microstructural characteristics in intra- and extra-
axonal environments of white matter including the axonal water fraction; intra-axonal diffusivity along axons; extra-axonal AD; extra-
axonal RD; and the derived tortuosity of the extra-axonal space. 





A possible objective and reproducible abnormality detectable in patients with 
mild TBI could be alterations in cerebral blood flow. There is evidence from 
animal models that after a traumatic brain injury there are regional ischaemic 
areas and regions of reduced blood flow.148,149 This is supported by the finding 
that in 21 patients with mild TBI, there was significantly lower cerebral blood 
flow to the thalamus compared with controls (Table 1.6).150 The thalamus is a 
complex deep grey matter structure consisting of multiple groups of nuclei and 
white matter tracts. It acts as a relay station for transmitting information around 
the brain and is particularly vulnerable to acceleration-deceleration injury.150 
However this study was performed on average more than two years after injury. 
Lower cerebral blood flow was also seen in the cerebellum, cuneus, anterior and 
middle cingulate and middle temporal gyri in patients with mild TBI on average 
four months after injury.151 In patients with mild TBI assessed on the day of 
injury, low cerebral blood flow was also described, as was low cerebral blood 
volume and increased blood mean transit time, in the frontal and 
frontotemporal regions.152 Similarly in 18 concussed American football players, 
there was reduced cerebral blood flow in the supplementary and pre-
supplementary motor areas on the day of injury.132 Furthermore, when assessed 
eight days after injury there was reduced cerebral blood flow in multiple cortical 
regions and the hypothalamus. Several other studies also report reduced 
cerebral blood flow in patients with mild TBI, in deep structures including the 
insula and thalamus, and in cortical regions including frontal, temporal, parietal 
and occipital lobes.132,153-155 




Although most studies describing cerebral blood flow in patients with mild TBI 
report it to be reduced, some report increased cerebral blood flow, and this 
discrepancy does not seem to be related to time from injury to scan. In 14 
patients with mild TBI who were scanned on average 31 hours after injury, 
cerebral blood flow was increased in the left striatum, and particularly in the 
caudate, putamen, and pallidum.156 The authors postulated that the unexpected 
increase in cerebral blood flow could be an early change in physiology associated 
with mild TBI since the patients were scanned so early. This theory is not 
supported by prior or subsequent evidence. Only one other study reported 
increased cerebral blood flow, and this was in athletes from several sports that 
had suffered a concussion. In this study, increased cerebral blood flow was 
found in posterior brain structures, including the cerebellum and occipital 
lobe.157 
Few studies describe an association between clinical outcomes and changes to 
cerebral blood flow. Reduced cerebral blood flow in the frontal and occipital 
lobes correlated with increased nausea and dizziness at 12 days after injury.153 
Conversely in concussed athletes, increased posterior cerebral blood flow was 
associated with higher symptom scores.157 Low cerebral blood flow in the frontal 
and frontotemporal regions was associated with lower executive function and 
lower social cognitive function.152 




Reference Number/condition Imaging technique &  
Regions of interest scanned 
Timing of MRI Findings (change 
compared with 
control) 




21 (mild TBI) 
20 (control) 
Conventional & ASL 
Bilateral thalamus, putamen, heads 
of caudate nuclei, frontal grey 
matter & white matter 
24.6 months Reduced CBF 
 
Left & right thalamus. 
Reduced thalamic CBF significantly correlated with 




27 (mild TBI) 
11 (control) 
T1, T2, fMRI, DTI, SWI, spectroscopic 
and DSC perfusion imaging. 
DSC images acquired using 
gadolinium & manually & automatic 
arterial input function calculation. 
113 ± 74 days Reduced CBF Left cerebellum, left cuneus, right anterior 








Patients with lower executive function had lower 
perfusion (lower CBV) in the right frontal white 
matter, & right and left frontotemporal white 
matter.  
Patients with poorer social cognitive function had 
lower perfusion (higher MTT) in bilateral frontal 
white matter, and (lower CBF) in left parieto-




14 (mild TBI) 
18 (control) 
SWIM, ASL Median 31 hours 






Increased blood oxygenation in left thalamostriate 
vein & right basal vein of Rosenthal. 
Increased CBF in the left striatum, particularly the 











Mean 1.4 days, 
8.7 days, & 31.5 
days. 
Reduced CBF Right dorsal mid-insular cortex and right superior 
temporal cortex at first time point compared to 
follow up and compared to non-concussed 
athletes. 




23 (mild TBI) 
22 (control) 
ASL 
ROI in bilateral frontal, parietal, 
temporal, & occipital lobes, bilateral 
anterior, middle & posterior 
cerebral artery & posterior 
cerebellar artery territories. 
Mean 12 days. Reduced CBF Bilateral frontal cortices and left occipital cortex. 
Left frontal lobe CBF correlated with dizziness & 
nausea. Right frontal lobe & left occipital lobe CBF 
correlated with nausea. 













ASL <24 hours and 8 
days 
Reduced CBF Right supplementary motor area and pre- 
supplementary motor area regions at 24 hours. 
Cortical grey matter, in bilateral prefrontal regions, 
temporal lobes, parietal regions, & thalamus at 8 
days 





35 (athletes with 
concussion) 
35 (athletes without 
concussion) 
ASL 1 to 7 days Increased CBF 
 
Superior cerebellum, occipital lobe and cuneus. 









ASL 24-48 hours Reduced CBF  Left inferior parietal lobule, right supramarginal 
gyrus, right middle frontal gyrus, posterior 
cingulate cortex, left occipital gyrus, and thalamus. 
Table 1.6. Studies reporting cerebral blood flow in mild TBI 
MRI, magnetic resonance image; TBI, traumatic brain injury; ASL, arterial spin labelling; CBF, cerebral blood flow; fMRI, functional 
magnetic resonance image; SWI, susceptibility weighted imaging; DSC, Dynamic susceptibility contrast; CT, computed tomography; 
CBV, cerebral blood volume; MTT mean transit time; SWIM, susceptibility weighted imaging and mapping; ROI, region of interest.




Functional neural network injury 
Resting state functional MRI can be used to describe interactions between 
networks of neural regions. These interactions can be described using 
neurophysiological indices which correlate when measured at the same time in 
different brain areas.158 The interaction is calculated by determining functional 
connectivity, defined as “The temporal correlation of a neurophysiological index 
measured in different brain areas”.159 One resting state network is the Default 
Mode Network and another the Task Positive Network, also known as the 
executive network. The default mode network consists of several regions 
including the anterior and posterior cingulate cortices, lateral parietal cortex, 
and the medial prefrontal cortex.160,161 These are active during resting state 
conditions but consistently deactivated during task-based activity.162 In contrast 
to the default mode network, the task positive network includes the dorsolateral 
prefrontal cortex and posterior parietal cortex and is operative during externally 
directed activity.163 In patients with mild TBI, the default mode network is not 
affected in the acute phase, but in the chronic phase there is increased resting-
state functional connectivity.158 Consistent with this, in patients with ongoing 
post-traumatic complaints, there is higher functional connectivity between the 
anterior and posterior elements of the default mode network, which was 
associated with a higher number of post-traumatic complaints at three 
months.164 The authors speculated that relatively higher functional connectivity 
in the default mode network in patients with mild TBI could reflect ongoing 
internally focused mental activity including thoughts about the injury and 
recovery. Furthermore, since the default mode network is associated with 
spontaneous thought processes like daydreaming and envisioning past and 




future events, activation of the default mode network may present a barrier to 
recovery or response to therapy in patients with mild TBI.164-166 
In summary, diffusion tensor imaging and arterial spin labelling, two relatively 
recent imaging techniques, hold promise for developing an objective and 
consistent measure of mild TBI. Based on these techniques, deep brain 
structures appear to be injured more frequently than superficial structures. 
Furthermore, tests of cerebral autoregulation, which are relatively cheap and 
non-invasive, may also be correlated with symptoms and predictive of 
outcomes. Association and correlation with clinical outcomes have been 
inconsistently described in several mild TBI populations including patients 
identified in the Emergency Department and individuals that have experienced 
sports related concussion. Further development of these procedures may result 
in a test for mild TBI. 
  




Neurocognition in mild traumatic brain injury 
Symptoms following mild TBI 
The burden of symptoms that patients experience following a mild TBI cause 
the most significant impact on quality of life. The constellation of symptoms is 
complex and includes pain and cognitive dysfunction. In 538 patients with mild 
TBI, persistent headaches were the most common symptom (79%), followed by 
memory problems (59%).3 In 145 patients with concussion, 51% had one or more 
symptoms six weeks later, the most common of which was headache (24%), 
followed by anxiety (19%), insomnia (15%) and dizziness (14%).10 Patients with 
mild TBI also have more disturbed sleep than patients with severe TBI.167 In 689 
patients with mild TBI, more than half had one or more symptoms at three 
months after injury, and the most common symptoms were fatigue, sleep 
disturbance and headaches.11 In 123 patients with mild TBI, at one week the 
most common symptom was also fatigue, followed by headache.12 In 94 patients 
with mild TBI, headache, followed by fatigue, dizziness, and taking longer to 
think, were the most common symptoms both in the Emergency Department 
and at one month follow-up.13 Loss of consciousness at the time of injury, and 
post-traumatic amnesia following injury, are both associated with recovery 
times following mild TBI of over one week.168 
Cognitive difficulties following mild TBI 
Mild TBI causes difficulty in thinking. Broadly there are two ways of objectively 
assessing subjective cognitive deficits; using self-report scores, and specific tests 
of neurocognitive function. The domains which these assessments occupy are 
numerous, and include assessments of fatigue,169 stress,169 depression,74 




symptoms,170 intelligence,171 memory,172 learning,173 attention and executive 
function,173 processing speed,174 and reasoning.172 
In 57 patients with minor head injury, memory and information-processing was 
reduced at baseline but improved to the same level as a control group by three 
months.175 In 62 patients with concussion, attention, measured three times in 
the Emergency Department, was persistently reduced compared to normal 
levels.176 In 25 Emergency Department patients with mild TBI, visual motor 
speed and reaction times were low compared with controls, but there was no 
difference in the other two assessment domains, verbal and visual memory.177 
In an assessment of patients with severe burns injuries, grouped into those with 
mild TBI and those without, the mild TBI group had significantly worse 
processing speed.178 In 123 patients with mild TBI, visual memory was 
significantly worse in the Emergency Department at one week, and at three 
months, compared with non-head injured controls.12 In 29 patients with mild 
TBI, immediate and delayed memory was worse than non-head injured 
controls, and head injured patients also had significantly worse symptoms 
scores.179 Even when symptoms resolve however, neurocognitive dysfunction 
may persist. In athletes with mild TBI, the mean time to become asymptomatic 
for concussion was 6 days, but 38% of asymptomatic athletes had ongoing 
neurocognitive deficits.180 
The time taken for resolution of neurocognitive deficits is unclear and reports 
vary from just over a week to six months or more. In 28 athletes with concussion, 
neurocognitive function resolved by day eight following injury, and in 400 
athletes with a history of concussion but no concussion within six months 
preceding assessment, there was no measurable neurocognitive deficit, 




implying that the neurocognitive deficit completely resolves by six months.181,182 
In contrast, in 94 Emergency Department patients with mild TBI, 63% still had 
concussive symptoms at follow up a month later, and in a separate cohort of 795 
Emergency Department patients with mild TBI, most had concentration and 
memory disorders six months later.13,183 In a large literature review that 
included 120 articles, cognitive defects and post-concussion symptoms had 
resolved in the majority by three to twelve months.184 Furthermore, in those 
patients in which resolution had not occurred, only litigation was identified as a 
factor associated with ongoing symptoms. 
Age as a factor in predicting severity of outcome following mild TBI remains 
controversial. In 190 patients with TBI there was no difference in neurocognitive 
function of mild TBI cases of greater and lesser age, indicating that age may not 
be an important predictor of neurocognitive function following mild TBI.185 
However, in a separate cohort recruited from the Emergency Department older 
and younger patients did have greater symptom severity and number than a 
middle group aged 35-54 years at three month follow up.11 TBI can also increase 
the risk of developing psychiatric sequelae. Having a history of three or more 
concussions is associated with a three times increased chance of being 
diagnosed with depression than having a history of no concussions.186 In a 
comparison of patients with dementia that had and had not sustained a TBI 
there was an increased risk of dementia in the group that had previous TBI.187 
Mild TBI following motor vehicle collision predisposed to a range of psychiatric 
disorders including personality disorder, persistent altered consciousness, post-
traumatic stress and psychodynamic reactions to impairment.188 




There is also an association between having post-concussion symptoms and 
having a neurocognitive deficit. Following a mild TBI, patients with symptoms 
perform more poorly on neurocognitive testing than patients without, although 
patients without symptoms may still perform more poorly than controls.189 
Athletes with mild TBI that take more than ten days to become asymptomatic 
also have poorer neurocognitive function compared with athletes with mild TBI 
that recover within ten days.190 Conversely, the absence of premorbid physical 
problems, low levels of post-concussion symptoms, and no post-traumatic 
stress early after injury are associated with low levels of late post-concussion 
symptoms.169 Similarly, having been educated for 11 years or more, the absence 
of nausea or vomiting, no additional extra-cranial injuries and low levels of pain 
early after injury are associated with a 90% chance of full return to work.169 
Assessment of cognitive function and symptoms in the acute phase 
In 1997, the American Academy of Neurology published guidelines on the 
management of concussion in sports and within it was a call for a standardised 
assessment of concussion.191 In response, an examination containing 
assessments of orientation, immediate memory, concentration and delayed 
recall was devised, and termed the Standardized Assessment of Concussion 
(Appendix 2).192 This is a 30 point tool with higher scores indicating better 
neurocognitive function (Table 1.7). An initial evaluation found differences 
between American football players with concussion and those without of 4.2 
points, with most of the difference being in the immediate memory domain.192 
Validation usually takes the form of a larger set of baseline SAC scores, 
performed on all players, and a smaller set of post-concussion scores, taken only 
from head injured players. The tool was validated in several studies that 




included concussed and non-concussed athletes. There were differences 
between concussed and non-concussed players of 3.7 points, and all domains 
were significantly different between the two groups.193-200 Importantly, a 
decrease of 1.7 points was calculated to be sufficiently sensitive and specific to 
discriminate between concussed and non-concussed groups. Since this is an 
aggregate score, and an individual cannot score a fraction of a point, a change 
of 2 points can be taken as being clinically significant. This was confirmed in a 
review that concluded a change of two to four points was the most common 
change seen before and after injury.201 The first validation in patients rather 
than athletes was from a mild TBI clinic associated with the US military.202 
Crucially, the assessment was not performed at the time of the head injury, but, 
on average 100 to 135 hours after injury. SAC scores were lower by 2.65 points 
in patients that had post-traumatic amnesia compared to those that hadn’t, but 
absolute scores were not reported. The first investigation of the SAC in the 
Emergency Department was on 62 patients with concussion and negative CT 
head scan (Table 1.7).176 Measurements were made at arrival then at three and 
six hours, and cognitive function improved from 21.0 to 23.5 points over six 
hours. In a second study of Emergency Department patients, the SAC was 
performed a median of 30 hours after injury and at one month follow up. 
Included patients had mild TBI (WHO definition) and orthopaedic injuries, the 
latter recruited as a non-head injured comparison group. At baseline, the SAC 
in the mild TBI group was 25.3, which improved by 1.4 at follow-up one month 
after injury.203 These patients also differed from the comparison group, which 
had an average initial SAC score 2.4 points higher that mild TBI patients, at 27.3 
points. These results were partly replicated in a small study of 26 Emergency 
Department patients with mild TBI and 33 patients with ankle injury, recruited 




as a comparison group. 204 In this study, the SAC was measured only once. 
However, the time of measurement was different in the two groups; in the mild 
TBI group the SAC was measured in the Emergency Department, but in the 
ankle injury group it was measured 1-2 years after the injury. The mild TBI and 
ankle injury groups had average SAC scores of 26.00 and 27.7 respectively. In 
the first assessment the SAC in mild TBI patients grouped by CT scan 262 
patients were recruited into four groups; CT positive (acute trauma related 
pathology visible on CT), CT negative (no acute abnormality on CT), healthy 
non-injured group comparator, and a comparison group that had sustained 
musculoskeletal injuries.205 A single measurement was taken in the Emergency 
Department. The CT positive, CT negative, musculoskeletal injury, and healthy 
controls scored 21.4, 22, 24.3, and 26 respectively. In this study the key 
eligibility criterion for the head injured groups was that the patient warranted a 
CT scan. This excludes patients with head injuries and potentially mild TBI, that 
are less injured, and therefore the results may be biased. They are also similar 
to those noted above in which only patients with negative CT were included.176 
A study was therefore performed to determine whether positive findings on a 
CT will always reduce the SAC, and only patients with positive CT scans were 
recruited.206 The average SAC score was 22.6 but when the cohort was split into 
a group with the SAC ≥25 and <25, the average scores were 26.1 and 20.2 
respectively, indicating that the SAC alone cannot discriminate between a 
positive or negative head scan. This finding was replicated in an almost identical 
study in which only patients with positive CT scans were recruited.207 In this 
study, the mean SAC score was 20.8 and when the patients were split into SAC 
≥25 and <25 groups, the respective scores were 26.4 and 19.0. The scores in this 
study are worse than in the previous study of CT positive patients, and this may 




be because the proportion of patients with more severe intracranial 
haemorrhages was higher in the study with worse scores. The interpretation of 
these studies is that the SAC can be used in an Emergency Department 
population, and that it does not in isolation identify structural injury seen on CT 
scans.




Reference Setting Number mild TBI (%) Number uninjured Baseline Post-injury Difference 
McCrea192 1997 High school American football  6 (4) 141 25.6 21.5 (sideline) 4.1 
McCrea193 1998 High school and college 
American football  
33 (6) 568 26.6 22.9 (sideline) 3.7 
Daniel195 2002 US Navy American football 21 (7) 298 27.9 24.5 (sideline) 3.4 
McCrea197 2003 College American football 94 (6) 1631 27.6 24.7 (sideline) 2.9 
Naunheim176 2008 ED patients with concussion & 
CT-ve 
62 --- --- 21.0 (arrival) 
22.7 (3 hrs) 
23.5 (6 hrs) 
1.7 (0-3 hrs) 
2.5 (0-6 hrs) 
Luoto203 2014 ED patients with mild TBI 49 --- --- 25.3 (0-120 hrs) 
26.7 (1 month) 
1.4 
Silverberg204 2014 ED patients with mild TBI 26 --- --- 26.0 (in ED) --- 
O’Neil206 2014 ED patients with head injury, 
GCS > 8 & CT performed 
66 
25 (SAC ≥25) 
41 (SAC <25) 
--- --- 22.6 (in ED) 
26.1 (SAC ≥25) 
22.2 (SAC <25) 
 
--- 
Bin Zahid205 2018 ED patients with head injury 










All in ED 
--- 
Curley207 2018 ED patients with mild TBI & CT+ 191 
46 (SAC ≥25) 
145 (SAC <25) 
--- --- 20.8 
26.4 (SAC ≥25) 
19.0 (SAC <25) 
<72 hrs after injury 
--- 
 
Table 1.7 Derivation and validation studies of the Standardised Assessment of Concussion (SAC) 
Hrs, hours; CT, computed tomography; CT-ve, no acute haemorrhage on CT; CT+ve, acute haemorrhage on CT; ED, Emergency 
Department; GCS, Glasgow Coma Scale; LOC, loss of consciousness; OI, orthopaedic injury (non-head injured); NI, no injury.




Differences between females and males 
Females seem to have poorer neurocognitive and symptom outcomes 
following mild TBI. Among 155 athletes with mild TBI, females had 
significantly worse reaction times, were more cognitively impaired and 
reported more post-concussion symptoms than males.208 In another study of 
athletes with mild TBI, females had higher numbers of symptoms and poorer 
visual memory, but better verbal memory than males.209,210 In Association 
football players with concussion, females also had a significantly greater 
neurocognitive deficit than males.211 The trend for more symptoms in female 
patients than males is also seen in injuries not related to sports. In Emergency 
Department patients with mild TBI, females were three times more likely than 
males to develop acute post-concussion syndrome, and in another study in the 
Emergency Department females had greater symptom severity than 
males.11,212 In 1425 patients with mild TBI, females had greater odds than 
males of having post-concussion symptoms.213 In another study females with 
mild TBI performed worse in visual memory but equally in four other 
neurocognitive domains.214 Of note, phase of menstrual cycle has not been 
shown to have influence on neurocognitive function.215 However, in athletes 
with more than one prior concussion, females had better verbal and visual 
memory, and were better overall on processing speed and reaction times 
compared with males, suggesting that the apparent poorer outcomes in 
females may be reversed when there is a history of prior concussion.216 
Importance of repeated head injuries 
A mild TBI in a patient with a history of prior concussion results in poorer 
neurocognitive performance than in a patient that has never had a concussion. 




Occasionally the consequences of a repeat injury can include cerebral oedema 
and be devastating. This is often called ‘second impact syndrome’ and was first 
described in 1984.217 However, the existence of second impact syndrome is 
controversial.218 It is undisputed that a head injury can result in brain 
swelling.219 It is not clear that a second concussive head injury is a risk factor 
for this. The evidence for second impact syndrome is based on anecdotal case 
reports. The case reports are dependent on team mates recalling whether 
players had previously sustained a concussion, and are therefore subject to 
recall bias.220 In a structured review of potential cases of second impact 
syndrome, 17 published cases were assessed and none were found to be 
‘definitely second impact syndrome’. Five were ‘probable’ and 12 were not 
second impact syndrome.220 Whilst catastrophic cerebral oedema may not be 
a direct consequence of a second concussion, athletes with a history of two or 
more mild TBIs that sustained a further mild TBI have had recorded poorer 
memory and reaction times at day five, compared with those that had no 
history of previous mild TBI.221 Complete resolution of symptoms and 
neurocognitive deficit may also be prevented by repeated concussions, which 
also can increase the risk of mild cognitive impairment in later life. In a study 
of retired American football players, compared to players with no prior 
concussions, players with a history of three or more concussions had a five 
times higher prevalence of mild cognitive impairment and three times greater 
prevalence of significant memory problems.222 Having a history of three or 
more concussions is also associated with a three times increased chance of 
being diagnosed with depression.186 Having prior concussions even increases 
the risk of sustaining a further concussion. American football players with 
previous mild TBI are three times as likely to sustain a further mild TBI than 




those with no history of previous concussion.223 Second impact syndrome is 
also described in resources provided for England Rugby Football Union 
players, including children and coaches, and the recent rule change that 
mandates two weeks off play and graduated return to play following 
concussion is in part based on poorer outcomes associated with repeated 
concussions. 
Importance of intracranial haemorrhage 
Mild TBI with acute intracranial abnormalities on CT scan, namely extra-dural 
haemorrhage, sub-dural haemorrhage, contusion, intra-parenchymal 
haemorrhage or intra-ventricular haemorrhage, is termed ‘complicated mild 
TBI’. Complicated mild TBI is associated with increased risk of poorer 
outcome. In 150 patients with mild TBI, those with complicated mild TBI had 
worse neurocognitive outcomes in three domains including information 
processing and memory at one to three months following injury, compared 
with uncomplicated mild TBI.224 Complicated mild TBI is also associated with 
longer times to return to pre-injury employment levels compared with 
uncomplicated mild TBI, and is the primary predictor of memory and 
emotional complaints.171,225 However, having an acutely abnormal CT scan 
does not necessarily result in poor neurocognitive function. In 191 patients 
with mild TBI and acute haemorrhage on CT, 25% had normal neurocognitive 
function and were GCS 15.207 Some studies have found that neurocognitive 
outcomes in complicated mild TBI and moderate TBI are so similar that there 
is a call to consider the two entities as the same, whereas others report poorer 
neurocognitive function in patients with complicated mild TBI in the acute 




phase but slower improvement in patients with uncomplicated mild TBI over 
time.226,227 
Sports related concussion 
The Professional Rugby Injury Surveillance Project is an ongoing project 
running within the English Rugby Football Union. It has found that the 
likelihood of a player sustaining any injury is 62/1000 player-hours. The most 
common injury is concussion with a rate of 15.8/1000 player-hours, which 
resulted in a mean time off play of 13 days. Head high tackles account for a 
large number of concussions.228 The Rugby Football Union has changed the 
rules surrounding play following a head injury for both adults and children, 
which now state that after a concussion, players can only return to play after 
two weeks following the injury and only if they are symptom free. At that point 
their return to play must be graduated, both in time and activity.229 
Concussions sustained playing rugby football most commonly involve 
amnesia, headache and unsteadiness but rarely loss of consciousness. Players 
also exhibit poorer memory and poor attentional task function, compared with 
themselves pre-injury, and compared with controls.230 
In Association football players that ‘head’ the ball, those that had the highest 
heading frequency and that had headed the ball within the last seven days 
exhibited the poorest neurocognitive function.231 However, in players divided 
into ‘low exposure headers’, ‘intermediate exposure headers’, and ‘high 
exposure headers’ groups, there were no differences in neurocognitive 
function.232 
In a landmark study, the prevalence of concussion in American football players 
was found to be 6.3%.223 The most common symptom players experienced was 




headache, and the mean symptom duration was three days. In another study, 
neurocognitive function had returned to normal by three days, and balance 
control by five days.197 By seven days, 91% of concussed athletes were symptom 
free. In players that required seven or more days out of play following 
concussion, the most common signs and symptoms were disorientation to 
time, retrograde amnesia, and cognitive defects.233 American footballers that 
have had a concussion in the past also have a high risk of sustaining a repeat 
concussion; 16.5% in players with previous concussion versus 2.9% with no 
previous concussion in one study, and of the 5.1% of players that sustain a 
concussion, 15% sustained a repeat in another study.234,235 Neurocognitive 
function is significantly worse in players that have sustained a concussion 
compared to those that haven’t.192 In this study, neurocognitive function was 
measured on the SAC, and there was a 4.1 point difference between controls 
(25.6 points) and concussed players (21.5 points). Most affected were the 
immediate and delayed recall elements of the memory domain. In a separate 
group of American football players, there was again a significant difference in 
neurocognitive function measured on SAC between non-concussed (26.6 
points) and concussed players (22.9 points).193 There was also a significant 
drop between pre-injury baseline score (26.3 points) and immediate post-
injury testing (22.8 points) within the concussed group, however scores 
returned to normal within 48 hours of injury. In this study no single domain 
was responsible for the deficit and all four contributed.  




Biomarkers in acquired brain injury 
Patients that have sustained a head injury are at risk of a TBI. Outcomes 
following TBI are varied and include persistent symptoms, reduced capacity to 
perform tasks that they could previously perform, and new mental health 
diagnoses. Being able to stratify patients on the day of injury to high and low 
risk groups for various outcomes is of critical importance. An established way 
of stratifying patients is to perform a non-contrast CT head scan. If a patient 
fulfils criteria for mild TBI and has acute abnormalities on CT, then they may 
have poorer outcomes in the future. However, performing CT scans is 
expensive, time and resource consuming, and delivers radiation to patients 
with a cumulative increased lifetime risk of malignancy.236 An alternative to an 
initial diagnostic or prognostic step of doing a CT scan is to stratify patients 
based on blood-based biomarkers, which may be elevated in physiological 
states or clinical conditions. A commonly utilised diagnostic strategy is to treat 
the biomarker as a screen. In this strategy, biomarker levels are dichotomised 
into a positive or negative category, and the disease ‘ruled out’ based on a 
negative biomarker result. However, in this strategy, the disease is not ‘ruled 
in’ based on a positive biomarker result. Instead, a second diagnostic test is 
then used, usually a CT scan. In mild TBI research the disease that is screened 
for may be present on the day of the injury, for instance a positive result on the 
CT, or simply having mild TBI. In those disease cases the converse must be 
possible too. Consequently, if the research is investigating CT positives for 
‘disease present’ then there must be a population who are CT negative. 
Similarly, if the research is investigating whether biomarkers can identify mild 
TBI, then there must be a population without mild TBI. In mild TBI research 




these groups are usually either healthy volunteers or patients with 
musculoskeletal injuries below the clavicle. These groups act as controls. The 
disease of interest may however only be definable some months after the 
injury. An example of this is post-concussion syndrome, which is defined as 
being present three months after injury. Another example is simply a ‘good’ 
versus ‘not good’, or ‘poor’ versus ‘not poor’ outcome, defined by a 
dichotomised Glasgow Outcome Scale-Extended score. 
Biomarkers in mild TBI reflect pathophysiological areas of the brain micro-
architecture from which the biomarker molecules derive. These include axons, 
dendrites, neuronal cell bodies, myelin sheaths, synapses, astroglia and 
microglia (Figure 1.8).237-239 Biomarkers can also be isolated from serum, 
cerebrospinal fluid and saliva. In clinical practice, cerebrospinal fluid 
biomarkers are measured in patients with severe TBI who are cared for on a 
critical care unit and who have an extra-ventricular drain placed. Salivary 
biomarkers are researched but not used in clinical practice.240 I have therefore 
limited this review to serum biomarkers.  
A search of the PubMed database using the terms 
((((((((((((biomarker[Title/Abstract]) OR S100B[Title/Abstract]) OR 
Ubiquitin C-terminal hydrolase-L1[Title/Abstract]) OR UCH-
L1[Title/Abstract]) OR Neurone specific enolase[Title/Abstract]) OR 
NSE[Title/Abstract]) OR neurofilament[Title/Abstract]) OR Glial fibrillary 
acidic protein[Title/Abstract]) OR GFAP[Title/Abstract]) OR spectrin 
breakdown product*[Title/Abstract]) OR tau protein[Title/Abstract])) AND 
((((((mtbi[Title/Abstract]) OR mild tbi[Title/Abstract]) OR mild traumatic 
brain injury[Title/Abstract]) OR concussion[Title/Abstract]))) was performed 




for this narrative review and identified 454 articles. Relevant references of 
included articles were also included.  
 
 
Figure 1.8. Sites of biomarker source 
UCH-L1, ubiquitin C-terminal hydrolase L1; NSE, neurone specific enolase; GFAP, 
glial fibrillary acidic protein; NF, neurofilament; SBDPs, spectrin breakdown 
products. 
 
Neuronal cell body injury 
Ubiquitin C-terminal hydrolase-L1 (UCH-L1) 
Ubiquitin is a protein that combines singly or as chains to target proteins, 
thereby altering their function.241 Ubiquitin is essential for almost all processes 
in cells.242 The process of removing a ubiquitin from a substrate protein is 
mediated by a group of enzymes called deubiquitinases, of which UCH-L1 is a 
member. UCH-L1 is found predominantly in the brain where it makes up as 
much as 5% of all neuronal protein, but is also present in the gonads and 
weakly present in fibroblasts that are active in wound healing.243 UCH-L1 has 




been investigated as a biomarker of potential use in mild TBI since 2012 and 
has shown promise in discriminating between patients with and without 
intracranial abnormality on CT (Table 1.8). 
In 206 Emergency Department patients with predominantly mild TBI, UCH-
L1 was higher in patients with moderate or severe TBI compared to those with 
mild TBI, and was higher in patients with mild TBI with acute intracranial 
abnormality on CT compared to those without.244 UCH-L1 had only moderate 
ability to discriminate between CT positive and negative patients (AUC 0.67), 
poor ability to discriminate between complete and incomplete recovery 
(GOSE-E 8 vs < 8) at three months (AUC 0.59), but good ability to 
discriminate between poor and not poor outcome (GOSE-E ≤ 4 vs > 4) (AUC 
0.8). When UCH-L1 and GFAP were taken together, there was improved 
discrimination with the combined biomarker panel (compared to either one 
alone) in discriminating between healthy volunteers and TBI patients, and at 
discriminating between poor and not poor outcomes at three and six months. 
However, since the cohort studied included all grades of TBI, it is not possible 
to extrapolate based on this study alone that UCH-L1 or even UCH-L1 and 
GFAP is predictive in a mild TBI cohort. In a study of 96 Emergency 
Department patients, UCH-L1 was significantly higher in mild to moderate 
TBI compared with 176 healthy volunteers and 23 ‘control’ Emergency 
Department patients.245 Within the TBI group, UCH-L1 was also significantly 
higher in patients that had an acute intracranial abnormality on CT scan. At a 
threshold of 0.09 µg/L, UCH-L1 had a sensitivity of 100% and specificity of 
21% for an abnormality on CT. In a further study of 247 Emergency 
Department patients with head injury, UCH-L1 was significantly different in 




the three groups of no TBI, CT negative mild TBI, and CT positive mild TBI.246 
However, the AUC to discriminate between groups was moderate at 0.65 for 
mild TBI versus no TBI and 0.60 for uncomplicated mild TBI versus no TBI. 
In a landmark study that included 584 trauma patients, 325 had mild to 
moderate TBI, and 259 were classified as “trauma controls” (and had no 
TBI).247 This study is important because the investigators describe serum 
concentration with time; UCH-L1 and GFAP were measured at 19 time points 
after injury, from the first one at less than four hours from injury to the last at 
180 hours after injury. In TBI patients, UCH-L1 peaked at enrolment and was 
significantly higher than trauma control patients until 16 hours after injury. At 
enrolment, UCH-L1 discriminated well between patients with and without 
acute intracranial abnormality on CT (AUC 0.77), and moderately between 
patients with TBI and controls (AUC 0.66).  
In a second landmark study, UCH-L1 and GFAP were measured in 1959 
patients with mild or moderate TBI (<1% had moderate TBI), of whom 125 
(6%) had an acute intracranial abnormality on CT scan.248 Prespecified 
thresholds for ‘positivity’ were determined as 0.327 µg/L for UCH-L1 and 
0.022 µg/L for GFAP. Together the sensitivity for an intracranial abnormality 
was 97% and the negative predictive value (NPV) was 100%. UCH-L1 alone 
had a sensitivity of 70% and NPV of 97%. There were three false negatives 
(patients whose blood tests were negative, but scans were positive), all of 
whom presented with a GCS of 15, and none of whom underwent 
neurosurgery. These data were the first considered to be of genuine clinical 
value and sufficiently so that the US Food and Drug Administration (FDA) 
authorised marketing of the platform used to assay UCH-L1 and GFAP in this 




trial.249 In 166 patients 73 of whom had musculoskeletal injuries and 93 of 
whom had mild TBI, there was no difference in UCH-L1 levels on the day of 
injury (0.40 µg/L and 0.41 µg/L respectively).250 
UCH-L1 has been shown to have some value in sports concussion. In 34 
concussed high school and college American football players, UCH-L1 was 
significantly higher within six hours of injury (0.204 µg/L) compared to 
preseason baseline (0.139 µg/L) and to non-concussed players (0.101 µg/L), 
with an AUC of 0.74 to discriminate between concussed and non-concussed 
players.251 After the six hour measurement, UCH-L1 then trended down such 
that at 48 hours after the concussion, it was lower (0.097 µg/L) than measured 
before the sports season had started. Similarly, in six American football 
players that sustained a high impact head injury, defined as a linear 
acceleration of > 95g and a rotational acceleration > 3760 rad/s2 as measured 
by helmet-based accelerometers, UCH-L1 had increased more than five times 
than the pre-game level baseline (0.18 µg/L to 0.94 µg/L).252 In players that 
had low impact or no head injury UCH-L1 increased too, but significantly less 
(less than three times, from 0.23 µg/L to 0.69 µg/L). The rise in the exercised 
non-head injured players is mirrored in a group with musculoskeletal injuries 
but no head injury.  
 
   





















38 62 LLOD 0.03 µg/L UCH-L1 in TBI vs non-injured controls vs 
non-head injured patient controls. 
UCH-L1 in CT+ vs CT- TBI patients. 
UCH-L1 higher in TBI (0.96 µg/L) vs all 
controls (0.08 µg/L) 
UCH-L1 higher in CT+ (1.6 µg/L) vs CT- (0.6 
µg/L) 
AUC 0.87 for TBI vs controls 






171 (mild TBI) 
8 (moderate TBI) 
27 (severe TBI) 
42 73 LLOD 0.03 µg/L UCH-L1 in moderate & severe TBI vs mild. 
UCH-L1 in CT+ mild TBI vs CT-. 
UCH-L1 to predict GOS-E at 3 months. 
43% of mild TBI patient CT+ 
UCH-L1 higher in moderate/severe TBI (0.5 
µg/L) vs mild TBI 
UCH-L1 higher in CT+ mild TBI (0.23 µg/L) vs 
CT- mild TBI (0.18 µg/L) 
AUC 0.67 for CT+ vs CT- 
AUC 0.57 for GOS-E 8 vs < 8 (complete 
recovery) 







406 (mild TBI) 
465 (Ctrl) 
NS NS ROD 0.056 to 10 
µg/L 
UCH-L1 & S100B in subconcussive head 
impact in American Football players. 
Compare with ED based mild TBI & healthy 
controls. 
No difference in UCH-L1 between mild TBI 
(0.09 µg/L) vs ctrls (0.09 µg/L 
No difference in UCH-L1 between mild TBI 






325 (mild & moderate 
TBI) 
259 (trauma, no TBI) 
40 62 LLOD 0.045 µg/L UCH-L1, GFAP & both to discriminate 
between CT+ & CT- at 19 time points after 
injury. 
UCH-L1 peaked at initial sample (mean 3 
hours after injury) 
UCH-L1 higher in TBI (0.26 µg/L) vs controls 
(0.17 g/L) 






20 (mild TBI) 
20 (Ctrl) 
30.5 90 ROD 0.2 to 30 µg/L 
 
UCH-L1 & S100B in mild TBI vs healthy 
volunteer controls. 
UCH-L1 & S100B to predict cognitive deficits 
at 3 months. 
No difference in UCH-L1 between mild TBI 
(4.43 µg/L) vs ctrls (4.65 µg/L) 
Weakly positive correlation between UCH-
L1 & 1 of 12 neuropsychological tests at 3 
months 
       







154 (CT- mild TBI) 
34 (CT+ mild TBI) 
59 (HI no TBI) 
46 60 LOD 0.01 µg/L UCH-L1 to discriminate between head 
injured patients with & without mild TBI 
UCH-L1 to discriminate between mild TBI 
CT+ & CT- 
UCH-L1 higher in CT+ (0.132 µg/L) vs CT- 
(0.064 µg/L) vs HI no TBI (0.043 µg/L) 









44 55 Limits of 
quantification: 
0.3-50 µg/L 
UCH-L1 & GFAP to discriminate between 
mild TBI CT- & no TBI extracranial 
musculoskeletal injuries. 
No difference between UCH-L1 in mild TBI 
CT- (0.40 µg/L) & patients with extracranial 





(CT- mild & mod. TBI) 
125 
(CT+ mild & mod. TBI) 
49 57 ROD 0.08-2.56 µg/L Determine NPV & sensitivity of UCH-L1 & 
GFAP for CT+. 
UCH-L1 higher in CT+ (0.60 µg/L) vs CT- 
(0.26 µg/L) 
Using a threshold of 0.327 µg/L: 
UCH-L1 alone; sensitivity 70% & NPV 97% 
UCH-L1 & GFAP together; sensitivity 98%, 
NPV 100% 
Table 1.8 Characteristics of ubiquitin C-terminal hydrolase L1 studies 
a = absolute values of UCH-L1 calculated from graph in source paper using plot digitizer; b = overall mean age and % male calculated 
from more than one group reported in source paper. % M, percentage male; LOD, limit of detection; ROD, range of detection; Ctrl, 
control; MVC, motor vehicle collision; TBI, traumatic brain injury; LLOD, lower limit of detection; UCH-L1, ubiquitin C-terminal 
hydrolase L1; CT, computed tomography; CT+, acute intracranial abnormality on CT; CT-, no acute intracranial abnormality on CT; 
AUC, area under the (receiver operating characteristic) curve; GOS-E, Glasgow Outcome Scale – Extended; GFAP, glial fibrillary 
acidic protein; HI, head injury. 




Neurone specific enolase 
Enolase is a metalloenzyme active in glycolysis. It catalyses the conversion of 
phosphoglycerate to phosphoenol pyruvate, which is the ninth and 
penultimate step in glycolysis. Neuron-specific enolase (NSE) is present in 
mature neurons, neuroendocrine cells and amine precursor uptake and 
decarboxylation cells. NSE been investigated for value in mild TBI and 
characteristics of NSE studies are reported in Table 1.9. 
In a study of 141 Emergency Department patients with mild TBI, 65% of 
patients had elevated NSE.255 The investigators measured the Galveston 
Orientation and Amnesia Test in the ED, the Rivermead Post Concussion 
Symptom Questionnaire at three days, and the Rivermead Post Concussion 
Symptom Questionnaire, the Balance Error Scoring System and other 
neuropsychological tests at one and six weeks.15,256,257 At each time point 
patients were classified as normal or abnormal based on an assessment by the 
treating clinician. NSE had an odds ratio of 5.32 for poor outcome at six weeks. 
In another study of 154 Emergency Department patients with mild to 
moderate TBI and 30 matched healthy volunteers, NSE was taken in the 
Emergency Department and at two to seven days after injury.258 NSE was twice 
as high in mild TBI patients than controls at both time points. Of note, if the 
threshold for ‘abnormal’ used in the previously described study (>12 µg/L), 
was used in this study, all patients, including the healthy volunteers, would be 
classified as abnormal. This discrepancy is because two different methods of 
analysis were used. 
In 334 Emergency Department patients with mild TBI, NSE was significantly 
higher than in a control group of 328 healthy volunteers.259 NSE increased 




with age in the control group, but this change was not seen in patients with 
mild TBI. NSE had an AUC of 0.85 to discriminate between patients with mild 
TBI and healthy volunteers. In contrast, in 104 patients with mild TBI and 91 
controls, was no difference in NSE levels although there was a difference when 
corrected for age and sex.260 Furthermore, in a study of 107 Emergency 
Department patients with mild TBI, of whom 25% were CT positive, NSE had 
an AUC of 0.65 to discriminate between patients that were CT positive and 
negative.261  
Three studies have investigated NSE in sports concussion. In 27 ice-hockey 
players that sustained a concussion, NSE was not elevated from before the 
season started to an hour after the concussion (6.1 µg/L and 6.5 µg/L, p = 
0.20).262 Similarly, in 12 College American Football players that sustained a 
concussion, there was no difference between baseline and post-concussion 
NSE levels (8.5 µg/L and 9.1 µg/L respectively).263 In contrast, in 18 boxers 
compared to 17 healthy volunteers, NSE was significantly elevated between 
before and after a boxing match (1.3 µg/L and 1.7 µg/L respectively) and the 
pre-match levels in boxers were significantly elevated compared with healthy 
volunteers (0.2 µg/L).264 In this small study, participating professional boxers 
had been boxing for three years, 5% of them had sustained previous 
concussions and during the boxing match sustained an average of 47 blows to 
the head. Furthermore, the control group is not described in any detail. The 
clear difference between boxers and Emergency Department patients with 
mild TBI, and the absence of any description of the control group, makes 
clinical interpretation of these data difficult. 























NS NSE & S100B in mild TBI vs controls No difference between mild TBI (10.2 µg/L) 





141 (mild TBI) 39 89 12 µg/L NSE to predict GOAT in ED;  
NSE to predict RPQ at 3 days;  
NSE to predict RPQ, BESS & other 
neuropsychological tests at 1 & 6 weeks 
NSE ≥ 14.6 µg/L had OR 5.32 for poor 
outcome at 6 weeks 
Wolf261 
2013 
107 (mild TBI) 59 56 16.4 µg/L Logistic regression model including NSE & 
S100B to discriminate CT+ from CT- 
25% were CT+ 
NSE higher in CT+ (22.5 µg/L) vs CT- (15.2 
µg/L) 
AUC 0.88 for CT+ vs CT- (using NSE, S100B, 
nausea, amnesia, unconsciousness, & 












NS Fold change discrimination index between 
TBI & controls 
NSE 30 µg/L (Ctrl) 
NSE 55.5 µg/L (baseline TBI) 
NSE 67.3 µg/L (2-7 days after TBI) 












NS Logistic regression model including NSE, 
NRGN & MT3 to discriminate between mild 
TBI & controls 
NSE higher in mild TBI (12.2 µg/L0 vs 
controls (3.48 µg/L) 
Model with NSE alone AUC 0.85 
Model with all 3 biomarkers AUC 0.88 
Table 1.9. Characteristics of neuron-specific enolase studies 
% M, percentage male; LOD, limit of detection; ROD, range of detection; TBI, traumatic brain injury; LLOD, lower limit of detection; 
NSE, neuron-specific enolase; GOAT, Galveston Orientation & Amnesia Test; RPQ, Rivermead Post-concussion Questionnaire; BESS, 
Balance Error Scoring System; OR, odds ratio CT, computed tomography; CT+, acute intracranial abnormality on CT; CT-, no acute 
intracranial abnormality on CT; AUC, area under the (receiver operating characteristic) curve; NRGN, neurogranin; MT3, 
metallothionein 3. 






Neurofilaments have a diameter of 10 nm, similar to that of neurones. They 
are particularly plentiful in axons and are essential for the radial growth of 
axons during development, and maintenance of axon diameter.265,266 They are 
composed of four subunits; neurofilament heavy, medium and light (NFH, 
NFM, NFL), and α-internexin.267 There is limited evidence that neurofilament 
is useful for assessing patients with mild TBI. In 34 patients with mild TBI, 
half of whom were CT positive, NFH was higher than in patients in a healthy 
volunteer group, and higher in patients that were CT positive compared to CT 
negative.268 In a separate study, in 107 patients with mild TBI, NFL was 
significantly higher in patients with a Glasgow Outcome Scale-Extended score 
of < 8 (i.e. not complete recovery) at six to 12 months but there was no 
difference in NFL between patients that were CT positive and CT negative.269 
This is consistent with the relatively low AUC of 0.676 for NFL to discriminate 
between CT positive and negative in a group of 93 patients with mild TBI.270 
NFL may be further limited in clinical use by the confounder that it is 
associated with several chronic neurological conditions, and has been found to 
be correlated with age and pre-existing neurological diagnoses in patients with 
mild TBI.271 NFL has been more extensively investigated in sports concussion, 
and may have some utility in identifying concussion and sub-concussion in 
boxing, American football, hockey, and soccer headers.272-276 
  




Astroglial cell injury 
Glial fibrillary acidic protein 
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament. 
Intermediate filaments are strong yet flexible protein polymers 10nm in 
diameter, and consequently intermediate to microfilaments (smaller) and 
microtubules (also known as myosin thick filaments, and larger than 
intermediate filaments).277 GFAP is thought only to be found in the central 
nervous system and makes up the cytoskeletal structure of astrocytes.278 
Characteristics of studies of GFAP are reported in Table 1.10. 
Several studies have investigated the value of GFAP in predicting severity and 
outcomes following severe TBI.279-282 In 92 patients with severe TBI, mortality 
and the Glasgow Outcome Scale was measured at three months after injury283. 
GFAP was significantly higher in non-survivors (4.8 µg/L) than in survivors 
(0.5 µg/L) (abstracted from bar chart using Plot Digitiser), and the AUC for 
mortality at three months was 0.84. Furthermore, GFAP was higher in 
severely brain injured patients than in multiply injured but not brain injured 
patients.284  
In one of the first investigations into GFAP in patients with mild TBI, GFAP 
was significantly higher in CT positive patients compared to CT negative, and 
in patients that had not fully returned to work at six months compared to those 
that had.285 However the diagnostic test characteristics were poor for 
diagnosing abnormalities on MRI, the Extended Glasgow Outcome Scale, or 
return to work (although the cut-off for dichotomisation was not reported). In 
contrast, in a study published in the same year, GFAP breakdown product 
(GFAP-BDP) demonstrated better diagnostic characteristics.286 In this study 




of 108 patients with mild to moderate TBI, GFAP-BDP levels were significantly 
higher in lower GCS groups. This was the case whether the dichotomisation 
was set at the conventional definitions of mild and moderate TBI of GCS 13-15 
versus 9-12, or GCS 14-15 versus 9-13. GFAP-BDP was also higher in a low 
acuity TBI group, that is a group with GCS 15, when compared to non-head 
injured trauma patients with musculoskeletal injuries. Furthermore, GFAP-
BDP was higher in CT positive than CT negative patients. The discriminatory 
ability of GFAP-BDP was also good with an AUC of 0.9 for TBI versus controls, 
0.88 for GCS 15 versus healthy volunteers with no injury, and 0.79 for CT 
positive versus CT negative TBI patients. A further study that included nearly 
400 patients also reported significantly higher GFAP levels in CT positive 
patients with mild to moderate TBI compared to CT negative patients, and also 
higher levels in CT negative patients compared to patients with 
musculoskeletal injuries but no head injuries.287 GFAP had good capacity to 
discriminate between CT positive and CT negative patients, with an AUC of 
0.84. In 215 patients with TBI, of which 83% were mild, GFAP-BDP also 
performed well at discriminating between CT positive and CT negative 
patients.288 The AUC was 0.88, and when adjusted for age, pupillary exam, 
GCS, and injury severity score, the AUC was 0.96. Using a threshold of 1.66 
µg/L, the specificity was 99% and sensitivity 45%. Using decision curve 
analysis, a net benefit of scanning only when the GFAP-BDP was positive 
would have resulted in 12% fewer scans being performed than if the decision 
to scan had been based on a clinical screen. In a paper by the same authors, 
584 patients recruited in the ED, 56% of whom had mild or moderate TBI and 
44% of which had trauma but no TBI, GFAP (and UCH-L1) was measured at 
19 points in time from arrival (median 3 hours from injury) until a week 




later.247 GFAP was significantly higher in the TBI group compared with the no 
TBI group, and in CT positive compared with CT negative patients. The AUC 
to discriminate CT positive from CT negative for GFAP alone was highest at 36 
hours at 0.97 and was 0.86 at initial assessment. When GFAP and UCH-L1 
were assessed together, the highest AUC was also at 36 hours at 0.97. The great 
value of this study compared with studies previously published is that a clear 
description is provided of the trend of GFAP and UCH-L1 over 19 points in 
time across a week. GFAP peaked at 20 hours after injury, and UCH-L1 peaked 
at the initial measurement. However, as described above, in a recent key 
publication, a panel consisting of GFAP and UCH-L1 was 98% sensitive and 
had a NPV of 99.6% for an acute abnormality on CT.248 Because not all patients 
in the study had results from both assays within the panel, a sensitivity 
analysis was performed which showed that compared to GFAP alone the 
combined biomarker test had neither superior sensitivity nor NPV. However, 
compared to UCH-L1, the combined biomarker test had both higher sensitivity 
and NPV. This is surprising because in the report by Papa and colleagues, 
GFAP peaked at 20 hours after injury.247 Nevertheless, the results were 
compelling enough to be fundamental to the decision by the US Food and Drug 
Administration (FDA) to endorse the panel as the first for use in US EDs.249  
One issue with using biomarkers in a clinical setting is the potential for leakage 
from non-brain tissue, which would produce false-positive results. This has 
been reported with S100B but seems not to be an issue with GFAP. When CT 
negative TBI patients were compared with patients with extracranial bony 
injuries, GFAP was lower in TBI patients on the day of injury, but there were 
no differences between groups on subsequent days.250 Furthermore, in 




another study comparing patients with TBI to patients with extracranial 
injuries and with fractures, there was no difference in GFAP between patients 
with fractures and those without (regardless of whether those patients had a 
TBI or not).287 














94 (mild TBI) 34  LLOD 0.045 µg/L GFAP in CT+ vs CT-  
GFAP in MRI diagnosed axonal injury vs no 
axonal injury 
GFAP in complete vs incomplete return to 
work at 6 months. 
GFAP higher in CT+ (1.2 µg/L) vs CT- (0.05 
µg/L).  
GFAP higher in patients with axonal injury 
on MRI at 3 months (0.65 µg/L) vs those 
without (0.07 µg/L) 
GFAP higher in incomplete return to work 
(0.69 µg/L) at six months vs complete return 





97 (mild TBI) 
11 (moderate TBI) 
23 (non-head injured 
musculoskeletal injured 
control) 
176 (healthy volunteer 
ctrl)  
38 58 LLOD 0.02 µg/L GFAP-BDP to discriminate between mild to 
moderate TBI vs non-head injured controls 
GFAP-BDP to discriminate between injury 
severity levels including mild vs moderate 
TBI, & CT+ vs CT- 
GFAP-BDP significantly higher in TBI (0.32 
µg/L) than controls (0.01 µg/L) 
AUC 0.9 for TBI vs. controls 
AUC 0.88 for mild TBI GCS 15 vs healthy 
volunteers with no injury 






171 (mild TBI) 
8 (moderate TBI) 
27 (severe TBI) 
42 73 LLOD: 0.1 µg/L Combined GFAP & GFAP-BDP to 
discriminate between patients with TBI vs 
healthy volunteers 






209 (mild to moderate 
TBI) 
188 (trauma without TBI) 
40 59 LLOD 0.008 µg/L GFAP to discriminate between CT+ vs CT- 
GFAP to discriminate between patients with 
TBI vs patients with fractures. 
GFAP higher in CT+ (0.74 µg/L) vs CT- (0.04 
µg/L) 
GFAP higher in CT- vs no TBI (0.01 µg/L). 




179 (mild TBI) 
9 (moderate TBI) 
27 (severe TBI) 
42 73 LLOD ~0.01 µg/L GFAP-BDP to discriminate between CT+ vs 
CT-  
GFAP higher in CT+ (2.86 µg/L) vs CT- (0.26 
µg/L) 





325 (mild & moderate 
TBI) 
259 (trauma, no TBI) 
40 62 LLOD: 0.008 µg/L UCH-L1, GFAP & both to discriminate 
between CT+ vs CT- at 19 time points after 
injury 
Peak GFAP at 20hrs.  
GFAP higher in TBI (0.112 µg/L) vs controls 
(0.008 µg/L) 
       











69 (healthy volunteer) 
39 85 LLOD: 0.0008 µg/L Determine whether:  
GFAP higher in TBI vs controls 
GFAP reduces over weeks following injury 
GFAP is associated with 6-month outcomes 
GFAP higher on day of injury (0.0176 µg/L), 
at 30 days (0.00133 µg/L) & at 90 days 
0.00135 µg/L) compared with controls 
(0.0008 µg/L).  
GFAP by day 30 but no further after day 30. 




154 (CT- mild TBI) 
34 (CT+ mild TBI) 
59 (HI no TBI) 
46 60 LOD 0.02 µg/L GFAP to discriminate between head injured 
patients with & without mild TBI 
GFAP to discriminate between mild TBI CT+ 
vs CT- 
GFAP higher in CT+ (0.12 µg/L) than either 
(CT- 0.02 µg/L) or head injury no TBI (0.02 
µg/L). 





93 (mild TBI) 
73 (musculoskeletal 
injuries, no TBI) 
44 55 Limits of 
quantification 
0.16-100 µg/L 
GFAP & UCH-L1 to discriminate between 
patients with mild TBI CT- & patients with 
extracranial musculoskeletal injuries & no 
TBI. 
Samples taken on arrival in ED & at days 1, 
2, 3 & 7.  
GFAP lower in TBI (0.19 µg/L) than 
musculoskeletal controls (0.23 µg/L) on day 




1834 (CT- mild & mod. 
TBI) 
125 (CT+ mild & mod. 
TBI) 
49 57 ROD 0.08-2.56 µg/L GFAP and UCH-1 NPV & sensitivity for CT+ GFAP higher in CT+ (0.135 µg/L) vs CT- 
(0.0222 µg/L) 
Using a threshold of 0.022 µg/L: 
GFAP alone; sensitivity 96% & NPV 99% 
UCH-L1 & GFAP together; sensitivity 98%, 
NPV 100% 
Table 1.10. Characteristics of glial fibrillary acidic protein studies 
a = absolute values of UCH-L1 calculated from graph in source paper using plot digitizer; b = overall mean age and % male calculated 
from more than one group reported in source paper. % M, percentage male; LOD, limit of detection; ROD, range of detection; LLOD, 
lower limit of detection; GFAP, glial fibrillary acidic protein studies; TBI, traumatic brain injury; CT, computed tomography; CT+, 
acute intracranial abnormality on CT; CT-, no acute intracranial abnormality on CT; BDP, breakdown products; AUC, area under the 
(receiver operating characteristic) curve; HI, head injury. 





The S100 family of proteins are predominantly intracellular calcium-
modulated proteins. There are 16 members, of which S100B is one of the 
original two to have been discovered in the 1960s.290 S100B is a 21-kDa 
calcium-binding glial-specific protein mainly expressed by astrocytes and has 
mitogenic and glial cell proliferative functions.291 S100B is estimated to have a 
half-life of 97 minutes in mild TBI patients.292 Characteristics of S100B studies 
in mild TBI are reported in Table 1.11.  
The half-life of S100B has been estimated to be from 25 to 120 minutes in head 
injured and cardiac surgical patients.292-294 This is relatively short for practical 
purposes, as during the time taken to transport a patient to hospital and within 
an Emergency Department prior to blood sampling, a significant proportion 
of circulating S100B will be metabolised. This may confound its use in decision 
rules, and although there is ample evidence that elevated S100B is sensitive 
for brain injury, there is no evidence that it adds value to clinical 
guidance.292,295  
S100B has also been investigated as a tool to predict outcome following cardiac 
arrest. Several studies have reported associations between higher levels of 
S100B and lower rates of survival to admission, the presence of brain damage, 
and poorer functional outcomes.296,297 
S100B to discriminate between CT positive and CT negative 
In 182 patients with mild TBI, S100B was detectable (>0.2 µg/L and defined 
as elevated at this level) in 38%.298 S100B was 90% sensitive with a NPV of 
99% for CT positive patients. The optimum threshold for abnormality was 
investigated using a definition of the 95th percentile in a healthy volunteer.299 




In this study, 1309 patients with mild TBI, 55 with moderate or severe TBI and 
540 healthy volunteers were included, and the threshold was found to be 0.1 
µg/L. Of the 1308 mild TBI patients, 7% were CT positive, and of the 55 
moderate to severe TBI patients, 42% were CT positive. S100B was 99% 
sensitive, 30% specific, had a NPV of 100%, a PPV of 10%, and an AUC of 0.80 
to discriminate between CT positive and negative patients. 
In 2007 S100B was introduced into local practice in some Scandinavian 
Emergency Departments to fit within an existing Scandinavian Neurotrauma 
Committee guideline on the management of head injured patients.299,300 
Patients with GCS 14-15, and loss of consciousness or amnesia were eligible for 
S100B testing prior to CT scan if the test was performed within 3 hours. If the 
S100B was < 0.1 µg/L, then the patient could be discharged home without CT. 
When validated, out of 512 patients, 27% were below the S100B threshold for 
CT.301 32% of those were ‘over-triaged’, that is either investigated with a CT 
(all of which were negative) or admitted. 73% were above the threshold, and of 
those 7% were ‘under-triaged’, that is not investigated with a CT, none of whom 
were found subsequently to have had intracranial abnormalities. Overall, 
S100B had a sensitivity and NPV of 100% for intracranial injury, and a 
specificity of 28%.  
In 1560 patients with minor head injury, of which 7% were CT positive S100B 
had an AUC of 0.76 to discriminate between CT positive and negative 
patients.302 At a threshold of 0.1 µg/L, the sensitivity and NPV were both 99%, 
and the likelihood ratio for a negative test (LR-) was 0.07. At a slightly higher 
threshold of 0.14, the sensitivity was 97%, NPV 99% and LR- was 0.06. Had 
S100B been part of the diagnostic algorithm, 12 or 25 CT scans would have 




been avoided at thresholds of 0.10 µg/L and 0.14 µg/L respectively. These 
findings contributed to the addition of S100B to the Scandinavian guidelines 
for initial management of minimal, mild and moderate head injuries in adults, 
which was one of the first head injury guidelines to include S100B.303 In 
separate large study that included 787 patients with mild TBI and 467 healthy 
volunteers, S100B was higher in patients with mild TBI compared to 
controls.304 S100B was also higher in mild TBI patients with a positive CT scan 
compared to those with a negative CT. The authors tested the diagnostic 
characteristics using several thresholds, including a threshold defined by the 
healthy volunteer group, a conventional threshold of 0.1 µg/L, and thresholds 
allowing 98% and 90% sensitivity, and 98% and 90% specificity. The intention 
was to balance CT usage against missing intracranial injuries. In this study, at 
a threshold allowing 90% sensitivity (0.097 µg/L), 31% of CT scans could have 
been avoided, but six CT positive mild TBI patients would have been missed. 
By reducing the threshold to allow 98% sensitivity (0.060 µg/L), 23% of CT 
scans could have been avoided and one patient with an abnormal CT scan (a 
small contusion) would have been missed. 
S100B in intoxicated patients 
A significant proportion of patients with head injuries and potential TBI that 
present to the Emergency Department are intoxicated with alcohol, and 
consequently it is important to determine whether alcohol affects biomarker 
levels. In 160 patients that presented to an Emergency Department in Canada, 
four groups were defined: medical controls (non-traumatic medical 
complaints), trauma controls (physical injuries not involving the head), mild 
TBI, and moderate or severe TBI.305 Each of these were separated into those 




that were and were not intoxicated with alcohol. S100B was significantly lower 
in the intoxicated compared with sober moderate or severe TBI groups, and 
trended to be lower in the intoxicated compared with sober mild TBI group. 
S100B was higher in the TBI groups compared with the non-TBI groups 
regardless of alcohol. The authors of this study replicated the methodology in 
a second cohort of patients who were categorised into identical groups and 
subcategorised by alcohol intoxication or sobriety.306 In this study similar 
findings were reported with higher S100B levels seen in patients with TBI 
compared with those without, but in contrast to the previous study there was 
no difference between intoxicated and sober patients in any group. The 
authors suggested this discrepancy may be due to tighter inclusion criteria in 
the second study but concluded that alcohol does not affect S100B levels. 
S100B to predict longer term outcomes after mild TBI 
S100B has been shown to have moderate value as a predictor of post-
concussion symptoms, and in mild TBI, at a cut off of 0.5 µg/L, had a 
sensitivity of 93% and an area under the receiver operating characteristic 
(AUC) curve of 0.70 for post-concussion syndrome at one month.307 In 182 
patients with mild TBI, patients with elevated S100B had significantly more 
symptoms than those with low S100B but there was no analysis reported for 
S100B predicting post-concussion syndrome.298 In a separate study, at a 
threshold of 0.5 µg/L, S100B had an AUC of 0.7 to predict post-concussion 
symptoms, and at a threshold of >0.13 µg/L, had an OR of 10.4 to predict post-
concussion symptoms. As a predictor of functional outcome in patients with 
all types of TBI, at a threshold of 0.32 µg/L, S100B had a sensitivity of 93% 
and an AUC of 0.9 for severe disability.308 In the same study, in a subset of 




patients with mild TBI for moderate disability, a threshold of 0.48 µg/L had a 
negative predictive value of 99%. S100B has also been reported to predict 
failure to return to work; in patients with mild TBI, 38% of patients with 
abnormal S100B (≥0.15µg/L) compared with 5% of patients with normal 
S100B were unable to return to work at one week following injury.309 In 
another study, elevated S100B had a sensitivity of 80% and a PPV of 38% for 
inability to return to work (or usual activities) at one week.310 In this study, of 
the patients with elevated S100B, 38% had not returned to work at one week, 
compared with only 5% of the patients with normal S100B. Elevated S100B 
has also been associated with post-traumatic stress at a year.311  
In contrast, there was no difference in S100B measured in 94 patients with 
mild TBI that were categorised by GCS, CT, MRI at three months, Extended 
Glasgow Outcome Scale at six months, or return to work at six months after 
injury.285 Although it may be expected that S100B might not predict longer 
term outcomes, it might be expected that S100B would predict acute 
outcomes, particularly whether patients were CT positive or negative. The 
authors suggest this may be because there is a high prevalence of CT positive 
patients in this study (20%) which would reduce the NPV, and indeed the 
mean S100B across all patients is 0.54 µg/L. In another study, there was no 
association between elevated S100B (> 0.1 µg/L) and return to work, or post-
concussive symptoms at three, six and nine months.312 
Limitations of S100B 
S100B has poor specificity both for diagnosing mild TBI and for discriminating 
between mild TBI patients with and without CT abnormalities. This means 
that S100B is frequently elevated in patients that either do not have mild TBI, 




or do not have an intracranial abnormality (false positives). One potential 
reason for this may be because S100B is present in adipocytes and 
melanocytes. Consequently, normal S100B levels may be naturally higher in 
people with more pigmented skin. In one study, the average S100B level in 
black people was twice that of Caucasian people.313  
Another reason for poor specificity may be due to extra-cerebral expression or 
release of S100B. In 397 patients with extracranial injuries, half of which had 
TBI, S100B was significantly higher in patients with fractures compared to 
those without, regardless of whether patients had TBI or not.287 Furthermore, 
in a study comparing patients with polytrauma and no head injury and healthy 
volunteers, S100B was highest in trauma patients with fractures.314 This 
suggests that there may be S100B false positives in patients with head injuries 
and fractures. 















Mild TBI (182) 33 61 LOD 0.2 µg/L 
Threshold 0.2 µg/L 
S100B to discriminate between CT+ vs CT- Of all patients, 38% elevated S100B, 5% CT+ 
Of CT+ patients, S100B elevated in 90% 
S100B 90% sensitive, 65% specific, NPV 99%, 




Mild TBI (254) 
Moderate TBI (16) 
Severe TBI (8) 
32 63 LOD 0.2 µg/L 
Threshold 0.2 µg/L 
S100B to discriminate between CT+ vs CT- Of all patients, 39% elevated S100B, 9% CT+ 
Of CT+ patients, S100B positive in 92% 
S100B 92% sensitive,66% specific, NPV 99%, 




Mild TBI (52) 
GCS < 8 (NS) 
Healthy volunteer (20) 
NS 73 Threshold 0.1 µg/L Evaluate diagnostic value of S100B for 
screening patients at high risk after mild TBI 
Of mild TBI patients, 71% elevated S100B, 
21% CT+ 
S100B 0.04 µg/L (CT-), 0.63 (CT+) in mild TBI 
S100B 0.05 µg/L, 0.47 µg/L, 7.16 µg/L in 
healthy volunteers, mild TBI, & low GCS 
groups respectively 
Sensitivity 100%, specificity 40%, NPV 100%, 




Alcohol intoxicated mild 
TBI (20) 
Sober mild TBI (29) 
Moderately intoxicated 
healthy volunteers (20) 
Severely intoxicated 
patients without TBI (20) 
43 NS LOD 0.02 µg/L Determine the influence of alcohol on S100B 
levels in patients with mild TBI & patients 
without mild TBI 
S100B higher in mild TBI vs no TBI 
S100B higher in mild TBI CT+ vs CT- patients, 
regardless of alcohol intake.  




Mild TBI (104) 
Healthy controls (92) 
40 70 LOD 0.03 µg/L Determine whether S100B (& NSE) higher in 
patients with mild TBI compared to healthy 
volunteer control. 
S100B higher in mild TBI (0.25 µg/L) vs 
controls (0.02 µg/L) 
Mussack318 
2002 
Intoxicated mild TBI (139) 
Healthy volunteers (20) 
36 76 LOD 0.02 µg/L 
 
S100B to discriminate between CT+ vs CT- in 
intoxicated patients 
14% CT+ 
S100B higher in CT+ (0.94 µg/L) vs CT- (0.22 
µg/L) 
AUC 0.86 for CT+ vs CT- 
At threshold 0.21 µg/L, sensitivity 100%, 
specificity 50%, PPV 24%, NPV 100%. 







Mild head injury (172) 
PCS at one month (37) 
No PCS at 1 month (135) 
31 75 LOD 0.02 µg/L 
Threshold 0.5 µg/L 
Determine if S100B (& other factors) predict 
post-concussion symptoms at one month 
after mild TBI. 
Elevated S100B had OR 5.5 for PCS at 1 
month 
AUC 0.7 for PCS at 1 month 
Sensitivity 27%, specificity 93% 
Stranjalis310 
2004 
Mild head injury (100) 33 52 Threshold 0.15 µg/L Determine the association between S100B & 
return to work or usual activities at one 
week. 
32% had elevated S100B.  
37% of elevated S100B patients had not 
returned to work at one week compared 
with 5% of patients with normal S100B 
Biberthaler299 
2006 
Mild head injury (1309) 
Moderate-severe TBI (55) 
Healthy volunteers (540) 
47 65 ROD 0.005-39 µg/L Determine a threshold set pre-hoc at 95th 
percentile to define S100B positive & 
negative in healthy volunteers. 
Calculate diagnostic test characteristics for 
S100B in mild TBI patients. 
95th percentile identified as 0.1 μg/L. 
AUC 0.80 for mild TBI vs no TBI 





Mild TBI (50) 
Healthy volunteers (21) 
NS 66 Threshold 0.1 µg/L S100B to discriminate between CT+ vs CT- Of mild TBI patients, 82% elevated S100B, 
21% CT+ 
S100B higher in CT+ (0.75 µg/L) vs CT- (0.26 
µg/L) 
AUC 0.82 for CT+ vs CT- 




Mild TBI (226) 39 74 LOD 0.013 µg/L 
 
S100B to discriminate between CT+ vs CT- 9% CT+ 
S100B higher in CT+ (0.36 µg/L) vs CT- (0.18 
µg/L) 
AUC 0.73 for CT+ vs CT- 
At threshold 0.1 µg/L, sensitivity 95%, 
specificity 31%, PPV 12%, NPV 98% 
Morochovič321 
2009 
Mild TBI (102) 42 70 LOD 0.005 µg/L 
Threshold 0.1 µg/L 
S100B to discriminate between CT+ vs CT- 73% had elevated S100B, 18% CT+ 




Mild TBI (233) 48 61 Threshold 0.105 
µg/L 
S100B to discriminate between CT+ vs CT- 72% had elevated S100B, 9% CT+ 





Mild TBI (141) 39 89 LOD 0.005 µg/L 
Threshold 0.1 µg/L 
Determine whether S100B (& NSE) was 
predictive of: GOAT in ED; RPQ at 3 days; 
RPQ, BESS & other neuropsychological tests 
at 1 & 6 weeks 
Elevated S100B had OR 3.9 for abnormal 
status according to a physician’s evaluation 
at 1 week, but not predictive for outcome at 
6 weeks 






Mild TBI (512) 42 62 ROD 0.005-39 μg/L 
Threshold 0.1 μg/L 
Determine whether including S100B in CT 
decision rule is safe 
S100B had sensitivity & NPV of 100% for 
intracranial injury 
Specificity 28%, PPV 6% 
Cervellin323 
2012 
Mild TBI (60) 58 68 ROD 0.02-30 µg/L S100B to discriminate between CT+ vs CT- 33% CT+ 
S100B higher in CT+ (1.35 µg/L) vs CT- (0.48 
µg/L) 
AUC 0.80 for CT+ vs CT- 
At a threshold of 0.38 µg/L, sensitivity 100%, 




Mild TBI GCS 15 (143) 49 62 ROD 0.005-36 µg/L 
Threshold 0.105 
µg/L 
S100B to discriminate between CT+ vs CT- in 
patients with mild TBI & no reduction in 
consciousness 
11% CT+  
S100B higher in CT+ (0.585 µg/L) vs CT- 
(0.369 µg/L) 
AUC 0.73 for CT+ vs CT- 




Mild TBI (94) 34 NS LOD 0.005-μg/L Determine whether S100B (& GFAB) can 
predict initial GCS, initial CT, MRI 3 months 
postinjury, GOS-E (dichotomised to good or 
poor outcome) & RTW 6 months after injury 
Mean S100B 0.54 µg/L 
No difference in S100B in patients with GCS 
13, 14 or 15; nor between groups in any of 
the other four categories 
Zongo302 
2012 
Mild TBI (1646) 57 56 NS Determine the NPV & LR- for S100B for CT+. 
Determine threshold most effective to keep 
NPV near 100% 
S100B higher in CT+ (0.46 µg/L) vs CT- (0.22 
µg/L) 
At thresholds of 0.1, 0.12, & 0.14 NPV was 
99% & LR- was 0.07, 0.04, & 0.06 
AUC 0.76 for CT+ vs CT- 
Bazarian304 
2013 
Mild TBI (787) 
Healthy volunteers (467) 
38 63 ROD 0.005-39 µg/L Determine whether S100B (& apoA-I) 
discriminate between patients with & 
without mild TBI, & between mild TBI 
patients with & without intracranial 
pathology 
S100B higher in CT+ (0.292 µg/L) vs CT- 
(0.144 µg/L) 
AUC 0.69 for CT+ vs CT- 
At threshold of 0.1 µg/L, sensitivity 87%, 
specificity 36%. 
S100B higher in mild TBI (0.149 µg/L) vs 
healthy volunteers (0.071 µg/L) 




     






Mild TBI (107) 59 56 NS Determine whether the combination of an 
increase of S100B (& NSE) is associated with 
CT+ 
S100B higher in CT+ (0.21 g/L) vs CT- (0.7 
µg/L) 
AUC for S100B alone 0.63 for CT+ vs CT- 
Regression model including S100B, 
NSE, nausea, amnesia, vomiting, & loss of 
consciousness had AUC 0.88 
Laribi325 
2014 
Mild TBI (431) 36 65 ROD 0.005-39 µg/L 
Threshold 0.1 µg/L 
S100B to discriminate between CT+ vs CT- 6% CT+ 
S100B higher in CT+ (0.21 µg/L) vs CT- (0.11 
µg/L).  
AUC 0.69 for CT+ vs CT- 




Mild TBI (782) 
 
83 31 ROD 0.005-39 µg/L 
Threshold 0.105 
µg/L 
Determine NPV for S100B for intracranial 
pathology in patients with mild TBI who are 
either on anti-platelet medication or aged 
>65 
6% CT+ 




Mild TBI (158) 35 52 ROD 0.02-30 µg/L 
Threshold 0.11 µg/L 
 
Determine predictors for intracranial 
abnormality in patients with mild TBI 
including S100B & clinical variables 
50% CT+ 
S100B higher in CT+ (0.68 µg/L) vs CT- (0.10 
µg/L) 
AUC 0.7 for S100B alone to discriminate 
between CT+ & CT- 
LOC & PTV associated with CT+ 
Welch328 
2016 
Mild to moderate TBI 
(251) 
46 60 NS Compare GFAP & UCH-L1 with S100B  
to discriminate between CT+ vs CT- 
14% CT+ 
AUC 0.75 for S100B to discriminate between 
TC positive & CT- 
Table 1.11. Characteristics of S100B studies 
a = absolute values of UCH-L1 calculated from graph in source paper using plot digitizer. % M, percentage male; LOD, limit of 
detection; ROD, range of detection; NPV, negative predictive value; PPV, positive predictive value; Ctrl, control; MVC, motor vehicle 
collision; TBI, traumatic brain injury; LLOD, lower limit of detection; CT, computed tomography; CT+, acute intracranial abnormality 
on CT; CT-, no acute intracranial abnormality on CT; AUC, area under the (receiver operating characteristic) curve; PCS, post-
concussion syndrome; NSE, neuron specific enolase; GOS-E, Glasgow Outcome Scale – Extended; MRI, magnetic resonance imaging; 
LR-, likelihood ratio for a negative test; GOAT, Galveston Orientation and Amnesia Test; RPQ; Rivermead Post-concussion Symptom 
Questionnaire; ED, Emergency Department; GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin C-terminal hydrolase L1; apoA-
I, apolipoprotein AI; HI, head injury; LOC, loss of consciousness; PTV, post traumatic vomiting. 




Neuronal cell death 
Spectrin breakdown products 
The spectrin family of proteins are molecules associated with the cell membrane 
of various tissues.329 Their functions include the maintenance of the cell 
membrane-cytoskeleton interface.330,331 Spectrin is composed of an alpha 
subunit, of which there are two, αI and αII, and a beta subunit, of which there 
are five.332 In the event of neuronal stress such as following a TBI, damage to 
the neuronal cell membrane leads to catabolism of membrane and cytoskeletal 
elements. This in turn leads to catabolism of spectrin by calpain or caspase-3 to 
signature breakdown products, which are described in terms of the catabolic 
agent and the molecular weight in kilodaltons.329,333 In patients with severe TBI, 
alpha-II spectrin breakdown products (αII-SBDP) are detectable in CSF, are 
higher in TBI patients than controls, are associated with severity of injury, and 
correlate with survival.333-335 Although there is limited evidence to support the 
clinical use of spectrin breakdown products in mild TBI, an αII-spectrin 
breakdown product called calpain-cleaved αII-spectrin N-terminal fragment 
(SNTF) was measured in 38 Emergency Department patients who had either 
mild TBI or musculoskeletal injuries, or were healthy volunteers.138 SNTF was 
elevated in seven of 17 mild TBI patients and three of 13 patients with 
musculoskeletal injuries, but in none of the healthy volunteers. SNTF also 
correlated with cognitive impairment at three months. SNTF was also elevated 
in concussed ice hockey players and exhibited diagnostic accuracy for 
concussion, particularly in players that had delayed return to play.336  






Tau proteins bind and stabilise microtubules, predominantly in cells of the 
central nervous system.337 How effective they are at binding microtubules 
depends on their phosphorylation status. Non-phosphorylated tau proteins are 
more effective than phosphorylated tau at binding and polymerising 
microtubules.338 Tau aggregates with ubiquitin (above) to form intracellular 
neurofibrillary tangles, which are the hallmark neuropathological changes 
found in Alzheimer’s Disease. Although Tau has been investigated as a 
biomarker in mild TBI, it is most commonly referred to as a diagnostic 
requirement in chronic traumatic encephalopathy. In a study of 36 patients with 
mild TBI, tau was not correlated with three month post-concussion symptoms, 
and had poor prognostic ability with an AUC of 0.6.339 A separate study looking 
at three month symptom outcomes also found no difference in tau levels in 
patients with and without post-concussion symptoms.340 The previously noted 
studies recorded tau levels on the day of injury. When measured at the time of 
outcome measurement, for instance at three months, and when measured on a 
novel ultrasensitive single molecule array (SIMOA) assay, a number of studies 
have identified elevated tau. Compared with healthy volunteers, tau was 
elevated in 70 US soldiers that sustained repeated mild TBI during deployment 
many months or years prior to tau measurement.341 In a study recruiting all 
types of TBI, tau was elevated (compared with healthy volunteers) at days 0, 30 
and 90, and most maximally at day zero.289 In 217 patients with TBI, 
phosphorylated tau and the total-tau-phosphorylated-tau ratio, when measured 
on a SIMOA assay, performed highly at discriminating between CT positive and 
CT negative TBI patients, with AUCs of more than 0.9 for both.342 Total tau 




discriminated more poorly with an AUC of 0.6. Phosphorylated tau and total-
tau-phosphorylated-tau ratio both discriminated weakly between patients with 
poor and not poor outcomes (GOS-E ≤ 4 vs >4) (AUC 0.66 and 0.66 
respectively), and good and not good outcomes (GOS-E ≥ 7 vs < 7) (AUC 0.77 
and 0.78 respectively) at six months. In 60 patients with mild TBI compared 
with 20 healthy volunteers, there was no difference between mean tau levels in 
each group, nor between mild TBI patients with and without acute intracranial 
abnormality on CT.343  
Future biomarkers: micro-RNA and interleukins 
Micro-RNAs are small non-protein-coding RNA sequences that are implicated 
in post-transcription protein regulation.344 Micro-RNAs play a role in regulating 
protein synthesis, and are implicated in cellular elements of nervous system 
injury and repair.345,346 In a study attempting to identify potential micro-RNAs 
that can discriminate between mild and severe TBI, miR-21 and miR-335 were 
significantly upregulated, and miR-425-5p and miR-502 were significantly 
downregulated.345 In another study, some micro-RNAs, including miR-21, miR-
16 and let-7i were found to discriminate between mild and severe TBI.347 The 
micro-RNAs miR-153-3p, miR-223-3p, and miR-let-7a-5p have been shown to 
be significantly higher in athletes with sports related concussion compared to 
pre-concussion baseline levels.344  
Interleukins are cytokines; inflammatory mediators released in response to 
insult or injury. In a study involving a series of validations, out of an initial panel 
of 92 biomarkers, IL-10 was identified as one of three biomarkers that were 
sufficiently specific at a sensitivity of 100% to show promise in discriminating 
between CT positive and negative patients with mild TBI.348 However, although 




IL-10 was significantly higher in CT positive compared to CT negative patients, 
at 100% sensitivity, the specificity was 31%, and neither the area under the 
receiver operating characteristic curve, nor the negative predictive value were 
reported. 
Copeptin 
Vasopressin, also known as arginine vasopressin or anti-diuretic hormone, is a 
nonapeptide produced by the hypothalamus.349 Circulating vasopressin is 
increased when a patient has an infection associated with physiological stress, 
including hypotension, hypoxia, and hyperosmolar states.350-352 Vasopressin 
has been used as a biomarker and pro-contractility agent in critical illness and 
septic vasodilatory shock, however its instability makes it difficult to use in 
routine clinical care.353-356 Arginine vasopressin is derived from a larger 
precursor peptide (pre-provasopressin) along with two other peptides, copeptin 
and neurophysin II.357 Copeptin is a 39 amino-acid glycopeptide, the C-terminal 
of pre-provasopressin, and is stable for days after blood withdrawal therefore 
accurately reflecting acute levels of vasopressin.357 In a study of patients with 
acute exacerbation of chronic obstructive pulmonary disease, using an assay 
with a threshold of normal of 2.25 pmol/L the average copeptin level was 12.4 
pmol/L, which was significantly associated with prolonged hospital stay and 
long term treatment failure.358 In patients with ischaemic stroke, copeptin levels 
increased with increasing severity of stroke, and were higher in patients with 
poorer outcomes both in the short and long terms.359-361 Similar findings were 
reported in patients with haemorrhagic stroke, with copeptin levels higher in 
patients that died or had poorer functional outcomes.362,363 Elevated copeptin 
levels have also been found to be associated with increased risk of all cause and 




cardiovascular mortality in primary care patients with heart failure.364 An 
association between abnormal levels of copeptin and severity of brain injury in 
TBI patients has been described, and in severe TBI patients elevated copeptin 
was significantly associated with short and long term mortality.365-367 Mild TBI 
may also be associated with upregulation of proinflammatory mediators such as 
copeptin, but has not been extensively investigated in this patient group.368,369 
In the only study investigating copeptin in mild TBI, copeptin rose by 3.4 times 
in the acute phase after injury, and had an AUC of 0.9 to discriminate between 
patients with mild TBI and healthy controls.370 
  





Acquired brain injury is a common reason for patients to attend Emergency 
Departments, and mild TBI is a commonly made diagnosis after a head injury. 
How mild TBI is diagnosed is contentious because some of the elements that 
make up the diagnostic criteria occur before the patient arrives at the 
Emergency Department and are elements that the patient often cannot 
remember. Hence a greater reliance is placed on witnesses, which are often 
unreliable. Assessment of the severity of mild TBI is important because it 
predicts outcomes, however, the best method of assessment is also 
controversial. There are multiple symptoms that may follow a mild TBI but the 
exact clinical course that a patient may take is not known. The consequences of 
mild TBI include post-concussion symptoms and cognitive dysfunction. These 
symptoms and signs are commonly assessed using specialist neuropsychological 
tests, which can take days to apply, and require specialist interpretation. There 
is a requirement for an accurate neuropsychological test that can identify the 
degree of cognitive impairment or function that a patient has and that can be 
applied after minimal training by clinicians in an Emergency Department. Of 
great value would be to have the capability to apply the test and be able to advise 
a patient with mild TBI how the test results might change over time, and how 
that might make them feel. The Standardized Assessment of Concussion and the 
Concussion Symptom Inventory are two tests that could provide that function. 
In addition to the symptoms and signs a patient may experience immediately 
after a mild TBI, the injury may subsequently affect that patient’s ability to 
remain in employment. Patient centred outcomes are particularly relevant when 
discussing consequences of injuries with patients in an Emergency Department 




setting. This may be the only opportunity to explain to a patient what has 
happened to them and what they can expect to experience. The capacity to be 
able to prognosticate, that is, to describe to a patient the chance of an outcome 
occurring, is of great value both to the patient and to the physician. A pragmatic 
real-world outcome that can be readily measured is whether or when a patient 
returns to work after an injury. 
S100B is the most established biomarker for mild TBI and is associated with 
compelling evidence for its use in discriminating patients with acute 
abnormality on CT from those without. The evidence that it discriminates 
between patients that will go on to have longer term sequelae and those that will 
not, is not as compelling. Nevertheless, S100B is incorporated into the head 
injury assessment guidance of several European countries. An important 
consequence of mild TBI is seizure, which can occur at the time of injury, soon 
after or persist to become post-traumatic epilepsy. Seizure is also a common 
reason for patients to attend the Emergency Department. Seizures carry a 
significant morbidity in themselves and can result in poor outcomes such as 
physical injury, time off from working, degeneration into status epilepticus and 
hypoxic brain damage and death. Identifying the proportion of patients with 
seizure that attend the Emergency Department following a mild TBI, and the 
risk of recurrence after seizure of any kind, is important because an intervention 
could be made to reduce the risk of recurrence and consequent potential poor 
outcomes.  





1. To investigate the relationship between mild traumatic brain injury and 
the time it takes for a patient to return to work after the injury. 
2. To investigate the short-term changes in neurocognitive function and 
symptom burden following mild traumatic brain injury. 
3. To determine the number of patients with traumatic brain injury that 
attend the Emergency Department with a seizure and investigate the 
value of the biomarkers S100B and copeptin in predicting outcomes 
following seizure.  




Chapter 2 A Systematic Review and Meta-analysis of Return 
to Work after Mild Traumatic Brain Injury 
Introduction 
There are many outcomes reported following mild TBI and their pragmatic 
relevance can be difficult to apply or communicate to patients immediately after 
injury. Mild TBI outcomes include assessments for symptoms, functional 
outcomes, fatigue, pain, insomnia, depression, resilience and 
neuropsychological test scores.371-373 Persistent symptoms or cognitive deficits 
can impact on a patient’s ability to work.371,374-377 Some researchers estimate up 
to a third of patients have persistent problems with employment at six 
months.378 This variation in rates of return to work may be due to differences in 
the definition of mild TBI, geography, classification of occupation, or payment 
systems.74,174,379-381 The indirect costs, i.e. cost of resources lost owing to illness, 
associated with TBI in Europe, is estimated at around €20 billion a year.76 
Return to work is a pragmatic real-world outcome with direct relevance to 
patients and quality of life, and thus a clear understanding of the numbers of 
patients that return to work is essential.77-79 This review aims to determine the 
time taken for an adult to return to work or usual activities after they sustain a 
mild TBI.  






The primary objective for this study was to determine how long it takes adults 
that have sustained a mild TBI to return to work following the injury. 
Outcomes 
Primary outcome 
The primary outcome was return to work. This could be reported either as an 
average (mean or median) time from injury to return to work, as the number of 
sick days taken, or whether the patient had returned to work at or by a pre-
defined point in time after injury. Return to work was defined as any return to 
work regardless of level of duty. The aggregation of all levels of return to work 
was taken for pragmatic reasons as the expectation was that the degree of 
heterogeneity associated with including levels of return to work would preclude 
analysis. 
Secondary outcome 
The secondary outcome was the degree of return to work, which was defined as 
either to the same duties as prior to injury, or to modified duties. Modified 
duties were defined as reduced time at work or less physically or mentally 
demanding duties at work.  






Articles were included if they met the following criteria: 
Population 
• Adults (16 years or above) with mild TBI. Articles were accepted if mild TBI 
was defined by the authors, but definitions of mild TBI were expected to be 
those derived by the American Congress of Rehabilitation Medicine, the 
American Academy of Neurology, the World Health Organisation 
Collaborating Task Force on MTBI, or the Center for Disease Control and 
Prevention (Appendix 1).6,8,382 Studies including patients with moderate or 
severe TBI were included if a mild TBI subgroup was reported separately. 
Setting 
• Patients were identified or recruited from any area so long as they fulfilled 
the inclusion criteria. This could have been from the Emergency 
Department, an in-patient ward, or an out-patient clinic. 
Study design/publication type 
• Controlled trial or observational cohort study (retrospective or prospective, 
i.e. case-control, cohort, or cross-sectional) reporting 30 or more patients 
with mild TBI. 
Language 
• English or translation into English available.  





• Studies that recorded the final measurement of return to work at less than 
one month, or the first measurement at more than one year were excluded. 
This excluded papers that measured return to work only over a very short 
time after injury or only following a very long time after injury. 
• Studies that recorded only moderate or severe TBI or studies from which it 
was not possible to isolate a mild TBI subgroup were excluded. This 
excluded papers that did not include analysable patients with mild TBI. 
Study design 
This was a systematic review and meta-analysis of return to work following mild 
TBI. The protocol for this study was written according to guidance set out in the 
Preferred Reporting Items for Systematic review and Meta-Analysis Protocols 
(PRISMA-P) 2015 statement.383,384 The methods described below were designed 
in accordance with the Preferred Reporting Items for Systematic review and 
Meta-Analysis (PRISMA) statement (Appendix 4Appendix ).385 The protocol 
was registered with PROSPERO (reference CRD42018086349).386 
Information sources 
The following electronic databases were searched: Embase, Medline, PsycINFO, 
PubMed, the Cochrane Central Register of Controlled Trials, the Trip database, 
Clinicaltrials.gov, the European Clinical Trials Registry, the International 
Standard Randomised Controlled Trials registry (ISRCTN), the Australia and 
New Zealand Clinical Trials Registry, the Clinical Trials Registry of India, the 
China Clinical Trials Registry, the Brazilian Clinical Trials Registry, and the Pan-
African Clinical Trials Registry.  





Medline was searched using the following terms: (((tbi).ti,ab OR (mtbi).ti,ab OR 
(mild tbi).ti,ab OR ("mild tbi").ti,ab OR (minor tbi).ti,ab OR ("minor tbi").ti,ab 
OR (mild traumatic brain injury).ti,ab OR ("mild traumatic brain injury").ti,ab 
OR (minor traumatic brain injury).ti,ab OR ("minor traumatic brain 
injury").ti,ab OR (mild head injury).ti,ab OR ("mild head injury").ti,ab OR 
(minor head injury).ti,ab OR ("minor head injury").ti,ab OR (mild head 
trauma).ti,ab OR ("mild head trauma").ti,ab OR (minor head trauma).ti,ab OR 
("minor head trauma").ti,ab OR (minor brain trauma).ti,ab OR ("minor brain 
trauma").ti,ab OR (concussion).ti,ab OR (concus*).ti,ab) AND (("return to 
work").ti,ab))) OR (((exp "BRAIN CONCUSSION"/) OR (exp "BRAIN 
INJURIES"/ OR exp "CRANIOCEREBRAL TRAUMA"/)) AND (exp "RETURN 




Articles were downloaded from the searched databases as a Research 
Information Systems (RIS) file into Endnote X8.0.1 (Clarivate Analytics, 
Philadelphia, PA, USA). From Endnote, all articles were uploaded into Rayyan, 
an online platform designed to assist in collaborative systematic reviews.387 
Selection process 
I performed an initial screen of identified articles by applying inclusion criteria, 
based on the titles and abstracts. Full text copies of the articles that met 
inclusion criteria, based on the title and abstract, were obtained and then 
reviewed as part of a second round of selection. During the second round, I and 




another reviewer (JA) independently re-applied inclusion criteria and applied 
exclusion criteria applied. In cases of non-agreement, a third reviewer (RW) 
adjudicated. 
Data collection process 
Once all eligible articles were identified, data were abstracted from the full text 
article into a Microsoft Excel file. In cases in which data were not present in the 
published article but it seemed likely that relevant data existed but was 
unpublished, I contacted the authors of the relevant articles. 
Risk of bias in individual studies 
Newcastle Ottawa Quality Assessment Scale 
Multiple tools for assessing bias have been developed, with no single tool being 
globally accepted.388 The most important domains of a tool are appropriate 
selection of participants, appropriate measurement of variables and appropriate 
control of confounding.388 In this review, I used a modified version of the 
Newcastle Ottawa quality assessment scale.389 The Newcastle Ottawa quality 
assessment scale comprises three domains: patient selection, patient group 
comparison, and whether the patient actually had the outcome purported to be 
measured. The scale categorises studies according to quality within each 
domain. Assessment of bias resulting from confounding factors, or patient 
group comparison, was less relevant to this review, because the focus was on a 
single patient group with a single outcome. Therefore, a modified version of the 
Newcastle Ottawa scale was used, which did not include an assessment of a non-
exposed cohort or comparability of cohorts. Disagreements between the 
abstractors over the risk of bias in specific studies were resolved by adjudication 
by a third abstractor. Within each of the domains of Selection and Outcome are 




three questions, and each question has a categorical answer, as below. Each 
study was subjected to six questions; three that assess selection bias and three 
that assess outcome bias. 
Assessment of selection bias 
A. Representativeness of the exposed cohort 
1. Truly representative of the average mild TBI 
2. Somewhat representative of the average mild TBI 
3. Selected group of users e.g. Nurses, volunteers 
4. No description of the derivation of the cohort 
B. Ascertainment of exposure 
1. Secure record (e.g. clinical record) 
2. Structured interview 
3. Written self-report 
4. No description 
C. Demonstration that outcome of interest was not present at start of study 
(Ascertainment of pre-injury employment status) 
1. All patients employed 
2. Patients were employed, including student/homemaker/other 
activity 
3. Pre-injury employment status unclear 
4. Pre-injury employment status not described  




Assessment of outcome bias 
A. Assessment of outcome 
1. Independent blind assessment 
2. Record linkage 
3. Self-report 
4. No description 
B. Was follow-up long enough for outcomes to occur 
1. Yes (at least one month) 
2. No 
C. Adequacy of follow up of cohorts 
1. Complete follow up - all subjects accounted for 
2. Subjects lost to follow up unlikely to introduce bias - lost <20% 
follow up, or description provided of those lost) 
3. Subjects lost to follow up likely to introduce bias - >20% loss to 
follow up 
4. No statement 
Data items 
See Appendix 2 for the data abstraction sheet. The following data items were 




4. Study or trial 
5. Prospective or retrospective 
6. Return to work reported as average or as proportion at pre-defined time 




7. Number of patients in study 
8. Number of patients followed up 
9. Percentage followed up out of included 
10. Number of patients in groups 





16. Definition of mild TBI 
17. Post traumatic amnesia 
18. Loss of consciousness 
19. Whether patients had intracranial haemorrhage 
20. Return to work level of duty 
21. Average time to return to work 
22. Pre-defined time point(s) at which proportion returned to work was 
measured 
23. Proportion of patients that returned to work by time point(s) 
24. Excluded patients if they had mental health problems, drugs/alcohol, 
previous TBI 
25. Assessment of bias measures in accordance with modified Newcastle 
Ottawa Quality Assessment Scale  





Data handling and descriptive analysis approaches 
Data were obtained in a systematic fashion as described above. Excel data were 
then imported in Stata for analysis (version 15MP, StataCorp, College Station 
TX, USA). All analyses were executed with Stata, using commands that are not 
actually included in the off-the-shelf versions of the software but are instead 
user written. Despite the “non-official” nature of the commands, they are quite 
well-documented (e.g. in the Stata Journal) and the meta-analysis command 
sets are broadly accepted. 
Some of the aggregate studies’ data were reported in descriptive fashion. For 
such reporting of continuous data, normality testing was first executed using the 
Shapiro-Wilk test. The Shapiro-Wilk tests the hypothesis that the data is not 
normally distributed, and therefore the null hypothesis that the data is normally 
distributed. A significant p value, which corresponds to rejection of the null 
hypothesis of normality, means that the data is not normally distributed. The 
central tendencies of non-normally distributed data were reported as medians 
with interquartile range (IQR), and that of normally distributed data as means 
± standard deviation (SD). Central tendencies were only calculated for data with 
at least six observations. 
Model formulation 
Fixed-effect vs. random-effects 
The fixed-effect assumption is that the published articles being assessed are all 
estimating a single effect-size “truth” that is theoretically shared in all of the 
studies. Whatever selection and other biases may exist in the study set; the 
judgment of an investigator is that the underlying “truth” is the same. In a fixed-




effect paradigm, the effect that is observed is denoted Ti and this is a function of 
the true population effect mean (μ) and an error term ε. The fixed-effect means 
that there are no other sources of deviation of Ti besides the within-studies 
error. The weighting of the meta-analysis thus follows a simple inverse-variance 
formula, weighting studies on the amount of information within those studies, 
so each study (i) has a weight equal to 1/vi. 
In the random-effects model, each study is said to estimate a different 
parameter (e.g. return to work in patients who are somehow different in one 
study as compared to another). The random-effects model postulates that 
differences in varying studies’ results are not simply a function of sampling. 
The random-effects model approach allows for differences in patients, study 
design, or any other factor(s) that could contribute to identification of different 
point estimates for return to work across the included analyses. In most cases 
the random-effects model is more conservative. The random-effects model 
calculates a variance parameter, which represents the heterogeneity across 
studies. When the variance parameter is estimated at zero the random-effects 
model essentially reduces to a fixed-effects model. 
In this study, a random-effects meta-analysis was preferentially used to pool the 
mean proportion of patients that had returned to work by a specific time point. 
The random effects rather than fixed effect method was selected because the 
sample populations were expected to be sufficiently varied to assume that any 
variation in return to work between studies would not have been due to chance. 
Specifically, patients were expected to have been recruited from different 
settings or to have different injury characteristics (proportions with complicated 




mild TBI, lengths or proportions of post-traumatic amnesia and loss of 
consciousness). 
Estimated parameter in this meta-analysis: Stata commands and associated 
statistical approach 
The study employed Stata’s metaprop command set, which is an extension of 
Stata’s metan suite of commands.390,391 The metaprop command suite includes 
reporting of I2 and also a reporting of a p value assessing for heterogeneity. 
Based on the work by Higgins et al the preferred measure of heterogeneity is the 
I2.392 This runs from 0%, meaning that all inter-study variation is due to chance, 
to 100%, meaning that all inter-study variation is due to heterogeneity between 
studies. I2 interpretation guidelines are not rigidly set. The suggested specific 
adjective wording for interpreting I2 is follows: ≤25% = low, 25-50% = 
moderate, and ≥75% = high heterogeneity. An alternative measure of 
heterogeneity is Cochrane’s Q, calculated as a weighted sum of squared 
differences between the individual effect and the pooled effect. It is distributed 
as a χ2 statistic. The hypothesis tested by the Cochran’s Q test is that the 
variables analysed are different, and therefore the null hypothesis is that there 
is no difference between the variables. If the p value is significant, then the null 
hypothesis is rejected. The conclusion therefore is that the proportions in at 
least two of the variables are significantly different to each other, i.e. that there 
is heterogeneity. The magnitude of variance between studies was measured with 
the τ2 statistic.393 The τ2 statistic is the estimate of the variance of the true effect 
size between studies, with the assumption that the effect is randomly, normally 
distributed between studies. 




Ninety-five percent confidence intervals and two-sided p-values were calculated 
for the summary effect sizes. Assessment of any sources of heterogeneity was 
performed using meta-regression. Publication bias is commonly reported in 
systematic reviews and meta-analyses investigating efficacy studies, however 
funnel plots have been found to be an inaccurate measure of reporting bias in 
studies of proportion and consequently were not be performed as part of this 
analysis.394  






Six databases and six clinical trial registries returned a total of 978 unique titles. 
Following application of the inclusion criteria to the titles and abstracts, and 
then reapplication of the inclusion and application of the exclusion criteria to 
full text copies, fourteen studies were identified for the final data abstraction 
(Figure 2.1).  
Two studies reported the outcome as the average time taken for patients to 
return to work (Reynolds et al, Iverson et al171,395), 11 reported the outcome as 
the proportion of patients that returned to work at pre-specified time 
points,74,169,174,312,376,396-401 and one reported both371 (Table 2.1 and Table 2.2). All 
studies except one reported mean age, which ranged from 28 to 46.5 years.376 
Five studies reported an age range, which was from 16 to 65 years.171,174,376,395,398 
The lower age was 16 in four studies and 19 in a fifth, and the upper age ranged 
from 46 to 65. The proportion of male sex ranged from 45% to 77% in the 14 
studies (Table 2.1 and Table 2.2).  





Figure 2.1 Article inclusion flow chart 
CENTRAL, Cochrane Central Register of Controlled Trials; EU-CTR, European 
Union Clinical Trials Registry; ISRCTN, International Standard Randomised 
Controlled Trials Number; ANZCTR, Australia and New Zealand Clinical Trials 
Registry; CTRI, Clinical Trials Registry of India; ChiCTR, Chinese Clinical Trial 
Registry; ReBec, Brazilian Clinical Trials Registry; PACTR, Pan-African Clinical 
Trials Registry; TBI, traumatic brain injury; RTW, return to work.  




Studies reporting average time to return to work 
Three studies reported average time to return to work (Table 2.1).171,371,395 Of the 
studies reporting average time to return to work, the largest, by Reynolds et al 
(n=118), reported a group with the shortest average time to return to work.395 
This study grouped patients into those not seeking compensation for their injury 
(non-seekers), those seeking social benefits, those in litigation, and both. For 
non-seekers (n=62), the median time to return to work was four days, but mean 
was 72 (SD 139). Those seeking social support (n=14) or in litigation (n=15) were 
similar to each other with median time to return to work 43 and 40 days (mean 
114 [SD 137] and 100 [SD 136]) respectively. Only six patients sought both, and 
their return to work times were longest; median 304 days (mean 245 [SD 175]). 
Iverson et al reported return to work in patients with uncomplicated and 
complicated mild TBI. In patients with uncomplicated mild TBI the median time 
to return to work was 6 days (IQR 1-15, mean 13 [19]), compared to 36 days (IQR 
14-53, mean 58 [84]) in patients with complicated mild TBI.171 There was a 
significant difference in return to work times between the two groups, but the 
differences between the mean and median, the large SD and IQR, and the small 
numbers in the groups, indicate significant variation. This variation was seen in 
all three studies that report average time to return to work. Iverson et al and 
Losoi et al reported the proportion of patients with complicated mild TBI (28% 
of 47 patients and 10% of 115 patients).171,371 Those same two studies report post-
traumatic amnesia, but the results are very different; 333-366 minutes in the 
study by Iverson et al, containing 47 patients, and 156 minutes in the study by 
Losoi et al, containing 115 patients. Losoi et al reported loss of consciousness 
and all three reported years of education, which were from 13 to 14 years (Table 
2.1). Reynolds et al did not report mechanism of injury, Iverson et al reported 




only the proportion of patients involved in an MVA (44%), and Losoi et al 
reported mechanism in all patients.171,371,395 






















Return to work in days 
Mean (SD) or 
median (IQR) 
Reynolds, S, 2003395 
Identified from hospital emergency wards, 
invited to enrol by telephone/ letter, 
recruited mean 12 days from injury. 
Mechanism not reported but these 
patients were classified according to their 
status of seeking compensation for their 
injury: 64% not seeking, 14% seeking 
administrative compensation, 16% in 
litigation, 6% both. 
ACRM 118 88% Yes 33 (12) 45% 14 years --- --- --- 93 (140) * 
Iverson, GL, 2012171 
Identified in and recruited from ED of 
Tampere, University Hospital, Finland. 
44% MVA. Divided patients into those 





100% No 30 (9) 51% 13 years 28% --- 
UC. 333 
C. 366 
Overall: Mean 25 (50) * 
Uncomplicated: Mean 
13 (19), Median 6 (1-15) 
Complicated: Mean 58 
(84), Median 36 (14-53) 
Losoi, H, 2016371 
Identified in and recruited from ED of 
Tampere, University Hospital, Finland. 
Sports 18%, falls from height 16%, car 
accidents 16%, bicycle accidents 15%, 
ground-level falls 14%, motorcycle 
accidents 7%, violence related injuries 5%, 
other 10%. 
WHO 115 87% Yes 37 (12) 61% 14 years 10% 37% 
156 min 
92% 
Mean 55 (139) 
Median 16 (5-42) 
Table 2.1 Studies that report an average number of days taken to return to work 
N, number included in study; % FU, percentage of sample followed up for return to work outcome at first follow-up time point; Excl., patients 
excluded if they had a history of mental health problems, drugs, alcohol or previous TBI; SD, standard deviation, where not reported, not available; 
IQR, inter-quartile range; ED, Emergency Department; definition is the definition of mild TBI used in the source article; LOC, loss of 
consciousness; PTA, post traumatic amnesia; ACRM, American Congress of Rehabilitation Medicine; ---, not available/reported; MVA, motor 
vehicle accident; UC, uncomplicated mild TBI (no acute abnormality on computed tomography [CT] head); C, complicated mild TBI (acute 
intracranial abnormality on CT head); WHO, World Health Organisation Collaborating Task Force on MTBI. *Overall mean (SD) calculated by 
authors.  










































Dikmen, SS, 1994396 
Identified in & recruited on wards at 
Shock Trauma Units in MA, USA, 
followed up in clinic. Sample 
reported included patients with 
moderate and severe TBI. Data on 
mTBI extracted for this review. 




213 --- Yes 
30 
(11) 











Ruffolo, CF, 1999174 
Identified as in-patients at large 
tertiary care centre in Toronto, 
Canada, recruited average 13 (SD 7) 
days post injury. All patients had 
MVA. 
ACRM 63 79% Yes 
31 
(10) 






--- --- --- 
Haboubi, NHJ, 2001399 
Identified from ED or <48hrs hospital 
admission in North Staffs, UK. 
Recruited in 1st assessment in head 
injury clinic 2 weeks post injury. 
MVA 31%, other 28%, assault 27%, 
sport 8%, industrial 6%. 
Clinical 
diagnosis 






McCullagh, S, 2001397 
A consecutive sample of mild TBI 
patients receiving follow-up care at 
a tertiary TBI referral clinic in 
Toronto, Canada. Recruited ~6 
months post injury. MVA 74%, 
sports 9%, falls 8%, assaults 2%, 
other 7%. 
 











--- --- --- 




Hughes, DG, 2004401 
Identified in and recruited from ED in 
Salford, UK. Assaults 60%, falls 30%, 
MVA 9%, 1%. 
ACRM 73 49% Yes 31 73% --- 6% 53% 39% 
6 months 
81% 
--- --- --- 
Stulemeijer, M, 2008169 
Identified in and recruited from ED in 
a level I trauma centre in Nijmegen, 
Netherlands. MVA 55%, falls 20%, 
sports 10%, other 15%. 






20% 36% 61% 
6 months 
76% 
--- --- --- 
Ryb, GE, 2014312 
Identified in and recruited from 
Shock Trauma Center, MA, USA. 
Excluded complicated mTBI. 55% 
MVA. 















Vikane, E, 2014398 
Identified during admission to 
Department of Neurosurgery in 
Level 1 Trauma Centre, Bergen, 
Norway, recruited in clinic ~2 
months post injury. RTW 
ascertained from national database. 
Falls 46%, MVA 20%, assault 24%, 
sports && other 11%. 10% were 
injured at work. 
WHO & 
ACRM 












Waljas, M, 201474* 
Identified in and recruited from ED in 




112 97% No 
37 
(13) 














               
Vikane, E, 2016376 
Identified during admission to 
Department of Neurosurgery in 
Level 1 Trauma Centre, Bergen, 
Norway. Recruited from clinic ~2 
months post injury if sick-listed or at 
risk of being sick-listed with 
persistent post-concussion 
symptoms. MVA 55%, falls 20%, 
sports 10%, other 15%. 
WHO & 
ACRM 
















Losoi, H, 2016371 
Recruited from ED of Tampere, 
University Hospital, Finland. Sports 
18%, falls from height 16%, car 
accidents 16%, bicycle accidents 
15%, ground-level falls 14%, 
motorcycle accidents 7%, violence 
related injuries 5%, other 10%. 
WHO 115 87% Yes 
37 
(12) 











de Koning, ME, 2017400 
Identified in and recruited from EDs 
of three Level 1 Trauma Centres in 
the Netherlands. MVA 17%, bicycle 
32%, pedestrian 3%, fall 38%, 
violence 5%, sports 2%, other 3%. 
WHO 319 92% Yes 
47 
(19) 










Table 2.2 Studies that report the proportion of patients that have returned to work at a pre-specified time point 
Def. definition of mild TBI used; N, number included in study; FU, percentage of sample followed up for RTW outcome at first follow-
up time point; Excl, patients excluded if they had a history of mental health problems, drugs, alcohol or previous TBI; ED, Emergency 
Department; SD, standard deviation, where not reported, not available; %M, percentage of population that were male; LOC, loss of 
consciousness; PTA, post traumatic amnesia; RTW, return to work; ED, Emergency Department; ACRM, American Congress of 
Rehabilitation Medicine; ---, not available/reported; MVA, motor vehicle accident; ED, emergency department; EFNS, European 
Federation of Neurological Societies; WHO, World Health Organisation Collaborating Task Force on MTBI; IQR, interquartile range. 
*This article reports a further two time-points: at 2 months 92% had RTW and at 12 months 97% had RTW. 
 




Studies reporting the proportion of patients returned to work by a pre-
specified time point 
In the 12 studies that described return to work as a proportion, the time points 
at which patients were most frequently assessed were 12 months (seven studies), 
six months (six studies), and two months, one month, and two weeks (three 
studies each) (Figure 2.2). The number of time points at which return to work 
was assessed in each study varied from one to six (Figure 2.3). 
Table 2.3 shows all time points with return to work proportions. Ten studies 
excluded patients with mental health problems, alcohol or drug use, and 
previous TBI, nine reported acute abnormalities on CT, five reported loss of 
consciousness, and six reported post-traumatic amnesia. Two did not report 
mechanism of injury, and one reported only the proportion involved in a motor 
vehicle accident. Five recruited patients in the Emergency Department, five as 
in-patients, and two in clinic. Recruitment times varied from <24 hours from 
mild TBI to six months (Table 2.1 and Table 2.2).  





Figure 2.2 Frequency of follow up time points reported 
 
 
Figure 2.3 Number of follow ups by article  




Table 2.4 and Figure 2.4, Figure 2.5, Figure 2.6, and Figure 2.7 show pooled 
proportions of return to work at pre-specified time points. In the two studies 
that report return to work at one week after mild TBI, almost half of patients 
had returned to work.74,400 Both of those studies recruited patients from the ED, 
i.e. patients were not deemed sufficiently unwell by treating physicians to 
warrant admission into hospital. 
Three studies reported return to work at one month with rates of 25%, 68% and 
75%.74,371,396 The pooled proportion of patients having returned to work at one 
month was 56% (95% CI 30-79%). Dikmen et al reported 25% having returned 
to work at one month, but the results reported in this study are outliers for all 
time points at which return to work was recorded.396 This study is more than 20 
years old, reported all severities including severe TBI, and patients were drawn 
from three prospective longitudinal studies. I extracted data on the mild TBI 
subgroup for this review, and although all patients were unwell enough to 
warrant admission to hospital, further detail regarding injury severity for the 
mild TBI subgroup was not available.  





Figure 2.4 Forest plot of proportion of patients returned to work by 
one month 
 
Three studies reported return to work at two months with rates of 44%, 80%, 
and 92%.376,398,400 The pooled proportion of patients that had returned to work 
by two months was 72% (95% CI 48-96%). Vikane et al reported a substantially 
lower return to work rate of 44%.376 The patients in this study were identified 
whilst admitted acutely to a neurosurgical department and then selectively 
recruited around two months post injury if they were taking sick leave, or had 
sufficient persistent post-concussion symptoms that they were deemed at risk 
of taking sick leave. Therefore, patients with mild TBI without persistent 
symptoms were excluded from this study. In an adjusted logistic regression 
model, the authors found one pre-injury variable and three post-injury variables 
that predicted failure to return to work at 12 months, namely having taken sick 
leave the year before injury, having anxiety or depression, poorer scores on the 
Glasgow Outcome Scale Extended or taking sick leave at two months after 
injury. This study also included patients with the highest proportion of 
complicated mild TBI at 27%, and although this was not found to be predictive 




of return to work at 12 months, the authors did not analyse for return to work at 
two months. 
 
Figure 2.5 Forest plot of proportion of patients returned to work by 
two months. 
  




At six months, most patients had returned to work in all studies. The pooled 
proportion of patients that returned to work by six months was 81% (95% CI 73-
89%). The lowest rates of return to work were 63%, reported in the study by 
Dikmen et al, and 76% in the study by Stulemeijer et al of 280 patients with mild 
TBI identified and recruited from an Emergency Department in the 
Netherlands.169,396 The patients in this latter study included one of the highest 
proportions of patients with complicated mild TBI. This is despite the sample 
having been recruited from the Emergency Department, and therefore 
potentially having included patients that were discharged and not admitted into 
hospital. 
 
Figure 2.6 Forest plot of proportion of patients returned to work by 
six months. 
  




At 12 months, the great majority of patients had returned to work, with two 
studies reporting more than 90% of patients returned to work, four studies 
reporting 80-90% of patients returned to work, and one study reporting 76% 
returned to work (Table 2.3). The pooled proportion of patients that returned to 
work by 12 months was 88% (95% CI 83-93%). The lowest proportion of patients 
having returned to work at 12 months was 76%, reported in the study noted 
above for having selectively recruited patients that were both ‘sick-listed’ or ‘at 
risk of being sick-listed’ with persistent post-concussion symptoms.376 
 
Figure 2.7 Forest plot of proportion of patients returned to work by 
one year. 
  




For the purposes of this review, I dichotomised any description of levels of 
return to work as either return to work in any capacity, or not returning to work. 
The category of ‘return to work in any capacity’ was an aggregate of ‘full’ (same 
duties as prior to injury) and ‘partial’ return to work (fewer hours and/or lighter 
duties). Two studies described partial return to work.174,400 In 42% of 63 in-
patients that returned to work at six to nine months, 12% had returned to work 
at pre-injury levels, and 30% had partial return to work.174 In 319 Emergency 
Department patients, the proportion of partial return to work remained broadly 
consistent at 16-17% at two weeks, three months, and six months but at 12 
months was reduced to 10%. In contrast, no return to work gradually dropped 
from 51% at two weeks to 12% at 12 months, and full return to work gradually 
rose from 33% at two weeks to 78% at 12 months.400 
 
Figure 2.8 Return to work proportions at time points by study. RTW, 
return to work 
 





























Dikmen396    25%     63%  80% 83% 
Ruffolo174          42%   
Haboubi399  44%   73%        
McCullagh397        52%     
Hughes401         81%    
Stulemeijer169         76%    
Ryb312       66%  90%  89%  
Vikane398      80%     88%  
Waljas74 47% 60% 67% 75%  92%     97%  
Losoi371    68%     93%  96%  
Vikane376      44%     76%  
De Koning400 49%      79%  84%  88%  
 
Table 2.3 Percentage of patients returned to work by each pre-specified time point in each article








   
One week   
Waljas 2014 0.47 0.38 - 0.57 
De Koning 2017 0.49 0.43 - 0.55 
Random pooled ES 0.48 0.44 - 0.57 
   
Two weeks   
Haboubi 2001 0.44 0.39 - 0.49 
Waljas 2014 0.60 0.51 - 0.68 
Random pooled ES 0.48 0.43 - 0.52 
   
One month   
Dikmen 1994 0.25 0.20 - 0.31 
Waljas 2014 0.75 0.66 - 0.82 
Losoi 2016 0.68 0.59 - 0.76 
Random pooled ES 0.56 0.30 - 0.79 
χ2 = 125.16, p < 0.01; I2 = 98.4%, τ2 = 0.09 
   
Two months   
Vikane 2014 0.80 0.75 - 0.85 
Waljas 2014 0.92 0.85 – 0.96 
Vikane 2016 0.44 0.36 - 0.52 
Random pooled ES 0.72 0.48 - 0.96 
χ2 = 102.08, p < 0.01, I2 = 98.0%, τ2 = 0.04 
   
Three months   
Ryb 2014 0.66 0.59 - 0.73 
De Koning 2017 0.79 0.74 - 0.83 
Random pooled ES 0.75 0.71 - 0.79 
   
Six months   
Dikmen 1994 0.63 0.56 - 0.69 
Hughes 2004 0.80 0.69 - 0.88 
Stulemeijer2008 0.76 0.71 - 0.81 
Ryb 2014 0.90 0.85 - 0.94 
Losoi 2016 0.93 0.87 - 0.96 
De Koning 2017 0.84 0.80 - 0.88 
Random pooled ES 0.81 0.73 - 0.89 
χ2 = 72.31 (df = 4), p < 0.01, I2 = 93.1%, τ2 = 0.01 
Test of ES=0: z = 5.67, p = 0.00 
   
12 months   
Dikmen 1994 0.80 0.74 - 0.85 
Ryb 2014 0.89 0.83 - 0.93 
Vikane 2014 0.88 0.83 - 0.91 
Waljas 2014 0.97 0.92 - 0.99 
Losoi 2016 0.96 0.90 - 0.98 
Vikane 2016 0.76 0.69 - 0.82 
De Koning 2017 0.88 0.84 - 0.91 
Random pooled ES 0.88 0.83 - 0.93 
χ2 = 63.23, p < 0.01, I2 = 90.5%, τ2 = 0.00 
Test of ES=0: z = 1.63, p = 0.10 
Table 2.4 Pooled return to work proportions by time point. 
RTW, return to work; ES, effect size  




Assessment of bias 
Selection bias 
Five of 14 studies were assessed to include patients truly representative of mild 
TBI. This assessment was based on those studies recruiting patients from the 
Emergency Department, and hence likely to include patients with a range of 
acuities within the category of mild TBI, including those eligible for discharge 
and those that needed admission.74,169,371,400,401 Five studies were assessed to be 
somewhat representative of patients with mild TBI. One of these included 
patients that were invited to attend by post, and hence were self-selected,399 
three recruited patients from an in-patient ward, and therefore excluded those 
that were discharged from the Emergency Department and consequently may 
have biased results to select a group with higher acuity,74,395,398 and one was 
from a larger study whose methods were not clearly described but the patients 
did present to the Emergency Department.171 Four studies included patients that 
were highly selected: one included only patients that sustained a mild TBI after 
a motor vehicle collision, one included patients with moderate and severe TBI, 
and one recruited only in-patients but excluded patients with complicated mild 
TBI.174,396,397 
Ascertainment bias: pre-injury employment 
Of the 14 included studies, two only included patients that were exclusively in 
paid employment prior to injury.396,400 Four studies included patients with mild 
TBI that were either in paid employment or otherwise occupied i.e. either 
students, home-makers, or carried out other daily activities, but not 
unemployed for reasons of sickness.74,174,371,395 The proportion of patients that 
were in paid employment, students, home-makers, or other were not reported. 
Seven studies reported rates of return to work but the number of patients that 




were working prior to injury was not reported in the articles,171,312,376,397-399,401 
however three of those studies explicitly excluded patients that were either 
retired or on sick leave prior to injury, thereby increasing the internal validity of 
the findings reported.376,397,401 One study did not include any description of 
employment status prior to injury.169 
Ascertainment bias: return to work after injury 
Six studies reported follow up in more than 90% of recruited patients (Table 2.1 
and Table 2.2).74,171,376,397,398,400 The outcome return to work was ascertained by 
self-report in 12 studies,74,169,171,174,312,371,395-397,399-401 and by data linkage from 
national databases in two studies.376,398
























Dikmen 1994 3 
Drawn from three studies that 
included moderates and severe, 
and inclusion criteria not clear - 
published across four separate 
articles. 
1 1 
All patients were 'workers' - 
defined as major pre-injury 






Proportion or patients 
followed up not described 
13 
Ruffolo 1999 3 
All patients had motor vehicle 
collisions so excludes other 
mechanisms of injury 
1 2 
Patients were working before 
the accident in paid or unpaid 
employment (e.g., as a student, 






79% followed up 
13 
Haboubi 2001 2 
Self-selected as invited to 
participate by post - 1255 invited, 
639 responded 
1 3 
Unclear exactly how the 
authors calculated RTW, but 
text implies that only patients 
that were employed pre-injury 





38% followed up 
13 
  




McCullagh 2001 3 
Recruited from TBI clinic so excludes 
those not followed up in clinic 
1 3 
90% of patients were employed 
prior to injury and RTW was 
defined as return to previous 
work or studies. Patients that 
were retired prior to injury, and 
those who remained off work 
for reasons other than their 
TBI, such as persisting 






100% followed up 
12 
Reynolds 2003 2 
Recruited as in-patient so excludes 
those discharged from ED 
1 2 
Patients reported their pre-
injury occupational status as 
working, student, 






88% followed up 
11 
Hughes 2004 1 
Recruited from ED 
1 3 
Describes RTW rates and 
excludes patients that were 
‘not applicable’, therefore 
implying that patients 











Recruited from ED 
1 4 
Patients pre-injury 






72% followed up 
13 
  




Iverson 2012 2 
Sample is from a larger study but no 
reference to methodology for 
recruiting to it 
1 3 
A 'known duration of time off 
work' is reported, therefore 
implying but not explicit that 






100% followed up 
11 
Ryb 2014 3 
Recruited as in-patient so excludes 
those discharged from ED, and 
excluded complicated mTBI 
1 3 
90% of patients were 
employed prior to injury. RTW 
rates not explicitly calculated 





61% followed up 
14 
Vikane 2014 2 
Recruited as in-patient so excludes 
those discharged from ED 
1 3 
Included patients that could 
have been employed prior to 
injury but didn't report which 
were employed. Excluded 
those on sick leave for a year 








1 1 10 
Waljas 2014 1 
Recruited from ED 
1 2 
All patients were working or 





97% followed up 
10 
Losoi 2016 1 
Recruited from ED 
1 2 
Included patients that were 
employed, students, or 
unemployed prior to injury. If 
students or unemployed, 
return to work was defined as 





87% followed up 
10 
  




Vikane 2016 2 
Recruited as in-patient so excludes 
those discharged from ED 
1 3 
RTW defined as not sick listed 
on Norwegian Welfare 
Registry. Included patients that 
were employed and 
unemployed and defined return 
to work as ‘not on sick leave’, 
therefore patients that were 
unemployed but not on sick 
leave after injury were 










100% followed up 
10 
de Koning 2017 1 
Recruited from ED 
1 1 
Recruited patients that were 





92% followed up 
9 
Table 2.5 Results of Newcastle Ottawa Score for the assessment of bias 
Representativeness of the exposed cohort (1=truly representative of the average mild TBI; 2=somewhat representative of the average mild TBI; 
3=selected group of users e.g. nurses, volunteers; 4=no description of the derivation of the cohort). Ascertainment of exposure (1=secure record 
(e.g. surgical records); 2=structured interview; 3=written self-report; 4=no description). Demonstration that outcome of interest was not 
present at start of study. (1=yes; 2=no). Assessment of outcome. (1=independent blind assessment; 2=record linkage; 3=self-report; 4=no 
description). Was follow-up long enough for outcomes to occur (1=yes; 2=no). Adequacy of follow up of cohorts (1=complete follow up - all 
subjects accounted for; 2=subjects lost to follow up unlikely to introduce bias - lost <20% follow up, or description provided of those lost); 
3=follow up rate <50% and no description of those lost; 4=no statement)





This systematic review is to my knowledge the most comprehensive review 
published that specifically and exclusively included mild TBI patients in whom 
return to work or usual activities was measured. It is also the most methodically 
performed and presented review with respect to mechanism of injury, injury 
characteristics (loss of consciousness and post-traumatic amnesia), exclusion 
criteria (e.g. psychiatric history or previous TBI), and years in education.  
The principal finding of this study was that by one month only 50% and by six 
months 80% of patients with mild TBI have returned to work. Fourteen studies 
were identified of which three reported return to work after mild TBI as an 
average, 12 reported return to work as a proportion at a pre-specified time point 
(one reported both). Average return to work times varied from mean 25 to 93 
days, but interpretation of these times is limited by the small number of studies, 
which include small numbers of patients, with wide variability and skewed 
distributions. Proportions of patients returning to work gradually increased as 
time passed from just under 50% at one and two weeks to the great majority by 
six months. There was significant heterogeneity at all time points. Study quality 
was poor, with only six studies reporting >90% follow up rates, and only five 
enrolling a representative sample of patients with mild TBI. i.e. enrolled 
patients with mild TBI from the Emergency Department prior to decision to 
admit or discharge. Only the study by De Koning et al recruited patients in paid 
employment prior to injury, and with only mild TBI, from the Emergency 
Department, and followed up more than 90% of them. 




There have been several previous reviews of return to work after TBI, but few 
included only studies of patients with mild TBI. This is also the first review that 
includes a meta-analysis of return to work in patients with only mild TBI. Van 
Velzen et al reported a review of return to work after acquired brain injury, 
which included traumatic and non-traumatic causes of brain injury.402 Forty-
nine studies were included and return to work rates in traumatic and non-
traumatic brain injury, at one and at two years, were very similar at around 40%. 
The patients included in this review were very heterogenous and included 
patients with stroke, sub-arachnoid haemorrhage and all types of TBI. Another 
review of return to work in patients with all types of TBI, by Saltychev et al, 
identified 12 controlled and 68 uncontrolled studies of rehabilitation or other 
treatment measures.403 They found that studies were very poorly designed but 
showed no strong evidence that vocational outcomes could be predicted or 
improved. In a 2014 systematic review of return to work after mild TBI, four 
studies were included, of which only one, by Stulemeijer et al, met eligibility 
criteria for my review.169,379 The authors concluded that up to 20% of patients 
with mild TBI may experience symptoms that persist for longer than six months. 
In this review I found that return to work rates are around 75% at three months 
and around 80% at six months. In line with several other reviews of recovery 
after TBI, most patients had returned to work by six months. This is broadly 
similar to patients with an ankle fracture requiring surgery, but patients that 
have surgery for an ankle fracture may undergo extensive physiotherapy.404 In 
contrast, in the US, 38% of all annual mild TBI Emergency Department 
attendances, accounting for more than two million patients, are discharged 
from the Emergency Department with no follow-up.50,54 




For return to work to be a meaningful outcome, the population studied should 
be working prior to injury. In January to March 2018, out of an estimated total 
UK population of 63.2 million people, 67% (41.2m) were of working age (16 to 
64).405 Data from the UK Labour Force Survey revealed that 76% (32.4m) of 
people of working age were employed and 3% (1.4m) were unemployed but 
seeking or available to work (these two categories being collectively described 
as ‘economically active’), whilst 20% (8.7m) people were without a job and not 
seeking to find one (described as ‘economically inactive’).406 The economically 
inactive group includes students, home-makers, and those unable to work for 
reasons of disability. However, not all people with disabilities are economically 
inactive. Using a definition of disability consistent with the 2010 Equalities Act, 
in January to March 2018, there were 7.4 million people with a disability aged 
16-65 in the UK.407,408 Less than half of those (3.3m, 44% of people with 
disabilities, 8% of the whole population) were economically inactive. However, 
the reason for the economic inactivity is not necessarily their disability. When 
asked to self-report whether they had a condition that affected the amount or 
type of work they could do, 6.3 million people answered ‘yes’. Nevertheless, 51% 
(3.2m) of those were economically active: 2.9m (46%) were employed and 0.3m 
(1%) were unemployed; only 3m (49%) were economically inactive. This means 
that 3m people reported that they had both a condition that affected their work 
and were neither employed nor looking for employment. However, since half of 
people that have a condition that affects their work are nevertheless employed, 
it is not possible to infer that the medical condition is the reason for the 
economic inactivity in people who are economically inactive and have a 
condition that affects their work. Consequently, although return to work as an 
outcome is most relevant in employed people, more than three quarters of the 




UK population aged 16-65 are employed. Furthermore, paradoxically, having a 
condition that affects a person’s capacity to work, doesn’t necessarily affect 
whether they are employed or not. 
All studies included in this review investigated patients of working age, but only 
two studies included exclusively employed patients at the time of injury. Seven 
studies did not include a description of the pre-injury employment status of the 
study population or did not include an analysis of the patients that were working 
prior to injury. Of those seven, two report pre-injury employment rates of 90% 
but do not include an analysis of return to work in that subgroup. At 12 months, 
10% overall have not returned to work. This group may represent patients that 
do not have work to return to for various reasons, including disability, mental 
health or substance misuse problems or homelessness. Ten of the included 
studies tackle this by excluding patients with the above diagnoses (Table 2.1 and 
Table 2.2). 
Complicated mild TBI has been reported to be associated with poorer 
neuropsychological test performances and extended return to work times 
compared with uncomplicated mild TBI.171,227,409-411 Seven studies reported CT 
findings. In a study of 47 patients, 34 (72%) had uncomplicated and 13 (28%) 
complicated mild TBI. There was a significant difference in return to work times 
between the two groups (median 6 [11-15] vs 36 [14-53] days), but the 
differences between the mean and median, the large SD and IQR, and the small 
numbers in the groups, indicate substantial variation.171 In contrast, in the two 
studies that included such an analysis, having complicated mild TBI was not a 
predictor for persistent post-concussion symptoms or return to work.169,376 This 
is consistent with recent calls to discredit the concept of complicated mild TBI, 




at least based on CT findings.412 This is because many patients with complicated 
mild TBI have favourable outcomes. Furthermore, although the commonest 
imaging modality in the acute phase after brain injury is CT scan, it is usually 
normal in patients with mild TBI, and many of those patients with a normal scan 
have persistent symptoms.413 Localised inflammatory reactions in the brain 
microvasculature, traumatic axonal injury and microhaemorrhages resulting in 
haemosiderin deposits can be identified on MR imaging, and particularly 
susceptibility-weighted imaging, in patients that have normal CT scans on the 
day of injury. These may result in chronic structural abnormalities and could be 
a more accurate model for complicated mild TBI.412,414 
The strengths of this meta-analysis are that it was written in accordance with 
international guidance, and adhered to a robust, prospectively written search 
strategy and analysis plan. Studies were rigorously assessed for strict adherence 
to eligibility criteria. It is also, to my knowledge, the first systematic review and 
meta-analysis examining return to work exclusively in mild TBI patients. The 
main limitation presented by this review is the high level of heterogeneity found 
in the included articles. This heterogeneity may exist because there is little 
standardisation of outcomes in mild TBI research. There were few commonly 
recorded outcomes across 14 studies. Return to work was the primary outcome 
in 10 studies, and not even all studies reported the overall age of the sample. 
Other variables that were reported inconsistently were mechanism of injury, 
definition of mild TBI used, education, severity based on day of injury CT (or 
whether CT was performed), and injury characteristics including post traumatic 
amnesia and loss of consciousness. This variation may have accounted for the 
heterogeneity found in the meta-analysis and makes drawing further 




conclusions difficult. The Core Outcome Measures in Effectiveness Trials 
(COMET) initiative designs outcome sets that are disease based and although 
not designed to be restrictive or exclusive, are expected to be collected and 
reported to allow studies to be compared.415 Mild traumatic brain injury 
research would benefit greatly by standardisation. 
Conclusion 
Around half of patients with mild TBI have returned to work by one month after 
injury, and most by six months. Most studies had poor internal validity. 
Reporting of outcomes in mild TBI was variable, which means that it is difficult 
to draw conclusions regarding the importance of factors that predated the injury 
such as education, or factors that were associated with the injury such as the 
presence of loss of consciousness or amnesia. This variability accounted for 
some of the heterogeneity found in this review.  




Chapter 3 Short term neurocognitive and symptomatic 
outcomes following mild traumatic brain injury 
Introduction 
Mild TBI is an acute condition characterised by transient altered mental status 
and disorders of memory.9 There is therefore a cognitive dysfunction 
associated with mild TBI. The evolution of neurocognitive dysfunction in the 
early phase of mild TBI is poorly understood. Several small studies report an 
immediate neurocognitive deficit, however most of these enrolled fewer than 
fifty patients with TBI and all were single centre studies.177,203,204,416 In a 
population of more than a million patients in the US alone, many of whom are 
of working age, the consequences of failure to understand how neurocognitive 
dysfunction develops are enormous. Mild TBI has been called the silent 
epidemic because neurocognitive deficits that are not immediately apparent 
may persist.417 There remains a need to understand how neurocognitive 
function deficits develop over the early period following injury. How 
neurocognitive function is affected in patients that attend the Emergency 
Department for non-neurological or non-neurotraumatic reasons is 
completely unknown. There may be a cognitive deficit associated with 
Emergency Department attendance for any reason. 
The objective of this study was to study the cognitive function, symptom 
severity and number of symptoms in patients with mild TBI at baseline in the 
Emergency Department, and to re-evaluate them at 72 hours. The secondary 




objective of this study was to compare cognitive function, symptom severity 
and number of symptoms at both time points between patients with and 
without mild TBI. I hypothesised that there would be an improvement in 
cognition, symptom severity and number of symptoms between baseline and 
72 hours, and a difference between patients with and without mild TBI.  






The primary objective of this study was to evaluate the short-term impact that 
mild TBI has on neurocognitive function and concussion symptoms in 
Emergency Department patients, and to compare that with comparable non-
head injured patients. 
Outcomes 
Primary outcome 
The primary outcomes were neurocognitive function, concussion symptom 
severity, and number of concussion symptoms. The outcomes were measured 
at baseline in the Emergency Department, and at follow up 72 hours later. 
Secondary outcomes 
Patients with previous head injuries, and patients with varying acuity of mild 
TBI were identified as subgroups of particular interest. Mild TBI was split into 
low and high acuity groups based on the presence of acute intracranial 
haemorrhage on CT, described as the CT positive group, or no acute 
haemorrhage on CT or CT not done, described as the CT negative group. 
Further subgroups of low acuity patients were defined as GCS 14-15 and CT 
done and negative, and GCS 14-15 and CT not done. Those patients that had a 
CT scan of the head performed, had one done so in line with national 
guidance.418  






Patients were included in the mild TBI group if they met the following criteria: 
• Aged 18 to 80 years 
• Attended the Emergency Department 
• Suspected of an acute traumatically induced structural brain injury 
and/or clinical manifestations of functional brain injury, because of an 
insult to the head from an external force, including acceleration or 
deceleration movements without direct external trauma to the head 
• Initial GCS 9-15 
Exclusion criteria 
Patients were excluded if they had any one of the following criteria: 
• Chronic neurological, psychiatric or cognitive conditions 
• Temperature ≥37.7°C 
• Critical illness 
• Open head injury/forehead abnormality 
• Received procedural sedation or were mechanically ventilated 
• Receiving dialysis or in stage four chronic kidney disease 
• Pregnant 
Patients were eligible to be in the comparable non-head injured group if they 
attended the emergency department with any condition excluding: 
• An injury with any trauma above the clavicle 




• Attending the Emergency Department because of a road traffic collision 
(because they may have a brain injury without a head injury due to 
acceleration-deceleration) 
• Having sustained a TBI within the past year 
• A primary acute neurological complaint or complaint of syncope. 
Study design and Setting 
This was a prospective observational cohort study conducted over the course 
of six months in the Emergency Departments of the Royal London Hospital 
and Salford Royal Hospital. Both hospitals are large university hospitals and 
designated Major Trauma Centres, which is equivalent to level one trauma 
centres. The annual Emergency Department patient attendance rates are 
130,000 and 85,000 respectively. The study was approved by the National 
Research Ethics Service, North West 6 Research Ethics Committee, Greater 
Manchester South (reference 11/H1003/6). I performed most of the screening 
and recruitment at Royal London, and a small proportion was done by 
research nursing staff. Screening and recruitment was done Monday to 
Saturday, from 0800hrs and 0000hrs. Sources of bias were minimised by 
measures taken to obtain a complete dataset, including data abstraction from 
medical and pre-hospital emergency services records; and discussion with 
medical and emergency medical service personnel. Written informed consent 
was obtained from the patient, and in instances where the patient was unable 
to provide consent, consultee declaration to participate was obtained from a 
family member or the primary treating physician.  





Neurocognitive function was measured using the Standardized Assessment of 
Concussion (SAC) (Appendix 2). The SAC provides an objective, reproducible 
and standardised report of the consequences of concussion.192 The SAC is a 
paper-and-pencil assessment consisting of four domains (orientation, 
immediate memory, concentration, and delayed recall). It has a maximum 
score of 30, with higher scores indicating better neurocognitive function. It 
takes between five and ten minutes to complete. The SAC has been extensively 
validated for use in sport related concussion and has been reported as sensitive 
to sports concussion if administered within the first 48 hours.193,194,197,199 
Symptom severity and number of symptoms was measured using the 
Concussion Symptom Inventory (CSI) (Appendix 2). The CSI is a list of 12 
symptoms that are graded in severity by the patient on a seven point Likert 
scale.16 The symptoms recorded are: headache; nausea; balance 
problems/dizziness; fatigue; drowsiness; feeling like “in a fog”; difficulty 
concentrating; difficulty remembering; sensitivity to light; sensitivity to noise; 
blurred vision; feeling slowed down. It has a maximum severity score of 72 
with lower scores indicating lower severity, and a maximum of 12 symptoms. 
The total number of symptoms reported on the CSI, i.e. any symptom that did 
not have a score of 0, was calculated. Within group (baseline vs follow up) and 
between group (patients with and without mild TBI) comparisons were 
calculated. The comparison of numbers of concussion symptoms between 
groups was calculated because the sensitivity of the diagnosis of post-
concussion syndrome is not limited to patients that have sustained a 




concussion, and consequently it is possible that symptoms of acute concussion 
are not limited to head injured Emergency Department patients.419 
Clinical variables collected were assessed by the treating physician or research 
personnel, and utilised information from the patient, the prehospital medical 
record, and witness reports. Loss of consciousness and amnesia were 
dependent on collateral reports. Altered mental state was assessed by the 
treating physician. Previous TBI was determined as remembered by the 
patient and defined as ‘head injury’ with or without loss of consciousness. 
Neurocognitive function, symptom severity and number were collected at 
baseline in the Emergency Department and at follow up at 72 hours. Data at 
follow up were collected either face to face if the participant was an in-patient, 
or via telephone. Seventy-two hours was chosen as an appropriate follow-up 
time because it is a suitable time point to determine resolution of signs, 
duration of symptoms, and repeat CT scans, and also because there is little 
evidence on short term neurocognitive follow up in Emergency Department 
patients with mild TBI.176,203,204 Demographic and clinical variables, 
mechanisms of injury and details of the TBI (loss of consciousness, amnesia) 
were obtained. A predefined subgroup of participants with acute intracranial 
haemorrhage on CT head scan was analysed. This was done to assess the 
cognitive changes in complicated mild TBI, in which patients have a GCS of 13 
or more but an acute intra-cranial haemorrhage on CT scan.420 
Statistical analysis 
The central tendencies of non-normally distributed data were reported as 
medians with interquartile range (IQR), and that of normally distributed data 
as means ± standard deviation (SD). Central tendencies were only calculated 




for data with at least six observations. Categorical data were represented as 
number (percentage). Normality was tested using the Shapiro-Wilk test and 
by visually assessing the frequency distribution. The Shapiro-Wilk tests the 
hypothesis that the data is not normally distributed, and therefore the null 
hypothesis that the data is normally distributed. A significant p value, which 
corresponds to rejection of the null hypothesis of normality, means that the 
data is not normally distributed. 
Continuous data were compared using the paired or unpaired t-test, the 
related samples Wilcoxon Signed Rank test, or the independent sample Mann-
Whitney U test as appropriate. 95% confidence intervals (CI) were calculated 
for differences between means. Categorical data were compared using the chi-
squared test. Analyses were performed using the R Project for Statistical 
Computing.421 Significance was set at p < 0.05. There was no imputation of 
missing data. Loss to follow up was managed with a whole group and 
longitudinal analysis. 
Data representation 
In this chapter I present three variables (neurocognitive function, symptom 
severity, and total number of symptoms), measured at two points in time 
(baseline and follow up), and in two groups (mild TBI and non-head injured). 
These several measurements are in effect all variations of paired data, i.e. an 
outcome measured from a single patient twice. There are several ways to 
represent paired data, including using measures of central tendency (e.g. mean 
or median of the baseline and follow up measurements) and variation range 
(standard deviation, interquartile ranges, or other centiles of the baseline and 
follow up measurements).422 A common method of graphically representing 




before and after measurements is to use box and whisker plots.423 These are 
graphs that represent the median as a horizontal line, within a box whose 
upper and lower margins represent the upper and lower limits of the inter-
quartile range. The original description of box and whisker plots was by J W 
Tukey, who described lines (whiskers) projecting above and below the box and 
representing 1.5 times the interquartile range. Individual outliers are plotted 
beyond these whiskers.423 One limitation of these plots in isolation is that the 
interpretation of the results of paired data studies can also be affected by 
incomplete data, for instance due to lost to follow up rates. This is particularly 
relevant when using measures of central tendency. For example, if many 
patients have poor neurocognitive function at baseline, and then those that 
persist in having poor neurocognitive function at follow up are lost to follow 
up, the addition of this bias may result in the median neurocognitive function 
at follow up appearing erroneously improved. A further limitation of summary 
statistics alone is that they provide little information about the distribution of 
the data, particularly if it is bimodal.424 This means that there can be several 
competing interpretations of the data.422 To demonstrate the change from 
baseline to follow up at a per patient level, and simultaneously to represent the 
summary statistic, I have utilised two types of plot. For representation of the 
primary results, I have used a hybrid parallel line plot, also known as a 
waterfall or lollipop plot.422 These depict each patient as a vertical line. The 
start of the line is the baseline score, and the direction and colour of the line 
represents whether the patient has clinically improved or deteriorated 
between measurements. The lines are ordered by patient from the worst to the 
best baseline score. The hybrid element refers to the inclusion of box and 
whisker plots of the before and after measurements on the left. The value of 




the hybrid parallel line plot is that the reader can see the distribution of scores, 
and how they change over time. To emphasise this, and to compare changes 
rather than simply scores, I have also created parallel line plots of the absolute 
difference in outcome, also known as bow-tie plots, ordered from most 
improved to most deteriorated, with each patient’s line starting at zero, and 
with the box and whisker plot of the difference to the left and using the same 
scale. These are useful in depicting proportions of improved or deteriorated 
patients and display this more clearly than the hybrid parallel lines plots. The 
limitation to these latter graphs is that a reader cannot tell how the baseline 
measure is associated with change in measure over time. These are seen in 
Figure 3.3 to Figure 3.8 and Figure 3.11 to Figure 3.22.  






A total of 240 patients were enrolled. Of these, 189 patients had TBI and 51 
patients were patients without TBI (Figure 3.1 and Figure 3.2). The mean age 
was 43 (16) years and 169 (70%) of participants were male. Demographic and 
clinical details of patients with and without TBI are given in Table 3.1, Table 
3.2 and Table 3.3. At Royal London Hospital 414 patients were screened of 
which 153 (37%) were recruited, and at Salford Royal Infirmary 253 patients 
were screened of which 87 (34%) were recruited. Further detail regarding 
screening and exclusion is given in Table 3.4. It was not possible to complete 
the 72 hours assessment in 110 cases (46%), which comprised 90 (48%) in 
patients with TBI group and 20 (39%) patients without TBI (Figure 3.2). Of 
the 189 patients with TBI, 174 (92%) provided consent themselves on initial 
recruitment, 15 (8%) were recruited via consultee declaration and 7 (4%) of 
those were able to provide retrospective consent. No patients withdrew.  





Figure 3.1 Patient inclusion diagram 
  




 TBI Non-TBI p-value (95% CI) 
    
Demographics    
Number 189 (79) 51 (21)  
Age 43 (16) 40 (15) 0.20 (-1.6 to 7.7) 
Male Sex 133 (70) 36 (71) 0.98 (-0.1 to 0.1) 
Years in education 16 (4) 17 (5) 0.12 (-2.5 to 0.3) 
    
Disposition    
Discharge home from ED 95 (50) 23 (45) 0.97 (-0.1 to 0.1) 
Admission to CDU 37 (20) 15 (29) 0.13 (-0.04 to 0.2) 
Admission to hospital 57 (30) 13 (26) 0.52 (-0.1 to 0.07) 
Neurosurgery performed 1 (0.5) N/A  
    
Previous head injury    
Total 62 (33) 10 (20) 0.016 (0.014 to 0.018) 
One 39 (21) 6 (12) 0.13 (-0.2 to 0.13) 
Greater than one 23 (12) 4 (8) 0.4 (-0.2 to 0.07) 
 
Table 3.1 Baseline data common to TBI and non-TBI groups 
TBI, traumatic brain injury; non-TBI, patients without TBI; CI, confidence 
interval; ED, emergency department; CDU, clinical decision unit; N/A, not 
applicable. Data are reported as number (%) or mean (standard deviation). 
 
  




Mechanism of TBI Number (%) 
Fall 55 (28) 
Other 41 (21) 
Assault 31 (16) 
Struck by vehicle 22 (11) 
Bicycle 15 (8) 
RTC 13 (7) 
Motorcycle 9 (5) 
Fall due to syncope 7 (4) 
Sports 2 (1) 
Fall due to seizure 1 (1) 
  
TBI characteristics  
GCS 14-15 183 (97) 
GCS 13 3 (1.5) 
GCS 9-12 3 (1.5) 
LOC 72 (38) 
Seizure 3 (1) 
PTA 64 (34) 
RGA 34 (18) 
AMS 90 (48) 
  
Radiological characteristics  
CT performed 102 (54) 
Of TBI group, CT positive 25 (13) 
  
Diagnosis within CT positive group  
EDH 5 (21) 
SDH 6 (25) 
SAH 3 (13) 
Contusion and IPH 9 (38) 
IVH 0 (0) 
Mixed 1 (4) 
 
Table 3.2 Baseline data specific to TBI group 
TBI, traumatic brain injury; RTC, road traffic collision; GCS, Glasgow Coma 
Score; LOC, loss of consciousness; PTA, post traumatic amnesia; RGA, 
retrograde amnesia; AMS, altered mental status; CT, computed tomography; 
EDH, extra-dural haematoma; SDH, sub-dural haematoma; SAH, sub-
arachnoid haemorrhage; IPH, intra-parenchymal haematoma; IVH, 
intraventricular haematoma. Data are reported as number (%). 
  




Presenting complaint inpatients 
without TBI 
Abdominal pain 12 (24) 
Fracture/sprain/dislocation 11 (22) 
Back/limb pain 10 (20) 
Other 10 (20) 
Chest pain 6 (10) 
Laceration 3 (6) 
 
Table 3.3 Presenting complaints of patients without TBI 
Data are reported as number (%) or number (standard deviation) 
 
 
Reason Royal London Salford Royal  
Total 261 166 
>24 hrs since head injury 51 (19.5) 26 (15.8) 
Other 48 (18.4) 37 (22.4) 
>80 years old 39 (14.9) 34 (20.6) 
Substance dependence 30 (11.5) 15 (9.1) 
Advanced airway management 20 (7.7) 0 (0) 
   
Psychiatric medications 14 (5.4) 9 (5.5) 
Neurological disorder 14 (5.4) 25 (15.2) 
<18 years old 11 (4.2) 1 (0.6) 
CVA/TIA < 1yr 4 (1.5) 1 (0.6) 
History of brain surgery 4 (1.5) 0 (0) 
Prisoner 2 (0.8) 1 (0.6) 
Procedural sedation medications 2 (0.8) 0 (0) 
Headache 1 (0.4) 1 (0.6) 
Pregnant 1 (0.4) 0 (0) 
Syncope 1 (0.4) 2 (1.2) 
Dialysis 0 (0) 1 (0.6) 
 
Table 3.4 Screened and excluded patients with reasons for 
exclusion, by recruitment site. 
Data are reported as number (%). CVA/TIA cerebrovascular 
accident/transient ischaemic attack.  





Figure 3.2 Patient follow up and CT outcomes 
  





Neurocognitive and symptom data are presented in Table 3.5, Figure 3.3, 
Figure 3.4, Figure 3.5, Figure 3.6, Figure 3.7, and Figure 3.8. Patients with TBI 
presented with marked neurocognitive impairment. Patients with TBI had 
poorer neurocognitive function than those without TBI at baseline (difference 
in SAC score 1, p=0.02, 95% CI -1.4 to -2.4), and at follow up at 72 hours 
(difference in SAC score 2, p=0.04, 95% CI -3.0 to 0.0). The hybrid parallel 
line plots show that although most patients with very poor neurocognitive 
function at baseline tended to improve, most patients whose baseline SAC 
score was 23 or above tended to deteriorate by follow up (Figure 3.3 and Figure 
3.6). This is seen in the box plots which show no improvement overall and 
greater variation with longer whiskers at follow up. The absolute change plots 
show that regardless of group, the majority of patients’ neurocognitive 
function had deteriorated by follow up (Figure 3.6). Neurocognitive function 
was measured on the SAC, which is a score from 0-30 and composed of four 
domains: orientation (0-5), immediate memory (0-15), concentration (0-5), 
and delayed recall (0-5). Because immediate memory makes up a potential 
half of the points available, when the SAC is broken into its components, 
immediate memory accounts for the greatest proportion of the median SAC at 
baseline and follow up. However, when the SAC is represented in its 
component parts as proportions of potential score, i.e. by percentage, there is 
a more even spread of score attributable to individual components (Figure 
3.9). Delayed recall makes up the greatest proportion (32%), then 
concentration (30%), with immediate memory and orientation contributing 
equally (19% each). There is no difference in the degree to which the SAC 
components contribute to the overall score between baseline and follow up. 




Patients with TBI also reported notably higher symptom severity than those 
without TBI. Patients with mild TBI’s symptom severity reduced significantly 
between baseline and 72 hours but was greater than that reported by patients 
without TBI at both time points (difference between TBI and non-TBIs in CSI 
score at baseline 9, p<0.001, 95% CI 8.4 to 13.7; and at 72 hours 5, p<0.001, 
95% CI 5.7 to 11.6) (Figure 3.4 and Figure 3.7). This shows an overall reduction 
in symptom severity regardless of baseline severity, except for 10 patients with 
very low baseline symptom severity whose scores deteriorated by follow up. 
Patients with TBI also had higher total numbers of symptoms than those 
without TBI at both time points (difference in total number of symptoms 
between TBI and non-TBIs at baseline 4, p<0.001, 95% CI 2.6 to 4.4; and 72 
hours 4, p=0.001, 95% CI 1.9 to 4.1). The hybrid parallel line plot shows an 
overall reduction in the number of symptoms experienced by follow up (Figure 
3.5 and Figure 3.8). In contrast to neurocognitive function, most patients had 
lower symptom severity and fewer symptoms, i.e. improved from a symptoms 
perspective, by follow up. The most frequently occurring symptoms at 
baseline, which were experienced by more than 50% of TBI patients were 
headache, fatigue, feeling slowed down and drowsiness (Figure 3.10). 
  




 Baseline 72 hours Difference p-value (95% CI) 
     
Patients with mild TBI (n=189) 
SAC 25 (23-27) 25 (22-27) 0 0.1 (-0.4 to 1.2) 
CSI 9 (4-21) 5 (1-18) 4 0.002 (1.2 to 6.3) 
No. symptoms 4 (2-8) 4 (1-6) 0 0.051 (-1.5 to 0) 
 
Patients without mild TBI (n=51) 
SAC 26 (24-28) 27 (24-29) 1 0.5 (-0.6 to 1.7) 
CSI 0 (0-2) 0 (0-2) 0 0.3 (-0.5 to 3.4) 
No. symptoms 0 (0-2) 0 (0-1) 0 0.15 (-0.1 to 0.9) 
 
Table 3.5 Neurocognitive function, symptom severity, and total 
number of concussive symptoms 
Measured on the standardised assessment of concussion (0-30, best = 30), the 
concussion symptom inventory (0-72, best =0), in TBI and non-TBI groups, at 
baseline and 72 hours. 
 
 





Figure 3.3 Hybrid parallel line plots representing change in neurocognitive function in patients with and without 
mild TBI. 
Box plots with Tukey’s hinges of neurocognitive function scores at baseline and follow up are displayed to the left of each chart. 
Neurocognitive function is measured on the standardised assessment of concussion (best = 30, worst = 0) and represented on the y-
axis. Individual patients are represented on the x-axis, are ordered from worst to best baseline score, and each vertical line represents 
a single patient. Blue indicates an upwards deflection and clinical improvement, and red indicates a downwards deflection and clinical 
deterioration. Flat horizontal lines indicate no change. BL, baseline; FU, follow up; TBI, traumatic brain injury.





Figure 3.4 Hybrid parallel line plots representing change in symptom severity in patients with and without mild 
TBI. 
Box plots with Tukey’s hinges of symptom severity scores at baseline and follow up are displayed to the left of each chart. Symptom 
severity is measured on the concussion symptom inventory (best = 0, worst = 72) and represented on the y-axis. Individual patients 
are represented on the x-axis, are ordered from worst to best baseline score, and each vertical line represents a single patient. Blue 
indicates a downwards deflection and clinical improvement, and red indicates an upwards deflection and clinical deterioration. Flat 
horizontal lines indicate no change. BL, baseline; FU, follow up; TBI, traumatic brain injury.





Figure 3.5 Hybrid parallel line plots representing change in number of symptoms in patients with and without mild 
TBI. 
Box plots with Tukey’s hinges of the number of symptoms at baseline and follow up are displayed to the left of each chart. The number 
of symptoms is represented on the y-axis (fewest = 0, most = 12). Individual patients are represented on the x-axis, are ordered from 
most to fewest symptoms at baseline, and each vertical line represents a single patient. Blue indicates a downwards deflection and 
clinical improvement, and red indicates an upwards deflection and clinical deterioration. Flat horizontal lines indicate no change. BL, 
baseline; FU, follow up; TBI, traumatic brain injury.  





Figure 3.6 Absolute difference in neurocognitive function in patients with and without mild TBI. 
A box plot with Tukey’s hinges of the difference in neurocognitive function scores between baseline and follow up is displayed to the 
left of each chart. Neurocognitive function is measured on the standardised assessment of concussion (best = 30, worst = 0) and the 
difference from baseline to follow up is represented on the y-axis. Individual patients are represented on the x-axis, are ordered from 
most improved to most deteriorated and each vertical line represents a single patient. Blue indicates an upwards deflection and 
clinical improvement, and red indicates a downwards deflection and clinical deterioration. TBI, traumatic brain injury.





Figure 3.7 Absolute difference in symptom severity in patients with and without mild TBI. 
A box plot with Tukey’s hinges of the difference in symptom severity scores between baseline and follow up is displayed to the left of 
each chart. Symptom severity is measured on the concussion symptom inventory (best = 0, worst = 72) and the difference from 
baseline to follow up is represented on the y-axis. Individual patients are represented on the x-axis, are ordered from most improved 
to most deteriorated and each vertical line represents a single patient. Blue indicates an upwards deflection and clinical improvement, 
and red indicates a downwards deflection and clinical deterioration. TBI, traumatic brain injury.  





Figure 3.8 Absolute difference in number of symptoms in patients with and without mild TBI. 
A box plot with Tukey’s hinges of the difference in number of symptoms between baseline and follow up is displayed to the left of 
each chart. The difference in the number of symptoms from baseline to follow up is represented on the y-axis (fewest = 0, most = 12). 
Individual patients are represented on the x-axis, are ordered from most improved to most deteriorated and each vertical line 
represents a single patient. Blue indicates an upwards deflection and clinical improvement, and red indicates a downwards deflection 
and clinical deterioration. TBI, traumatic brain injury.





Figure 3.9 Components of the SAC score 
Percentages mean absolute value and by proportion at baseline and follow up 
in TBI group 
 
 
Figure 3.10 Symptom frequency 
The percentage of patients with mild TBI group that experienced each 
symptom at baseline and follow up.  




Post hoc power calculations 
I performed no power calculations in the design phase of this study. Of the 
three primary outcomes (neurocognitive function, concussion symptom 
severity, and number of concussion symptoms), there was no statistically 
significant difference between baseline and follow up measures of 
neurocognitive function, nor of total number of symptoms. In order to 
determine whether a larger study would have detected a statistically 
significant difference, post hoc power calculations were performed. Firstly, the 
data for neurocognitive function and total number of symptoms were 
demonstrated to be non-parametric. This was done by performing the 
Shapiro-Francia test for normality, which tests the null hypothesis that the 
data is normally distributed. The test was performed for the baseline and 
follow up values for both outcomes and produced p-values less than 0.05 for 
all four variables (Appendix 7, Table 6.5). Assessment of the source of the non-
normality was then done, and were statistically significant for both skewness 
and kurtosis in all four variables (Appendix 7 Table 6.6). Sometimes even 
when the raw data is not normally distributed, the differences between before-
and-after data can be normally distributed. The differences between baseline 
and follow up for neurocognitive function and number of symptoms were 
tested for normality, skewness and kurtosis in the same way as described 
above (Appendix 7, Table 6.7 and Table 6.8). There was borderline statistical 
significance for the assessment of normality in the difference in the total 
number of symptoms. In order to be maximally conservative, this borderline 
p value (of 0.058) was judged to warrant treatment of these data as non-
parametric.  




Standard power calculations were then performed, using the sampsi Stata 
command. The sampsi requires entry of alpha, mean and standard deviation 
for each group, and specification of the number of assessments. The alpha was 
set at 0.05, and the mean and standard deviation for each group was calculated 
from the raw data. Stata also requires a set correlation between baseline and 
follow-up. However, the overall calculated power did not change regardless as 
to where that correlation was set. Regardless of whether it was set at 0.0 or 
either extremes of possible values (-0.9 to 0.9), the output was unaffected. This 
is because with the two means being equal it is extraordinarily difficult to 
project a study power to identify them as different. 
The calculated power of the study to detect a difference between baseline and 
follow up neurocognitive function was 0.05. The power to detect a difference 
between baseline and follow up total number of symptoms was also 0.05.  
Power is 1-beta. Beta is the (set) probability of the study having a type 2 error, 
that is not finding a difference when one does actually exist, and is 
conventionally set at either 0.2 or 0.1, so that power is usually 0.8 or 0.9. 
Technically this means that this study has only a 5% chance that a type 2 error 
doesn’t exist. However these results are a reflection on the fact that the means 
for baseline and follow up neurocognitive function are the same, as are the 
means for baseline and follow up total number of symptoms (Table 3.5), and 
consequently low power is expected when using this approach.  
Since there is expected low power provided by traditional calculations, when 
those calculations are used to determine the power of a study to find a 
statistically significant difference between two groups with the same mean, an 




alternative approach was adopted. There have been arguments for increasing 
emphasis on the employment of confidence intervals for conveying 
information about a study’s precision and overall results interpretation, rather 
than relying alone on a test of statistical significance.425 Therefore, confidence 
intervals about the median differences between baseline and follow up for the 
two variables were calculated. Confidence intervals about medians rather than 
means were calculated because the data was demonstrated to be non-normally 
distributed, and because this was thought to be a more conservative approach 
that made relatively few assumptions about the data. The Stata procedure 
utilised was cendif.426 
The median change in neurocognitive function from baseline to follow up was 
0, with a 95% confidence interval calculated as 0 to 1. A 99% confidence 
interval was also calculated and was also 0 to 1. The minimum significant 
clinical difference in neurocognitive function (as measured on the SAC) is 2.201 
Consequently, there is very little chance (<1% given the 99% CI results) that a 
larger study would identify a significant difference in neurocognitive function. 
The median change in total number of symptoms from baseline to follow up 
was 0, with a 95% confidence interval calculated as 0 to 1. A 99% confidence 
interval was also calculated and was also 0 to 1. Just as with neurocognitive 
function, this implies that the chances of a larger study identifying a significant 
change in number of symptoms from baseline to follow up is very low. 
Together this constitutes compelling evidence that although the post hoc 
power calculation is low, that is a factor of there being no change from baseline 
to follow up, and that the 95% and 99% confidence intervals suggest that the 




result of this study can be relied upon to represent truth, and that it is unlikely 
that the study contains a type 2 error. 
Patients with acute haemorrhage on CT brain 
Table 3.6 contains neurocognitive and symptom data for the subgroups with 
(CT positive) and without (CT negative) acute intracranial haemorrhage. 
Patients that did not have a positive CT scan were defined as CT negative, 
however, some patients within that group did not have a CT at all. Because this 
group may have had acute abnormalities on CT were a CT to have been 
performed, data for the subgroups of CT negative patients are also presented. 
Of the 189 TBI participants, there were 25 (13%) CT positive and 154 (87%) CT 
negative patients. Neurocognitive function was considerably worse in CT 
positive compared to CT negative patients at both time points (difference in 
SAC score between CT positive and negative at baseline 3, p=0.009, 95% CI -
1.0 to -3.0, and at 72 hours 3, p=0.009, 95% CI -1.0 to -5.0). Figure 3.11 shows 
the difference in baseline neurocognitive function between CT positive and CT 
negative patients, and shows the variation within the groups, specifically, that 
most CT positive patients deteriorated. Figure 3.14 shows that the degree of 
deterioration is substantial: the greatest deterioration is 5 points on the SAC 
score. Both CT negative and CT positive patients show a tendency to 
deteriorate by follow up if the baseline score is at the higher function end of 
the scale. Most patients had worse neurocognitive function by follow up 
compared to baseline (Figure 3.14). The differences from baseline function, 
whether an improvement or a deterioration, are less marked in CT positive 
patients than CT negative patients. Figure 3.11 shows that one of the two 
patients with the lowest baseline scores (13) is in the CT positive group and 




one in the CT negative group. Because the CT positive group is small, it is not 
possible to determine whether the smaller difference from baseline to follow 
up in that group is dependent on a lower baseline score. CT positive patients 
also had worse symptom severity than CT negative patients at baseline 
(difference in CSI 11, p = 0.01, 95% CI -15.0 to -2.0) and at 72 hours (difference 
in CSI 10, p = 0.06, 95% CI -13.0 to 0.0) (Figure 3.12). CT positive patients 
also had greater numbers of symptoms compared with CT negative patients at 
both time points (difference in total number of symptoms 4, p=0.027, 95% CI 
-4.0 to 0.0; and 3, p=0.038, 95% CI -5.0 to 0.0 at baseline and follow up 
respectively) (Figure 3.13). However, in contrast to neurocognitive function, 
more patients experienced an improvement in symptom severity and number 
of symptoms from baseline to follow up (Figure 3.15 and Figure 3.16). In case 
the group that were not scanned were more unwell than thought at clinical 
assessment, which would constitute a selection bias, a sensitivity analysis 
separating the CT negative group into those that had a CT which was negative 
and those that didn’t have a CT was performed. Three TBI subgroups 
consisting of CT not done, CT with no intracranial haemorrhage and CT with 
intracranial haemorrhage were analysed. There is a trend towards improved 
cognitive function and lighter symptom burden from intracranial 
haemorrhage to no CT performed (Table 3.6). Further sensitivity analyses 
designed to apply the outcome measures in the lowest acuity patients were 
performed. In patients with GCS 14-15 that had a negative CT scan, or no CT 
scan performed (n=162), there was no improvement in cognitive function or 
symptom burden between baseline and follow up (Table 3.6). This suggests 
that patients that qualify for a CT, even if their scan is normal, may have 
neurocognitive dysfunction and a symptom burden that persists. In patients 




with GCS 14-15 that had a scan which was negative (n=71), not only overall 
cognitive function, but also overall symptom severity and total number of 
symptoms remained unchanged between baseline and follow up. 
 
 Baseline 72 hours Difference p-value (95% CI) 
     
CT positive (n=25) 
SAC 23 (22-26) 22 (19-24) 1 0.5 (-0.6 to 1.7) 
CSI 20 (11-30) 15 (6-21) 5 0.3 (-0.5 to 3.4) 
No. symptoms 8 (4-9) 6 (5-9) 2 0.14 (-0.1 to 0.9) 
     
CT negative (all patients that are not CT positive), n=164 
SAC 26 (23-28) 25 (22-27) 1 0.2 (-0.6 to 1.2) 
CSI 9 (4-19) 5 (1-15) 4 0.006 (0.7 to 6.2) 
No. symptoms 4 (2-7) 3 (1-6) 1 0.01 (0.2 to 1.7) 
     
CT done and negative (n=78) 
SAC 25 (22-26) 25 (22-28) 0 0.80 (-1.5 to 1.4) 
CSI 13 (7-32) 13 (5-27) 0 0.16 (-1.5 to 9) 
No. symptoms 6 (3-10) 5 (3-8) 1 0.34 (-0.7 to 1.9) 
     
CT not done (n=86) 
SAC 26 (25-28) 26 (23-27) 0 0.11 (-0.3 to 1.8) 
CSI 6 (3-11) 2 (0-5) 4 0.002 (1.2 to 5.7) 
No. symptoms 3 (1-5) 1 (0-4) 2 0.005 (0.4 to 2.1) 
 
Table 3.6 Neurocognitive and symptom outcomes for TBI patients 
with and without intracranial haemorrhage 
Measured on the concussion symptom inventory, in TBI patients with and 
without intracranial haemorrhage, at baseline and at 72 hours. 





Figure 3.11 Hybrid parallel line plots representing change in neurocognitive function in CT positive and CT negative 
mild TBI patients. 
Box plots with Tukey’s hinges of neurocognitive function scores at baseline and follow up are displayed to the left of each chart. 
Neurocognitive function is measured on the standardised assessment of concussion (best = 30, worst = 0) and represented on the y-
axis. Individual patients are represented on the x-axis, are ordered from worst to best baseline score, and each vertical line represents 
a single patient. Blue indicates an upwards deflection and clinical improvement, and red indicates a downwards deflection and clinical 
deterioration. Flat horizontal lines indicate no change. BL, baseline; FU, follow up; CT, computed tomography.





Figure 3.12 Hybrid parallel line plots representing change in symptom severity in CT positive and CT negative mild 
TBI patients. 
Box plots with Tukey’s hinges of symptom severity scores at baseline and follow up are displayed to the left of each chart. Symptom 
severity is measured on the concussion symptom inventory (best = 0, worst = 72) and represented on the y-axis. Individual patients 
are represented on the x-axis, are ordered from worst to best baseline score, and each vertical line represents a single patient. Blue 
indicates a downwards deflection and clinical improvement, and red indicates an upwards deflection and clinical deterioration. Flat 
horizontal lines indicate no change. BL, baseline; FU, follow up; TBI, traumatic brain injury. 





Figure 3.13 Hybrid parallel line plots representing change in number of symptoms in CT positive and CT negative 
mild TBI patients. 
Box plots with Tukey’s hinges of the number of symptoms at baseline and follow up are displayed to the left of each chart. The number 
of symptoms is represented on the y-axis (fewest = 0, most = 12). Individual patients are represented on the x-axis, are ordered from 
most to fewest symptoms at baseline, and each vertical line represents a single patient. Blue indicates a downwards deflection and 
clinical improvement, and red indicates an upwards deflection and clinical deterioration. Flat horizontal lines indicate no change. BL, 
baseline; FU, follow up.  





Figure 3.14 Absolute difference in neurocognitive function in CT positive and CT negative mild TBI patients. 
A box plot with Tukey’s hinges of the difference in neurocognitive function scores between baseline and follow up is displayed to the 
left of each chart. Neurocognitive function is measured on the standardised assessment of concussion (best = 30, worst = 0) and the 
difference from baseline to follow up is represented on the y-axis. Individual patients are represented on the x-axis, are ordered from 
most improved to most deteriorated and each vertical line represents a single patient. Blue indicates an upwards deflection and 
clinical improvement, and red indicates a downwards deflection and clinical deterioration. TBI, traumatic brain injury.  





Figure 3.15 Absolute difference in symptom severity in CT positive and CT negative mild TBI patients. 
A box plot with Tukey’s hinges of the difference in symptom severity scores between baseline and follow up is displayed to the left of 
each chart. Symptom severity is measured on the concussion symptom inventory (best = 0, worst = 72) and the difference from 
baseline to follow up is represented on the y-axis. Individual patients are represented on the x-axis, are ordered from most improved 
to most deteriorated and each vertical line represents a single patient. Blue indicates an upwards deflection and clinical improvement, 
and red indicates a downwards deflection and clinical deterioration. TBI, traumatic brain injury.  





Figure 3.16 Absolute difference in number of symptoms in CT positive and CT negative mild TBI patients. 
A box plot with Tukey’s hinges of the difference in number of symptoms between baseline and follow up is displayed to the left of 
each chart. The difference in the number of symptoms from baseline to follow up is represented on the y-axis (fewest = 0, most = 12). 
Individual patients are represented on the x-axis, are ordered from most improved to most deteriorated and each vertical line 
represents a single patient. Blue indicates an upwards deflection and clinical improvement, and red indicates a downwards deflection 
and clinical deterioration. TBI, traumatic brain injury. 




Patients with previous head injuries 
In a subgroup of patients with mild TBI that had sustained one or more 
previous head injuries (n=63) there was no change in cognitive function or 
symptom burden between baseline and follow up (Table 3.7, Figure 3.17, 
Figure 3.18, Figure 3.19, Figure 3.20, Figure 3.21 and Figure 3.22). This 
contrasts with a subgroup of patients with TBI that had never had a previous 
head injury (n=111), where neurocognitive dysfunction persisted to follow up, 
but symptom burden improved. Figure 3.17 shows that more patients 
experience poorer rather than improved neurocognitive function at follow up 
in both the previous and no previous head injury groups and that the degree 
of deterioration may be worse in the group that has not had a previous head 
injury. 
 Baseline 72 hours Difference p-value (95% CI) 
     
Previous head injury (n=63) 
SAC 25 (23-28) 25 (22-28) 0 0.43 (-1.4 to 1.3) 
CSI 11 (5-24) 5 (2-13) 6 0.25 (-1.8 to 7.8) 
No. symptoms 5 (2-8) 3 (1-6) 2 0.8 (-0.8 to 1.7) 
     
No previous head injury (n=111) 
SAC 26 (23-27) 24 (22-27) 2 0.21 (-0.4 to 1.7) 
CSI 9 (4-19) 5 (0-19) 4 0.001 (1.3 to 7.3) 
No. symptoms 4 (2-8) 4 (0-6) 0 0.002 (0.4 to 2.0) 
 
Table 3.7 Neurocognitive and symptom outcomes for TBI patients 
that had had one or more previous head injuries compared to those 
that had had no previous head injuries 
 





Figure 3.17 Hybrid parallel line plots representing change in neurocognitive function in mild TBI patients with and 
without previous head injury. 
Box plots with Tukey’s hinges of neurocognitive function scores at baseline and follow up are displayed to the left of each chart. 
Neurocognitive function is measured on the standardised assessment of concussion (best = 30, worst = 0) and represented on the y-
axis. Individual patients are represented on the x-axis, are ordered from worst to best baseline score, and each vertical line represents 
a single patient. Blue indicates an upwards deflection and clinical improvement, and red indicates a downwards deflection and clinical 
deterioration. Flat horizontal lines indicate no change. BL, baseline; FU, follow up.  





Figure 3.18 Hybrid parallel line plots representing change in symptom severity in mild TBI patients with and 
without previous head injury. 
Box plots with Tukey’s hinges of symptom severity scores at baseline and follow up are displayed to the left of each chart. Symptom 
severity is measured on the concussion symptom inventory (best = 0, worst = 72) and represented on the y-axis. Individual patients 
are represented on the x-axis, are ordered from worst to best baseline score, and each vertical line represents a single patient. Blue 
indicates a downwards deflection and clinical improvement, and red indicates an upwards deflection and clinical deterioration. Flat 
horizontal lines indicate no change. BL, baseline; FU, follow up.





Figure 3.19 Hybrid parallel line plots representing change in number of symptoms in mild TBI patients with and 
without previous head injury. 
Box plots with Tukey’s hinges of the number of symptoms at baseline and follow up are displayed to the left of each chart. The number 
of symptoms is represented on the y-axis (fewest = 0, most = 12). Individual patients are represented on the x-axis, are ordered from 
most to fewest symptoms at baseline, and each vertical line represents a single patient. Blue indicates a downwards deflection and 
clinical improvement, and red indicates an upwards deflection and clinical deterioration. Flat horizontal lines indicate no change. BL, 
baseline; FU, follow up.  





Figure 3.20 Absolute difference in neurocognitive function in mild TBI patients with and without previous head 
injury. 
A box plot with Tukey’s hinges of the difference in neurocognitive function scores between baseline and follow up is displayed to the 
left of each chart. Neurocognitive function is measured on the standardised assessment of concussion (best = 30, worst = 0) and the 
difference from baseline to follow up is represented on the y-axis. Individual patients are represented on the x-axis, are ordered from 
most improved to most deteriorated and each vertical line represents a single patient. Blue indicates an upwards deflection and 
clinical improvement, and red indicates a downwards deflection and clinical deterioration. TBI, traumatic brain injury.





Figure 3.21 Absolute difference in symptom severity in mild TBI patients with and without previous head injury. 
A box plot with Tukey’s hinges of the difference in symptom severity scores between baseline and follow up is displayed to the left of 
each chart. Symptom severity is measured on the concussion symptom inventory (best = 0, worst = 72) and the difference from 
baseline to follow up is represented on the y-axis. Individual patients are represented on the x-axis, are ordered from most improved 
to most deteriorated and each vertical line represents a single patient. Blue indicates an upwards deflection and clinical improvement, 
and red indicates a downwards deflection and clinical deterioration. TBI, traumatic brain injury.





Figure 3.22 Absolute difference in number of symptoms in mild TBI patients with and without previous head 
injury. 
A box plot with Tukey’s hinges of the difference in number of symptoms between baseline and follow up is displayed to the left of 
each chart. The difference in the number of symptoms from baseline to follow up is represented on the y-axis (fewest = 0, most = 12). 
Individual patients are represented on the x-axis, are ordered from most improved to most deteriorated and each vertical line 
represents a single patient. Blue indicates an upwards deflection and clinical improvement, and red indicates a downwards deflection 
and clinical deterioration. TBI, traumatic brain injury.





The principal finding of this study was that patients with mild TBI have a 
clinically relevant neurocognitive deficit immediately after the injury that 
persists to at least 72 hours. More patients had deteriorated than improved 
neurocognitive function by follow up. Patients with mild TBI also have 
persistently greater severity of symptoms and more concussive symptoms than 
patients without TBI, both of which also persist to 72 hours. Patients with TBI 
with acute haemorrhage on their CT scan had poorer neurocognitive function 
than those without. 
To my knowledge, this study is the largest that enrolled patients with mild TBI 
and followed them over the short term. It is also the only multi-centre study 
that focuses on the neurocognitive effects of mild TBI in patients presenting to 
the Emergency Department. Neurocognitive function is usually measured 
either by psychological test that requires administration by a trained 
psychologist; by standardised paper and pencil tests such as the SAC; or by 
computer administered tests such as ImPACT.427 In this study, patients with 
mild TBI had clinically poorer neurocognitive function than non-head injured 
patients at follow up. A difference in SAC of two or more points is thought to 
be clinically relevant, although the SAC is not sensitive enough to pick up 
subtle changes in neurocognitive function, and there is a ceiling effect 
associated with its application.201,428 These findings of a neurocognitive deficit 
immediately following mild TBI are consistent with those in previously 
published studies, however a deficit persisting at 72 hours has not been 
reported before in this patient group. 




When measured using paper and pencil tests, in studies enrolling 100 and 246 
patients with TBI, there was a significant difference in neurocognitive function 
at baseline, but no follow up was performed.416 In further studies of 29 and 49 
patients with TBI, neurocognitive function had significantly improved by one 
month.203 In a study of 62 patients presenting to the Emergency Department 
with concussion, cognitive function measured on the SAC improved between 
baseline and six hours later (from 21 to 24).429 The results reported in this 
latter study present poorer baseline neurocognitive function than I report. 
This may be because the composition of the patients included in that study’s 
population comprised a greater proportion of patients that reported loss of 
consciousness and post traumatic amnesia compared with my sample, both of 
which have been associated with poorer SAC scores.196 A study of 29 patients 
with TBI found a significant deficit compared with patients without TBI at 
around 31 hours post injury.204 The same authors measured SAC at baseline 
post injury and a month later and reported significant improvement.203 I 
report no improvement by 72 hours, however the authors’ studies measured 
cognitive function at different time points to ours: a single observation at 31 
hours; and follow up at one month. The results of my study taken with previous 
work implies a continuum of recovery, during which there is a neurocognitive 
deficit present up to and beyond 72 hours, but which may resolve at some point 
before one month. This theory is backed up by the results of neurocognitive 
function testing by the computerised ImPACT programme, which showed 
gradual improvement in function measured at 24 hours, one week and three 
months post injury.430 




Normal values for SAC scores are primarily derived from athletes that 
completed the SAC prior to a sports season and therefore prior to any injury. 
A normal SAC varies from 27 to 28.193,194,197 Patients with TBI in my study had 
baseline and 72 hours SAC scores 2-3 points lower than this, and although the 
two populations are different, this represents a clinically relevant deficit. 
Patients without TBI reported in this thesis also had lower than normal SAC 
scores at baseline. However, they increased by one point, which was not a 
statistically significant increase, to 27, which seems to be the lower end of 
normal. I also report that there were significant differences in overall symptom 
severity as measured on the CSI, and total numbers of symptoms, between 
baseline and 72 hours, and between patients with and without TBI. These 
findings are in line with previously published work on symptom pattern post 
mild TBI, which suggests that both overall symptom severity and total number 
of symptoms may discriminate between patients with and without mild TBI.431 
However, these findings are important because I have reported the persistence 
of a neurocognitive deficit in the largest group of hospital Emergency 
Department patients thus far described. In addition, I report two subgroup 
analyses which suggest that cognitive deficit persists regardless of whether the 
patient has a GCS of 13, 14, or 15; or whether the patient is in a presumed low 
acuity group (i.e. did not require or did not have a CT scan); or whether they 
had a history of previous head injuries or not. Finally, I report that patients 
with mild TBI and intracranial haemorrhage have poorer neurocognitive 
function than those without intracranial haemorrhage. This adds weight to the 
concept of complicated mild TBI and emphasises the importance of this group 
of patients.420 




This study has strengths and weaknesses. It is one of the largest studies and 
the only multicentre study examining short term change in neurocognitive 
function following mild TBI. Although convenience sampling was necessitated 
based on resources, selection bias was minimised by approaching potential 
participants that had been admitted to hospital but were still within 24 hours 
of their TBI as well as by approaching all potential participants in real time. It 
was not possible to eliminate bias in the form of drop-outs or lost-to-follow-
up, and consequently bias was quantified and is reported in Figure 3.1 and 
Figure 3.2. The lost-to-follow-up rate is high; 46% in the TBI group and 43% 
in patients without TBI. The narrow follow-up window was defined by 
protocol. It was required because a patient’s cognitive function after a mild TBI 
can change day to day. Consequently, collecting cognitive data across a range 
of days in the short term following a mild TBI, for instance at day two for one 
patient and at day seven for another, would not produce a set of comparable 
data. This narrow window did however present significant difficulties in 
contacting participants. Another limitation is could be that the exclusion 
criteria could be said to be unnecessarily narrow. They are, however, in line 
with other similar studies.203 For many participants, follow-up was by 
telephone. Telephone based cognitive assessments are employed in cognitive 
research, particularly in screening for cognitive defects and dementia, however 
the SAC is not validated for use over the telephone. The proportion of follow 
ups completed by telephone was not recorded and so any difference between 
telephone and face-to-face follow groups is not known. There may be an 
element of learning that is dependent in part on visual stimulus, which clearly 
is missing during a telephone follow up. The theory that learning for the SAC 
memory recall may be partly dependent on visual stimulus is enforced by the 




observation that the domain that represented the greatest decrease in SAC 
between initial attendance and 72 hours in patients without TBI was the 
delayed recall domain. This may explain the results seen in patients without 
TBI, who had a wider SD between baseline and 72 hours. There were many 
more patients enrolled with than without TBI, which may introduce bias in 
comparisons between those with and without TBI. This was partly because the 
primary outcome was the difference between baseline and follow up within the 
head injured group, and partly because of the nature of convenience sampling. 
Whilst recognising this as a limitation, I do not believe that this is an 
insurmountable flaw in the methodology. Finally, because this was an analysis 
of data from a separate study, there was no specific sample size calculation 
associated with either TBI or non-TBI based endpoints. 
Methods for assessing and managing acute mild TBI in the Emergency 
Department are varied. This reflects the uncertainty surrounding optimal 
management strategies. Decision making tools that help determine whether or 
not a patient should have a CT scan of the head are based on studies that were 
designed to assess whether a patient has an intracranial haemorrhage, not 
whether or not they have concussion.418 I report that neurocognitive 
dysfunction is associated with mild TBI but the speed of recovery and the 
repercussions on patients’ work and home lives is still unknown. The clinical 
follow up for these patients is important. Leaflets explaining the likely clinical 
course and provision of access to TBI clinics may well contribute to an 
improvement in clinical variables.399  





Emergency Department patients with mild TBI experience a neurocognitive 
deficit and concussive symptoms that persist to at least 72 hours. This has 
significant implications on the management of mild TBI, including the 
potential for early treatment, and explicit explanations to patients on what 
they can expect following ‘normal’ scan results. Further work evaluating the 
pattern of neurocognitive recovery, repercussions on home and work life, and 
management strategies is warranted.  




Chapter 4 Seizure after mild TBI and biomarkers to predict 
outcomes 
Seizure as a consequence of traumatic brain injury 
Mild TBI is characterised based on peri- or post-injury features. These include 
many of the elements in the definitions of mild TBI, and include seizure (Table 
1.2 and Appendix 1). Seizure can occur at the time of injury, or in the minutes 
to hours following. When seizures occur more than a week after injury, they 
are considered evidence of post-traumatic epilepsy.432,433 Seizure is thought to 
be an important acute clinical manifestation of TBI as it reflects a structural 
abnormality that results in disordered electrical activity. The rate of seizure at 
the time or soon after injury is from 1-5%. In a landmark study from the US of 
520 patients with minor head injury, 5% (24) had a seizure, and four of those 
had positive CT findings.434 In a Canadian cohort of 3121 head injured patients, 
the rate of seizure in the Emergency Department was 0.1% (4) and one of those 
four patients had an acute CT abnormality.435 The same authors went on to 
recruit another large cohort of 1822 patients with minor head injury from 
mostly the same EDs, and found the rate of seizure to be 2.0% overall (37), 
with a rate of 4.3% in CT positive patients and 1.9% in CT negative patients.436 
The low rate of seizure of 0.1% in the first Canadian study is likely due to the 
criterion that the seizure happened in the Emergency Department rather than 
at any time after injury. 
The 4.3% rate of head injury induced seizure in CT positive patients noted 
above contrasts with a study of patients with mild TBI and isolated subdural 
haematoma, in which the rate of seizure occurring during the in-patient 




episode, not just during the Emergency Department episode, was reported as 
2.2%.437 In a more recent study of 453 patients with head injury and GCS 15, 
4.4% had seizure.438 This study was conducted in level one neurotrauma centre 
in Karnataka, India, and 43% were CT positive. This is an unusually high 
proportion of CT positive patients, particularly in the context of patients 
exclusively with GCS 15. This could in part be accounted for by the authors’ 
decision to include skull fractures within their definition of abnormality on CT, 
and possibly in part by the rural and lower middle-income nature of the 
catchment area from which patients were admitted to the hospital. 
After TBI, the rate of post-traumatic epilepsy ranges from 2-5% and the rate 
of seizures without a diagnosis of epilepsy may be even higher.439-444. Out of 
305 patients seen in a head injury clinic in the UK, 97% had never had a seizure 
prior to TBI, and 7% (24) had had seizures by the time they were seen in 
clinic.445 Of those patients with seizures, 80% had moderate or severe TBI. 
Furthermore, post-traumatic epilepsy is also more common in patients with 
more severe TBI. In Sweden, eight of 109 patients had had a seizure within 24 
hours of injury, and 12 of 109 were diagnosed with epilepsy within 10 years. 
Compared to a TBI cohort that did not develop epilepsy, there was a greater 
proportion of patients with moderate and severe TBI in the epilepsy group.446 
Less is known about the rate of sports related concussion convulsions, which 
is estimated to be 1 in 70 or less, and with very few patients going on to be 
diagnosed with post-traumatic epilepsy.447 In one systematic review, of those 
that did develop epilepsy, all were boxers.447 
Patients with seizures account for 1% of all Emergency Department 
attendances (250,000 patients in the UK), and 1.4% of all medical 




admissions.18,19,21,27,28,448 Previous studies have shown that 5 to 10% of the 
general population will suffer from a seizure in their lifetime.20,449-451 Among 
these patients, only a proportion is diagnosed with epilepsy. When managing 
a patient presenting with seizure activity a physician must consider several 
parameters to assess the risk of early recurrence and of complications. If there 
is a clear precipitant such as trauma, then that must be managed in addition 
to managing the seizure. However, important prognostic factors, such as 
predictors of seizure recurrence, the need for emergent therapy and 
consequently the requirement for hospital admission are not well studied. 
There is therefore a chance of admitting patients that may not require 
emergency therapy, and consequently utilising resources unnecessarily, or 
conversely, discharging patients that may require inpatient care. Thus, in 
emergency medicine when managing these patients, evaluation of the risk of 
short-term recurrence is essential for the physician to decide whether 
discharge is possible or not. 
Seizure recurrence 
After a first seizure, recurrence rates are around 20% during the following 
month, up to 50% at three years, and about 70% after more than one 
seizure.30,31,452,453 There is little evidence to inform whether patients that have 
a seizure at the time of a mild TBI are more or less likely to go on to have 
recurrent seizures compared to patients that have seizures for any other 
reason. Patients with a first seizure that attend the Emergency Department 
have a recurrence rate of 18.5% at 24 hours, and up to 40% of these patients 
chronically abuse alcohol.21,454 Chronic alcohol abuse increases the risk of 
seizure recurrence with an odds ratio of 1.7 for early seizure recurrence.454 




These data and other associated factors are used to evaluate the need for long 
term anti-epileptic treatment. Factors associated with long term recurrence 
were analysed in a large multi-centre European study: The Multicentre trial 
for Early Epilepsy and Single Seizures.31 This trial also evaluated the benefit of 
immediate antiepileptic drug introduction. In an ancillary study, the authors 
developed a model to predict the risk of long-term recurrence. The model 
included the number of seizures before presentation, the presence of a 
neurological disorder and EEG findings. Patients were stratified as having low, 
medium or high risk of recurrence at one, three and five years.32 However, Kho 
et al. found different results, with the number of seizures and type of epilepsy 
not being associated with increased recurrence of risk. The only independent 
factor identified in this study was the type of seizure: remote symptomatic 
seizure, versus provoked or idiopathic seizure (odds ratio 2.2).455 
Few studies have attempted to link clinical and biological parameters on 
admission with short-term seizure recurrence. One prospective observational 
study evaluated predictors of early rather than late seizure recurrence.454 In 
this study, alcoholism, low plasma glucose, and a low GCS were associated 
with a higher risk of early seizure recurrence, but this single study has not been 
replicated. There is conflicting evidence that the number of seizures before 
presentation, the presence of a neurological disorder and the EEG findings, or 
the type of seizure, predicts long term recurrence.32,455 There is therefore a 
deficiency of information available to clinicians when assigning a risk of early 
seizure recurrence in Emergency Department patients. 
The potential consequences of a seizure include physical injury, time off from 
work, degeneration into status epilepticus and hypoxic brain damage and 




death.23-25 In one study, 1.2% of Emergency Department attendances for 
seizure resulted in death, and injury or death was associated with 15% of 
seizure attendances.26 Recurrent seizures also result in altered functional 
brain connectivity, with patients that have frequent seizures exhibiting 
widespread areas of poor brain connectivity compared with epileptic patients 
that seize less frequently.456 Physicians must also evaluate whether the patient 
has any underlying illness that may have precipitated the seizure (for instance 
meningitis, intracranial haemorrhage or stroke) and complications resulting 
from it (for example brain injury or aspiration). A primary goal of the 
emergency physician is to identify underlying critical illness, institute 
appropriate treatment and identify those patients that need to be hospitalised 
and those that can be safely discharged. 
Biomarkers 
S100B is a glial-specific protein expressed by astrocytes and is a specific 
marker of cerebral injury.291 S100B has been extensively evaluated as a 
biomarker of immediate and long term outcomes in TBI (Table 1.11) as well as 
other neurological conditions such as cardiac arrest.317 Seizures can be 
associated with poor outcomes, particularly if they are prolonged, but many 
are not. S100B concentration is normal following febrile seizure in children, 
and that febrile seizures are considered to be relatively harmless contributes 
to the hypothesis that elevated S100B might predict adverse neurological 
outcomes.457 Copeptin, the C-terminal of pre-provasopressin, is a biomarker 
of endogenous stress. Recently it has been described as a good prognostic 
marker in neurological disorders, such as traumatic brain injury, intracerebral 
haemorrhage, and stroke.359,362,366  







The primary objective of this study was to test the hypothesis that the use of 
two biomarkers, a specific neurologic biomarker (protein S100B) and a 
biomarker of endogenous stress (copeptin), would improve the prediction of 
adverse events following seizures. 
Secondary objectives 
• To determine the rate of TBI-induced seizure attending the Emergency 
Department. 
• To evaluate the diagnostic performances and the area under the curve 
(AUC) for a predictive model based on clinical parameters alone and a 
model based on clinical parameters with the biomarkers for the 
prediction of the secondary endpoints. 
Outcomes 
Primary endpoint 
The primary outcome was a composite of seizure recurrence, death, hospital 
admission, and hospital re-admission by day seven. 
Secondary endpoints 
The secondary endpoints were: 
• Recurrence of convulsive seizure within seven days. 
• Hospital admission for more than 24 hours. 
• A composite of severe outcomes including ICU admission, 
neurosurgical procedure or death by 28 days.  






Patients were eligible if they met either one of the following criteria: 
• Attending the Emergency Department with one or more documented 
seizure before arrival 
• Patients having a convulsive seizure in the Emergency Department 
Exclusion 
Patients were excluded if they had any one of the following criteria: 
• Age less than 18 years 
• Pregnancy 
• Prisoners 
Study design and setting 
This was the UK arm of an international multicentre prospective observational 
cohort study designed to assess the incremental added value of serum S100B 
and copeptin measurements together with usual clinical and biological data to 
predict adverse outcomes following seizure related Emergency Department 
visits. I screened and recruited patients from the Royal London and Whipps 
Cross University Hospitals during a one-year period. The study was approved 
by the National Research Ethics Service Committee London, Camberwell St 
Giles (reference 12/LO/1783). The project followed the Standards for 
Reporting of Diagnostic Accuracy (STARD) recommendations for diagnostic 
studies.458  





Potential participants were screened on admission to the Emergency 
Department by local investigators, nurses and medical staff. There were no 
financial payments offered to subjects or volunteers. Written informed 
consent was sought prior to enrolment. Consent was always obtained prior to 
blood collection. The consent process included an explanation of the aims, 
methods and potential benefits of the study, as well as of the potential hazards. 
The physician or the nurse explained to all patients that they were free to 
refuse to enter the study, or to withdraw at any time during the study for any 
reason. Patients were approached as soon as their level of consciousness 
allowed them to understand the explanations given. Printed patient 
information sheets were left for the subjects to read, and the principal 
investigator was contactable by telephone and email to address further 
queries. 
The processes involved in obtaining and documenting informed consent were 
adherent to standards described in Good Clinical Practice and the Declaration 
of Helsinki. Prior to any study-related activity, the patient (and/or the 
patient’s legally acceptable representative) received oral and written 
information about the study in a form that the subject could read and 
understand. A voluntary signed and dated Informed Consent Form was 
obtained from the patient prior to any study-related activity. 
Inability to consent 
Many eligible subjects were likely to present with impaired cognitive ability, 
for instance due to being in a post-ictal phase, cognitive impairment, coma, or 
alcohol intake. In such situations an appropriate partner, relative or friend was 




sought to give assent. When a patient was enrolled through partner, relative or 
friend’s assent, the patient's consent was sought in retrospect once capacity 
was regained. When a patient refused to grant retrospective consent, further 
contact with the patient ceased and they were withdrawn from the study. In 
those situations, data that had already been gathered was included in the final 
analysis unless the subject requested that it be withdrawn, in which case it was 
destroyed. 
If a suitable friend or relative could not be identified, or if none were available, 
the Consultant in charge of the Emergency Department was approached to 
give assent for the patient to be enrolled into the study. The Consultant 
concerned was not in a position which could be considered subordinate to any 
member of the study team and was wholly independent of the research team. 
The process was the same as the process of partner, relative or friend's assent, 
involving provision of an information sheet and an opportunity to discuss the 
study and ask questions. When a patient was enrolled through Consultant 
assent, the patient's consent was sought in retrospect once capacity was 
regained. If a subject refused to grant retrospective consent, the process was 
the same as if a relative had provided assent and the subject retrospectively 
wished to withdraw.  









Past episode of seizure, known epileptic disorder, stroke with persistent 
neurological deficit, degenerative neurological disorder, brain tumour, 
meningitis/encephalitis, chronic alcohol abuse, other toxic abuse, chronic 
treatment. 
Seizure type 
Unwitnessed, simple partial, complex partial, generalised tonic-clonic, 
secondary generalised tonic-clonic, absence, status epilepticus, other. 
Provoked, idiopathic, or remote symptomatic. 
Time from seizure to presentation in Emergency Department. 
Number of seizures in the last month. 
Physiological and clinical data 
Heart rate, blood pressure, temperature, GCS with component breakdown, 
peripheral saturations of oxygen. 
Neurological deficit on examination. 
Headache, photophobia/phonophobia, neck stiffness. 
Main suspected cause (chronic epileptic disorder, recent alcohol intake, 
alcohol withdrawal, stroke, intracerebral haemorrhage, head injury, sepsis, 
cerebral neoplasia, metabolic disturbances). 





Serum glucose, white blood cell count, serum sodium, serum venous lactate, 
EEG. 
Outcomes 
Death at seven days and 30 days, seizure recurrence at 24 hours and seven 
days, length of hospitalisation, hospitalisation subsequent to first Emergency 
Department visit within one month, ICU admission, length of ICU admission. 
A retrospective analysis of the medical record was performed after the study 
closed to identify the cause of seizure in order to determine the proportion of 
patients that had a seizure as a consequence of TBI.  





Copeptin and Protein S100B were collected on the arrival of the patient in the 
Emergency Department, and no later than 24 hours following the seizure. The 
volumes were 5ml for S100B and 5ml for copeptin. The blood was collected in 
heparinised red topped sample tubes and allowed to stand from 30 minutes to 
four hours. The sample was then centrifuged at 2640g for 20 minutes followed 
by 3010g for 10 minutes. A volume of 0.75-1ml of serum was then pipetted into 
an Eppendorf and the sample frozen and stored at -80°C at Barts Health NHS 
Trust. S100B samples were analysed on an Elecsys® analyser (Roche 
Diagnostics). This method is based on the sandwich principle, in which a 
biotinylated S100B-specific antibody and an S100B-specific antibody labelled 
with a ruthenium complex react to form a sandwich complex. The complex is 
then bound to a streptin-biotin-paramagnetic bead complex and magnetically 
captured onto the surface of an electrode. Application of a current across the 
electrode induces a measurable electrochemiluminescent emission.459 
Copeptin samples were stored until the end of the study and transported 
together to Central Biological Ressource laboratoire (CRB) in Pitie-Salpetriere 
Hospital, Paris, France for batched immuno-analysis using the KRYPTOR® 
method, ThermoFisher BRAHMS. The KRYPTOR® method employs time 
resolved amplified cryptate emission technology in which europium cryptate 
and fluorophores bind with an immune complex to the copeptin molecule and 
emit light waves of predictable wavelength, which are detected and resolved as 
a concentration of copeptin.460  





Discharged patients were followed up with a phone call at seven and thirty 
days after recruitment. Recurrence of convulsive seizure, re-consultation, 
rehospitalisation, ICU admission and the presence of an abnormality on EEG 
was recorded. 
Statistical Analysis 
The central tendencies of non-normally distributed data were reported as 
medians with interquartile range (IQR), and that of normally distributed data 
as means ± standard deviation (SD). Central tendencies were only calculated 
for data with at least six observations. Categorical data were represented as 
number (percentage). Normality was tested using the Shapiro-Wilk test and 
by visually assessing the frequency distribution. The Shapiro-Wilk tests the 
hypothesis that the data is not normally distributed, and therefore the null 
hypothesis that the data is normally distributed. A significant p value, which 
corresponds to rejection of the null hypothesis of normality, means that the 
data is not normally distributed. Sensitivities and negative predictive values of 
the combination of copeptin and S100B for the primary outcome were 
calculated. 
Comparison of the two groups was performed using the Student t test, the 
Mann-Whitney U test, and Fisher's exact method when appropriate. Multiple 
backward logistic regression was performed to assess variables associated with 
the severity of the seizure, and odds ratios with 95% confidence intervals were 
calculated. Severe outcome probability was tested initially using a score 
derived from the logistic regression model without the two biomarkers, then 
including the biomarkers. To avoid overestimation, a conservative approach 




was used and only significant variables in the univariate analysis were 
included. Calibration of the model was estimated with Hosmer-Lemeshow 
test, and discrimination with the c-index. 
Pre-existing literature suggests a low correlation between standard clinical 
and biological data with the primary outcome. A receiver operating 
characteristics (ROC) curve with predictive probability for the primary 
endpoint was calculated using clinical data alone, then a second one calculated 
using the addition of the one biomarker; then a third calculated with the 
addition of the second biomarker. The threshold was that which minimised 
the distance to the ideal point (1 = sensitivity = specificity). 
Diagnostic data (sensitivity, specificity, negative predictive value [NPV], 
positive predictive value [PPV]) with their 95% confidence intervals were 
calculated. A NPV greater than 98% is required for an acceptable diagnostic 
test, which corresponds to a rate of errors related to discharge of less than 2%. 
A sub-group analysis was conducted to establish the rate of the primary 
endpoint and seizure recurrence by day seven in epileptic patients because the 
incidence of the primary endpoint may differ in epilepsy.454 Epileptic patients 
were defined as those prescribed anti-epileptic drugs. A further sub-group 
analysis was conducted to determine the rate of seizure recurrence by day 
seven in the group that was initially discharged from the Emergency 
Department. This was conducted because the composite primary endpoint 
might have led to a higher rate of endpoint than expected.  






The UK arm recruited 97 patients out of a total of 443 internationally (Figure 
4.1). Baseline data is shown in Table 4.1 and comparisons between UK and 
French baseline data is shown in Appendix 8. Fifty (52%) patients met the 
composite primary endpoint of seizure recurrence, death, hospital admission, 
or hospital re-admission by day seven. Of those, 31 (32%) had seizure 
recurrence, 33 (34%) were admitted (28 under acute medicine, four under 
critical care, two under neurosurgery), and 8 (8%) were readmitted by day 7 
(Table 4.3). No patients died. Some patients had more than one element of the 
composite endpoint (Figure 4.2). The most common cause for a seizure was 
epilepsy (47%), followed by alcohol associated seizures (21%) (Table 4.2). 
Alcohol associated seizures could have been associated with abuse of alcohol 
or withdrawal from alcohol use. First fits accounted for 11% of all patients and 
convulsive syncope for 8%. 





Figure 4.1 Participation inclusion diagram  











    
Eligibility    
Seizure prior to ED arrival 91 (94%) 46 (92%) 45 (96%) 
Seizure in ED 19 (20%) 18 (36%) 1 (2%) 
Male Sex 59 (61%) 28 (56%) 31 (66%) 
Age 41 (15) 43 (14) 36 (14) 
Previous seizures 91 (94%) 46 (92%) 45 (96%) 
    
Previous diagnoses    
Epilepsy 39 (40%) 21 (42%) 18 (38%) 
Alcohol abuse 25 (26%) 16 (32%) 9 (19%) 
Stroke 12 (12%) 5 (10%) 7 (15%) 
Other neurological path. 7 (7%) 6 (12%) 1 (2%) 
Substance abuse 6 (6%) 4 (8%) 2 (4%) 
Meningitis 4 (4%) 3 (6%) 1 (2%) 
    
Regular prescriptions    
Anti-epileptic drugs 31 (32%) 15 (30%) 16 (34%) 
Benzodiazepines 5 (5%) 2 (4%) 3 (6%) 
    
Symptoms in ED    
Headache 28 (29%) 14 (28%) 14 (30%) 
Confusion 16 (16%) 13 (26%) 3 (6%) 
Photophobia 6 (6%) 4 (8%) 2 (4%) 
Meningism 6 (6%) 4 (8%) 2 (4%) 
Focal neurol. deficit 5 (5%) 5 (10%) 0 (0%) 
    
Seizure characteristics    
Generalized Tonic-clonic 82 (85%) 39 (78%) 43 (91%) 
Complex Partial 9 (9%) 8 (16%) 1 (2%) 
Absence 1 (1%) 1 (2%) 0 (0%) 
Other seizure 3 (3%) 1 (2%) 2 (4%) 
Simple Partial 2 (2%) 1 (2%) 1 (2%) 
Provoked/Acute sympt. 31 (32%) 22 (44%) 9 (19%) 
Witnessed? 73 (75%) 42 (84%) 31 (66%) 
    
Physiological    
Heart rate (bpm) 92 (20) 98 (24) 85 (18) 
SBP (mmHg) 129 (23) 131 (33) 125 (18) 
DBP (mmHg) 76 (15) 80 (17) 74 (13) 
Temperature (°C) 36.5 (0.7) 36.6 (0.8) 36.3 (0.7) 
SpO2 (%) 97 (2) 97 (2) 97 (2) 
GCS 13-15 85 (88%) 42 (84%) 43 (91%) 
GCS 9-12 5 (5%) 4 (8%) 1 (2%) 




GCS 3-8 7 (7%) 4 (8%) 3 (6%) 
    
Laboratory    
White blood cell count 
(x103) 
8.7 
(6.4 to 12.4) 
9.1 
(7.0 to 14.2) 
8.7 
(5.8 to 11.2) 
Glucose (mmol/L) 6.1 
(5.2 to 7.7) 
6.7 
(5.3 to 8.0) 
6.1 
(5.1 to 7.7) 
Sodium (mEq/L) 140 
(138 to 142) 
140 
(137 to 141) 
141 
(139 to 143) 
Calcium (mmol/L) 1.23 
(1.20 to 1.28) 
1.23 
(1.19 to 1.29) 
1.23 
(1.22 to 1.27) 
Lactate (mmol/L) 2.5 
(1.4 to 4.4) 
2.9 
(1.8 to 6.9) 
2.2 
(1.5 to 3.9) 
S100B (µg/L) 0.09 
(0.06 to 0.18) 
0.1 
(0.07 to 0.21) 
0.08 
(0.06 to 0.12) 
Copeptin (pmol/L) 22.0 
(7.7 to 48.4) 
25.1 
(9.3 to 93.5) 
19.4 
(6.6 to 38.7) 
Table 4.1 Baseline data 
Categorical data are reported as number (%), continuous data as mean (SD), 
or median (IQR). ED, Emergency Department; SBP, systolic blood pressure; 
mmHg, millimetres of mercury; DBP, diastolic blood pressure; SpO2, 
peripheral saturation of oxygen; GCS Glasgow Coma Score; mmol/L, 
millimoles per litre; mEq/L, milliequivalents per litre; µg/L, micrograms per 
litre; pmol/L, picomoles per litre. 
 
Cause of seizure Number Percentage 
Epilepsy 46 47% 
Alcohol 21 21% 
First fit 11 11% 
Convulsive vasovagal syncope 8 8% 
Stroke 3 3% 
Other 9 9% 
Table 4.2 Cause of seizure 
Alcohol, any seizure presumed to be precipitated by alcohol use, which could 
be abuse or withdrawal. Other causes were recreational drug overdose, 
sertraline & diphenhydramine overdose, venlafaxine overdose, neurosarcoid, 
hydrocephalus due to cerebral abscess, hypoglycaemia, cerebral neoplasm, & 
encephalitis. 
  





Figure 4.2 Composition of the primary endpoint of recurrence, 
admission, readmission and death 
 
Thirty-one (32%) patients fulfilled the secondary endpoint of a recurrence of 
seizure by day seven, 31 (32%) patients were admitted into hospital for more 
than 24 hours, and five (5%) patients had the composite severe secondary 
outcome of ICU admission, a neurosurgical procedure or death by 28 days. Of 
those five, all achieved the endpoint by being admitted to ICU, and one of those 
also had a neurosurgical procedure and died of a brain tumour (Table 4.3).  













Composite primary outcome 50 (52%) 81 (23%) 131 (30%) 
    
Secondary outcomes    
Severe composite secondary outcome 5 (5%) 32 (9%) 38 (9%) 
Length of stay > 24 hours 31 (32%) 76 (22%) 107 (24%) 
Recurrence of seizure by day 7 31 (32%) 29 (8%) 60 (14%) 
    
Discharge destination from ED    
Discharge home 52 (54%) 238 (69%) 290 (65%) 
Admission any service (not obs. unit) 33 (34%) 62 (18%) 95 (21%) 
Admission observation unit 11 (11%) 95 (27%) 106 (24%) 
Admission under medicine 28 (29%) 44 (13%) 71 (16%) 
Admission under critical care 4 (4%) 6 (2%) 10 (2%) 
Admission under neurosurgery 2 (2%) 12 (3%) 14 (3%) 
Death 0 (0%) 2 (1%) 2 (1%) 
    
Day 7 follow up    
Re-admitted into hospital by day 7 8 (8%) 10 (3%) 18 (4%) 
Death between admission and day 7 0 (0%) 5 (1%) 5 (1%) 
Readmitted to critical care by day 7 4 (4%) 3 (1%) 7 (2%) 
Neurosurgical intervention by day 7 1 (1%) 2 (1%) 3 (1%) 
    
Day 28 follow up    
Seizure recurrence  38 (39%) 48 (14%) 86 (19%) 
Readmission into hospital  9 (9%) 21 (6%) 30 (7%) 
Readmission under critical care  3 (3%) 1 (0%) 4 (1%) 
Readmission under neurosurgery  1 (1%) 5 (1%) 6 (1%) 
Death by day 28 1 (1%) 3 (1%) 4 (1%) 
Table 4.3 Outcomes in the UK and France 
  





The median S100B and copeptin levels were 0.09 µg/L (IQR 0.06-0.18) and 
22.0 pmol/L (IQR 7.7-48.4) respectively. S100B and copeptin were 
significantly higher in patients with compared to without the composite 
primary endpoint: 0.22 µg/L (95% CI 0.14 to 0.31) vs 0.11 µg/L (95% CI 0.08 
to 0.14) (p = 0.01, 95% CI 0.02 to 0.2) for S100B; and 77.0 pmol/L (95% CI 
44.3 to 109.7) vs 27.0 (95% CI 18.2 to 35.9) (p = 0.004, 95% CI 16.2 to 83.8) 
for copeptin (Figure 4.3).  
No power calculation was performed in the design phase of this study. 
However, S100B and copeptin in patients with the composite primary 
endpoint were both significantly higher than in those without the endpoint. 
Therefore, there is no type 2 error and consequently, no post-hoc power 
calculation is necessary. 
 





Figure 4.3 S100B and Copeptin levels by group 
Outcome is the composite primary endpoint of recurrence, admission, 
readmission and death. Box plot shows median, 25th centile, 75th centile, 
Tukey’s hinges, and outliers. 
   




Diagnostic test characteristics 
The area under the receiver operating characteristic curves (AUC) for the 
composite primary endpoint were 0.6 (95% CI 0.5 to 0.7) and 0.6 (95% CI 0.5 
to 0.7) for S100B and copeptin respectively (Figure 4.4). The AUC for 
recurrence of seizure by seven days were 0.5 (95% CI 0.4 to 0.7) and 0.5 (95% 
CI 0.4 to 0.7) for S100B and copeptin respectively (Figure 4.5). 
 
Figure 4.4 Receiver operating characteristic curve for S100B and 
copeptin to diagnose the composite primary endpoint 
 
 
Figure 4.5 Receiver operating characteristic curves for S100B and 









Using Youden’s method, a threshold of 0.088 µg/L and 6.26 pmol/L was 
identified for S100B and copeptin respectively. This threshold was selected as 
closest to the ideal point (where sensitivity and specificity are 100%). 
However, as the capacity to rule in rather than rule out a diagnosis is often of 
greater value to physicians when the diagnosis has a high morbidity, further 
thresholds were identified to maximise the specificity. The diagnostic 
performances for these thresholds are shown in Table 4.4.






Sensitivity Specificity PPV NPV LR+ LR- 
S100B>0.09 58% (43-72) 60% (44-74) 60% (50-70) 57% (47-67) 1.44 (0.94-2.18) 0.71 (0.47-1.05) 
S100B>0.1 52% (37-66) 66% (51-79) 62% (50-72) 56% (48-65) 1.53 (0.95-2.47) 0.73 (0.51-1.04) 
S100B>0.2 26% (15-40) 87% (74-95) 68% (47-84) 53% (48-57) 2.04 (0.84-4.92) 0.85 (0.7-1.03) 
S100B>0.5 14% (6-27) 98% (89-100) 88% (47-98) 52% (49-55) 6.58 (0.84-51.48) 0.88 (0.78-0.99) 
Copeptin >6.2 80% (66-90) 21% (11-36) 52% (47-57) 50% (31-69) 1.02 (0.83-1.25) 0.94 (0.43-2.05) 
Copeptin>15 68% (53-80) 43% (28-58) 56% (48-63) 56% (43-68) 1.18 (0.87-1.62) 0.75 (0.45-1.27) 
Copeptin>50 30% (18-45) 85% (72-94) 68% (49-83) 53% (48-59) 2.01 (0.9-4.5) 0.82 (0.66-1.02) 
Copeptin>100 24% (13-38) 96% (85-99) 86% (59-96) 54% (50-58) 5.64 (1.33-23.88) 0.79 (0.67-0.94) 
 
Table 4.4 Diagnostic performances of S100B copeptin at various thresholds 
PPV, positive predictive value; NPV, negative predictive value; LR+, likelihood ratio for a positive test; LR-, likelihood ratio for a 
negative test; S100B (µg/L), copeptin (pmol/L), numbers in brackets 95% confidence intervals.




Logistic regression model 
A multivariate logistic regression was performed with pre-specified variables. 
After assessment for collinearity, the variable ‘provoked/acute symptomatic 
seizure’ was found to be correlated with ‘alcohol dependence’, and ‘epilepsy’ 
was found to be correlated with ‘previous seizures’. Alcohol dependence and 
previous seizures were removed from the model for statistical rather than 
clinical reasons (because they had a lower pseudo R2 than the variables they 
were correlated with), and focal neurology was removed as there were no 
events in patients with focal neurology. Two models were derived, the first not 
including, and the second including the biomarkers. In the first model, 
independent risk factors for the composite primary outcome were a diagnosis 
of epilepsy, complex partial seizure, provoked/acute symptomatic seizure, and 
pyrexia. Discrimination of the model was good, with a C-statistic of 0.75, and 
the Hosmer-Lemeshow goodness of fit test had a p value of 0.70 (Table 4.5). 
Adding the two biomarkers did not change the model and neither of the 
biomarkers were independently associated with the outcome (C-statistic 0.79, 
Hosmer-Lemeshow goodness of fit p = 0.27). 
 Clinical model alone Clinical model with biomarkers 
   
Variable Adjusted OR P value (95% CI) Adjusted OR P value (95% CI) 
Epilepsy 3.1 0.044 (1.0 – 9.0) 4.2 0.020 (1.3 – 14.3) 
Complex Partial 13.7 0.021 (1.5 – 127.9) 17.5 0.015 (1.8 – 173.6) 
Provoked 7.0 0.001 (2.2 – 22.5) 8.4 0.001 (2.3 – 29.7) 
Pyrexia 10.4 0.050 (1.0 – 108.3) 12.4 0.058 (0.9 – 167.8) 
Copeptin   1.0 0.058 (1.0 – 1.0) 
S100B   11.9 0.246 (0.2 – 771.6) 
 Hosmer-Lemeshow p=0.70 Hosmer-Lemeshow p=0.27 
 C-statistic 0.75 C-statistic 0.79 
 
Table 4.5 Adjusted odds ratios of independent predictors of the 
primary outcome  





Two subgroup analyses were performed to investigate the rate of the primary 
outcome and early seizure recurrence in patients with epilepsy, and to 
determine the rate of early seizure recurrence in patients discharged home. 
Out of 97 patients in total, 39 (40%) patients had a pre-existing diagnosis of 
epilepsy. Of those, 21 (54%) experienced the composite primary outcome of 
admission, readmission, or early seizure recurrence, and 18 (46%) experienced 
an early recurrence of seizure. The median S100B was 0.08 µg/L (IQR 0.06 to 
0.13) and 0.09 (IQR 0.06 to 0.14), and median copeptin was 18.0 pmol/L (IQR 
5.4 to 49.7) and 10.9 (IQR 1.5 to 23) in epileptic patients that did and didn’t 
have the primary endpoint respectively. There was no significant difference in 
S100B (p = 0.8, 95% CI -0.8 to 0.06), or copeptin (p = 0.06, 95% CI -2.4 to 
103) in epileptic patients that did and didn’t have the primary endpoint. 
Fifty-two (54%) patients were discharged home from the Emergency 
Department, and of those 15 (29%) experienced the primary endpoint and 15 
(29%) had early seizure recurrence. Medians for S100B were 0.07 µg/L (IQR 
0.05 to 0.15) and 0.08 (0.06 to 0.10), and copeptin 21.1 pmol/L (IQR 5.4 to 
35.9) and 15.8 (IQR 6.4 to 39.4) in discharged patients with and without early 
seizure recurrence respectively. There was no difference in S100B (p = 0.4, 
95% CI -0.04 to 0.10) or copeptin (p = 0.5, 95% CI -16.4 to 33.4) in patients 
that were discharged home from the Emergency Department that did and did 
not have the primary outcome.   





The principle findings of this study are that in adult patients presenting to the 
Emergency Department with a seizure, the biomarkers S100B and copeptin 
were both significantly higher in patients that had a composite primary 
endpoint of recurrence of seizure, admission or readmission by day seven, 
compared to those that didn’t (0.22 vs 0.11 µg/L and 77.0 vs 27.0 pmol/L for 
S100B and copeptin respectively). However, the predictive power of each 
biomarker was poor, with areas under the receiver operating characteristic 
curve of 0.6 and 0.6 respectively, and in a logistic regression analysis, neither 
biomarker was independently associated with the outcome. Furthermore, no 
patient presented with a seizure as a consequence of TBI. The most common 
reason for having a seizure was a pre-existing diagnosis of epilepsy, followed 
by alcohol associated seizure and first fit. Of the 97 patients recruited from a 
UK Emergency Department, 50 (52%) had the composite primary endpoint of 
seizure recurrence, admission or readmission into hospital by day seven; five 
(5%) had the composite severe secondary endpoint of death, critical care 
admission or neurosurgical intervention by day 28; 31 (32%) had the 
secondary endpoint of seizure recurrence by day seven; and 31 (32%) had the 
secondary endpoint of admission for more than 24 hours by day seven. This 
was the UK arm of an international study that recruited patients from the 
Royal London Hospital in London and three hospitals in France.461 Although 
the principle findings in the overall study are the same as in the UK arm, there 
are some differences noted between the UK and French populations. The main 
difference between the UK and the French populations are the rates of the 
primary outcome: 52% vs 23% in UK and France respectively. This difference 




is due to higher rates in the UK of all components of the primary outcome 
except death: seizure recurrence 32% vs 8%, admission 29% vs 13%, 
readmission 8% vs 3%. In the UK no patients died by day seven in contrast to 
France in which five patients died. This difference may indicate a UK 
population that has an overall lower seizure threshold, and this hypothesis is 
supported by the higher numbers of pre-morbid conditions, specifically 
alcohol dependence, substance misuse and stroke, seen the UK population. 
This pre-morbid burden may be attributable to the population that the Royal 
London Hospital serves, which is central and urban, with higher than average 
alcohol associated attendances, both for chronic and acute alcohol abuse. In 
addition, the emergency care systems of the two countries are different. In the 
French system patients with low acuity are seen in the Emergency Department 
whereas in the UK they are not. This could mean that low acuity patients with 
a lower risk of achieving the primary endpoint were recruited in France but 
could not have been in the UK. 
In recent years S100B has been reported to have a very high specificity for 
death (95% to 98%) and unfavourable neurological outcomes (85 to 98%), and 
a very high sensitivity for the diagnosis of brain lesions (99 to 100%) in 
traumatic brain injury (Table 1.11).302,462,463 In the context of seizure, the 
diagnostic performance of S100B is poor, with failure to obtain thresholds that 
would allow greater sensitivity with acceptable specificity, or vice versa. At 
thresholds of 0.1 and 0.2 µg/L the rate of false positives (S100B greater than 
the threshold but the patient not having the outcome) was high at 34% and 
13% respectively, i.e. S100B was raised in many cases that did not meet the 
primary endpoint. This suggests that there is an increase in blood 




concentration of S100B after a seizure, regardless of whether that patient will 
go on to develop the primary endpoint or not. Similarly, there was no added 
value of copeptin in the setting of seizure. No threshold was determined for 
S100B or copeptin that could help clinicians either to rule in or rule out the 
occurrence of adverse events. 
The high frequency of the primary endpoint contrasts with previously 
published work. This could be explained by the fact that the endpoint is a 
composite whereas previous studies report singular primary endpoints such 
as seizure recurrence. One study reported an early seizure recurrence rate of 
19% (within 24 hours), whilst another suggested that a rate of at least 28% of 
patients not initially admitted experienced the endpoint within six 
weeks.454,464 In my study, nearly 30% of patients that were initially discharged 
home had early seizure recurrence. 
S100B and copeptin have not previously been tested in Emergency 
Department patients with seizure, however the difference in biomarker levels 
seen in the groups that had and didn’t have the primary outcome is consistent 
with studies of S100B in mild head trauma and in alcohol associated 
admissions.317,465 The median S100B was 0.1 µg/L and 0.08 µg/L in the groups 
with and without the primary endpoint respectively. In a study of 1560 patients 
with minor head injury, those with intracranial lesions on CT scan had a 
median S100B of 0.46 µg/L compared with 0.22 µg/L in those with no lesion 
on CT.302 The S100B analyser in this study was the same type as used in the 
study reported in this thesis, namely an Elecsys (Roche Diagnostics), and the 
results may therefore be comparable. The medians reported here are more 
than twice as low as in the study of patients with minor head injuries, 




particularly when comparing the seizure group with no outcome with the head 
injury group with no intracranial injury. In another study of patients with mild 
head injury, the median S100B, measured on an immuno-luminometric assay 
kit (LIA-mat, AB Santec, Sweden), was 0.11 µg/L (IQR 0.08 to 0.18), which is 
comparable with the results presented here.309 There was a predefined 
threshold of 0.15 µg/L and an outcome of return to work, with a sensitivity and 
specificity of 80% and 74% respectively. In patients with out of hospital cardiac 
arrest and return of spontaneous circulation within 20 minutes, the mean 
S100B was 3.68 µg/L (measured on the Roche Elecsys), more than thirty times 
higher than the median S100B in the seizure population with the primary 
outcome.296 The degree of cerebral and other organ injury consequent to 
cardiac arrest is significantly higher than that following a seizure, and so the 
differences in S100B levels in these two groups is not unexpected. 
Furthermore, on retrospective analysis of the medical record, 8% of patients 
were subsequently diagnosed with convulsive syncope rather than seizure, so 
did not experience the same disordered electrophysiological state that occurs 
in a true seizure, and consequently S100B release may be reduced even further 
in this subgroup. 
In a study comparing patients with acute spontaneous intracerebral 
haemorrhage with healthy controls, mean copeptin levels were 622.5 pmol/L 
and 96.8 pmol/L respectively.466 The analyser in this study was by enzyme-
linked immunosorbent assay using commercial kits (Phoenix 
Pharmaceuticals, Burlingame, CA, USA), and is reported in pg/ml and 
converted using the formula 1 pg/ml copeptin = 0.249 pmol/L. A further study 
comparing survivors and non-survivors with acute spontaneous intracerebral 




haemorrhage reported copeptin levels of 847 and 1237 pmol/L respectively 
(analyser also enzyme-linked immunosorbent assay by Phoenix 
Pharmaceuticals).467 In another study comparing survivors and non-survivors 
of acute spontaneous intracranial haemorrhage, copeptin levels were 18.5 
pmol/L and 31.9 pmol/L. In patients with ruptured aneurysmal subarachnoid 
haemorrhage the mean copeptin was 21.2 pmol/L.468 The analysis technique 
in this case was an enzyme-linked immunosorbent assay (Cusabio Biotech Co. 
Ltd, Wuhan, Hubei Province, China). In 94 patients with severe TBI, mean 
copeptin was 103 pmol/L, and 141 vs 89 pmol/L in non-survivors vs survivors 
(analysis technique also enzyme-linked immunosorbent assay by Cusabio 
Biotech Co. Ltd).366 In this series, a threshold of 112 pmol/L had an AUC of 
0.87, which was far in excess of the discrimination achieved by copeptin in 
patients with seizures. In non-acute patients with heart failure, baseline 
copeptin was 31 and 55 pmol/L in the lowest and highest quartiles for 
cardiovascular mortality over 13 years respectively, and 45 and 82 in the lowest 
and highest quartiles for all-cause mortality respectively (analyser same as in 
this thesis, Kryptor Compact platform, BRAHMS, Hennigsdorf, Germany).364 
In patients with stroke, copeptin levels ranged from 8.6 pmol/L to 30.1 pmol/L 
in patients with low to high National Institute of Health Stroke Scale scores.359 
The analyser in this study was the similar to that used in this thesis, namely a 
commercial sandwich immunoluminometric assay (BRAHMS LUMItest CT-
proAVP, Hennigsdorf/Berlin, Germany).357 The range of copeptin levels seen 
in these studies that included patients with spontaneous intracranial 
haemorrhage, severe TBI, occlusive stroke and non-acute heart failure, is wide. 
Higher levels are seen with more severe pathology and the results reported in 
this thesis are amongst the lower levels reported. This indicates that although 




there may be a rise in copeptin following a seizure, the rise is not predictive of 
severe outcomes following seizure. The outcomes reported in this thesis are 
also not directly comparable to those reported in previous work as, in contrast 
to previously published work, there were no deaths and long-term disability 
was not measured. A further reason for variation in copeptin levels seen in the 
studies may be accounted for not only by acuity but also by analyser, of which 
two main methods are utilised; enzyme-linked immunosorbent assay and 
sandwich immunoluminometry. 
This study presents strengths and weaknesses. It is the first to assess the value 
of the biomarkers S100B and copeptin in the setting of patients presenting to 
the Emergency Department with a seizure. One limitation was the choice of 
the composite endpoint of admission, readmission, seizure recurrence and 
death. The decision to admit (or readmit) a patient that has had a seizure is 
subject to the idiosyncrasies of an individual doctor, and dependent on the 
values of the healthcare system to which the patient presents. In the UK, there 
were significantly more patients that had the primary endpoint, and the 
difference was made up of all components of the primary endpoint except 
mortality. This difference and the subjective nature of the endpoint 
components admission and readmission make the results difficult to 
generalise. There may also be an element of inclusion bias because the 
diagnosis of seizure may be uncertain in the Emergency Department, and 
consequently some patients that did not have a true electrophysiological 
seizure but instead may have had a pseudo-epileptic seizure or convulsive 
syncope could have been included. Indeed, on retrospective analysis of the 
medical record, 8 (8%) of recruited patients were subsequently diagnosed with 




convulsive syncope. This limitation is inherent to the design and reflects the 
day to day work of an emergency physician, in which it is sometimes 
impossible to fully confirm than an epileptic seizure has occurred. In the same 
way, information on the type of seizure was retrieved from the history of 
patients and witnesses and are consequently also subject to bias. This again 
mirrors the real-life information to which a clinician has access. 
The biomarkers S100B and copeptin have shown promise in predicting poor 
outcomes in mild TBI as well as several other modes of acquired brain injury, 
but the subjective nature of much of the combined primary endpoint in this 
study make their specific value in Emergency Department patients with 
seizures of any cause hard to establish. Further work in patients with mild TBI 
and seizures looking at purely clinical and patient centred outcomes such as 
seizure recurrence should be performed with sufficient numbers of patients in 
subgroups including alcohol dependence, drug dependence and epilepsy.  
Conclusion 
Although levels of S100B and copeptin were higher in patients with seizure 
and poor outcomes, no patient had a seizure as a consequence of mild TBI, and 
the biomarkers did not improve the prediction of poor outcomes more than 
routinely collected clinical and physiological data.  




Chapter 5 Conclusions 
Summary of findings 
In this thesis I investigated outcomes in patients with mild acquired brain 
injuries after attendance at an Emergency Department. I investigated the 
effect that a mild traumatic brain injury has on how long it takes for a patient 
to return to work following injury. I used a structured methodology to identify 
the academic literature containing data on patients with mild TBI and in which 
return to work was measured. Out of more than 900 articles reviewed, 14 fit 
the inclusion criteria for the study. I devised a tool that allowed me to abstract 
data reproducibly and categorically so that it was in an analysable form, then 
applied the tool to the 14 articles. I collated the data to create summary 
findings on baseline characteristics reported in the 14 articles. I then pooled 
the data to create a meta-analysed estimate of proportions of patients that 
have returned to work by a pre-set time after the injury. I applied a previously 
validated tool to assess for bias.389 The average time taken to return to work 
was only reported in three studies and ranged from six to 16 days but was 
highly skewed. By one month 56%, by three months 75%, by six months 81%, 
and by one year 88% of patients had returned to work. 
I then investigated the short-term effects that a mild TBI has on patients’ 
capacity to think, and the symptoms they experience. I recruited 240 patients, 
of whom 189 had mild TBI and 51 were non-head injured comparators. I found 
that in patients with mild TBI, there is no statistical difference in 
neurocognitive function between baseline and follow up three days later, but 




patients with mild TBI have marked neurocognitive impairment compared to 
patients without TBI. Furthermore, more patients with mild TBI deteriorated 
than improved by follow up. In contrast, in patients with mild TBI, the severity 
of symptoms improved from baseline to follow up, but were worse than 
patients without TBI both at baseline and at follow up. The number of 
symptoms patients with mild TBI experienced remained the same at baseline 
and follow up. Patients with acute haemorrhage on CT had considerably worse 
neurocognitive function, symptom severity, and number of symptoms than 
those without. Neurocognitive function remained poor at follow up, but 
symptom severity and number of symptoms improved. When comparing 
patients that had had previous head injuries and those that hadn’t, there was 
no difference in neurocognitive function from baseline to follow up in either 
group, nor was there a difference between the groups at either time point. 
There was also no improvement in symptom severity nor number of symptoms 
in patients with previous head injuries, but there was improvement in those 
outcomes in patients without previous head injuries. 
I then assessed the value of two novel biomarkers in predicting poor outcomes 
after seizure of any cause. Both S100B and copeptin showed promise in 
previous work in predicting poor outcomes following brain injury. I recruited 
97 patients that had had a seizure and presented to the Emergency 
Department, and measured a composite endpoint of seizure recurrence, death, 
hospital admission, and hospital re-admission by day seven. The secondary 
endpoints were seizure recurrence by day seven, admission into hospital for 
more than 24 hours, and a composite severe outcome of ICU admission, 
neurosurgical procedure or death by 28 days. More than half of patients (52%) 




met the primary endpoint, 32% had seizure recurrence, 32% were admitted for 
more than 24 hours, and five patients experienced the composite severe 
outcome ICU admission, neurosurgical procedure or death by 28 days. S100B 
and copeptin were both significantly higher in patients that experienced the 
primary endpoint, but the prognostic value of each biomarker for each 
outcome (primary and secondaries) was low. A multivariate logistic regression 
model using clinical variables only had good discrimination. Adding the 
biomarkers to the model neither improved the discrimination nor were either 
biomarker independently associated with the outcomes. 
Strengths and weaknesses of this work 
The systematic review and meta-analysis was conducted in line with 
international guidelines, and according to a methodologically robust protocol, 
which was prospectively registered with a globally recognised registry of 
reviews. To my knowledge it is the only systematic review and meta-analysis 
published on return to work following mild TBI. It is also the most 
comprehensive review in this group with this outcome. In it I have collated and 
presented not only the raw data of how long it takes for patients to return to 
work following mild TBI, but also the significant variation in outcome 
reporting. This constitutes strong evidence that a consensus in outcome 
reporting amongst researchers of mild TBI is needed. The main limitation of 
the methodology of the review was the choice of using an outcome as an 
inclusion criterion, rather than a characteristic of the patient at the time of 
injury. Specifically, I chose to include studies based on whether they reported 
the outcome return to work, not based on whether patients were working at 




the time of injury. This was because I wanted to be as inclusive as possible to 
answer the question of how long it takes to return to work after injury. I 
accepted that this might be at the expense of introducing bias, in the form of 
including patients in the pooled analysis that were reported as having returned 
to work or usual activities, rather than exclusively as returned to work. I 
quantified the bias as far as possible given the heterogeneity of reporting in the 
source studies. I found that only two out of 14 studies exclusively included 
patients that were in paid employment prior to injury, and only one of those 
reported the follow-up rate. Another important limitation of the review was 
the heterogeneity of the included studies. The variables I abstracted included 
years in education, CT findings, presence of loss of consciousness, and 
presence of post-traumatic amnesia, and I found that there was significant 
variation in reporting these characteristics. If different researchers are 
reporting different outcomes, the variation in outcome reporting presents 
specific challenges in studying mild TBI and its effect on patients. In addition 
to the variation in outcome reporting noted in the included studies, there is 
also a problem with selection bias in studies on mild TBI.469 In order to reduce 
the effect of confounding factors in observational studies, multiple exclusion 
criteria are applied. The consequence of the introduction of exclusion criteria 
such as previous TBI, psychiatric comorbidities, or previous neurosurgery, is 
that they can reduce the proportion of eligible patients to as low as 5% of all 
patients with mild TBI.469 The reverse perspective of this is that patients that 
sustain a mild TBI are a profoundly heterogenous group. Although studying 
selected samples may be necessary, the outcomes can’t be generalised to the 
greater population, and outcomes in excluded groups cannot be known unless 
they are explicitly studied. Another limitation was the intention to pool the 




average time it takes to return to work (in contrast to the proportion returned 
by a specific time-point). Only three studies reported average times to return 
to work, and the way they were reported was different in each study. Reynolds 
et al reported central tendencies (median, mean, and standard deviation) in 
four sub-groups but not overall and complete measures of central tendency.395 
Iverson et al reported measures of central tendency (mean, median, standard 
deviation, interquartile range, minimum and maximum) in two sub-groups 
but not an overall measure; whilst Losoi et al reported overall central 
tendencies.171,371 Where means and medians were reported, they were very 
different, indicating the distribution of the return to work outcome to be non-
parametric. With so few studies, and such variation within the data, pooling 
was not a suitable statistical approach. 
The study of short-term outcomes following mild TBI demonstrated an 
ongoing and potential deterioration in cognition. This was particularly seen in 
patients with acute haemorrhage on CT. The main limitation in this study was 
the high rate of loss to follow up; 46% in patients with mild TBI group and 43% 
in patients without mild TBI. This is mitigated against by quantifying the bias, 
and most clearly seen in the hybrid parallel line plots of change and difference 
in outcomes (Figure 3.3 to Figure 3.8). The other limitation may be that follow 
up was at times over the telephone, which could have impacted on a patient’s 
capacity to perform the delayed recall domain of the neurocognitive 
assessment. There is no direct evidence to support this hypothesis, but it may 
be a possibility. 
The study of S100B and copeptin to predict outcomes following seizure 
remains the only study utilising those biomarkers and that outcome. Although 




serum levels of both biomarkers were elevated in patients with the outcome 
compared to those without, there was no prognostic value associated with the 
biomarkers. The main limitation in this study was the choice of the composite 
endpoint of admission, readmission, seizure recurrence and death. The only 
entirely objective element to that endpoint is death, which occurred in only 
one patient, who died of a brain tumour. Admission into hospital is 
fundamentally a subjective outcome and dependent on the treating physician 
and the norms of the healthcare system. Even the diagnosis of seizure can be 
inaccurate because patients can commonly have a convulsive syncope which is 
cardiac in nature, with no deranged electrophysiological activity consistent 
with an epileptic seizure. However, this last potential source of bias is 
pragmatic and reflects routine diagnostic challenges faced in the Emergency 
Department, where accurate descriptions of convulsive episodes may not be 
available. Because the endpoint was so broad, the outcome was experienced by 
half of the study population. This influences the discrimination of the test 
under investigation – at higher prevalence a test will have a higher positive 
predictive value and lower negative predictive value, and vice versa. 
Regardless of prevalence, neither biomarker showed promise for 
discriminating between patients that did or did not have either the primary or 
the secondary outcomes. 
  




Comparison to previous work 
I found that half of patients with mild TBI have returned to work by one month 
and three quarters by three months. This is similar to that found in the only 
previously published systematic review of return to work exclusively in 
patients with mild TBI, in which the authors concluded that that most workers 
return to work three to six months after injury.379,470 In that review, four 
studies were included, compared to 14 in my review. I was able to include more 
studies in my review because the eligibility criteria I used incorporated all four 
definitions of mild TBI, compared to only two in the previously published 
review. In addition, in the previously published review, studies were only 
eligible for inclusion providing both functional recovery (such as return to 
work) was measured and an examination of modifiable prognostic factors was 
performed. The focus of my review was not to identify prognostic factors and 
consequently of the four included studies in the previously published review, 
only one was included in my review.169 Of the three that they included and I 
did not, one reported data that was also reported in another study that I did 
include, one included patients with severe TBI, and one did not report return 
to work outcomes.174,471,472 Despite the differences in included studies, the 
findings were similar, adding strength to the conclusion that most patients 
with mild TBI have returned to work by three months. 
My study of neurocognition following mild TBI was the largest performed in 
an Emergency Department population using the SAC, and the first to be 
conducted in more than one hospital. I found that patients with mild TBI had 
worse neurocognitive function than patients without TBI, and that their 
cognitive dysfunction had not improved by follow up three days later. 




Compared to another study of Emergency Department patients with mild TBI, 
the patients I recruited had better initial neurocognitive function (25 vs 21 
points on SAC).176 This may be because in the comparison study, the 
population had almost twice the proportion of patients that sustained a loss of 
consciousness or post-traumatic amnesia, indicating that possibly the degree 
of mild TBI was more severe. In addition, the average first cognitive 
assessment was very soon after injury (less than four hours), allowing less time 
for recovery in the very early stages after injury, which could also explain the 
difference. One other study reports such poor neurocognitive function in mild 
TBI patients in the Emergency Department.205 In this study of 118 patients 
with mild TBI, the neurocognitive function measured in the Emergency 
Department was 21.5 to 23 SAC points, in CT positive and negative groups 
respectively. Unfortunately, no information regarding injury characteristics 
was reported so postulating reasons for the relatively low scores is not possible. 
In contrast, in two smaller studies, neurocognitive function was higher at 
baseline at 25 and 26 SAC points.203,204 These studies included 49 and 26 
Emergency Department patients with mild TBI. The higher neurocognitive 
function could be explained by the patients being younger, and that a third 
were involved in sports injuries, compared with only 1% in the patients 
reported in this thesis. 
The astroglial protein S100B has proved to have diagnostic value in predicting 
the presence of traumatic intracranial haemorrhage. There has been particular 
interest in the value of S100B in paediatric populations because radiation 
exposure from CT scanning in childhood may be associated with a higher risk 
of cancer in later life.236,473,474 The sensitivity of S100B for intracranial 




haemorrhage has been reported as greater than 90% in several studies 
(although specificities are universally poor).475-480 In a meta-analysis the 
pooled sensitivity and specificity was 100% and 34% respectively.481 S100B has 
also been reported to have a negative predictive value of 99-100% to exclude 
intracranial haemorrhage in adults with head injury.301,302,482 My findings are 
very different to these. I found that the highest negative predictive value for 
excluding the composite primary outcome in patients with seizure was 58%. 
This is likely in part to be a function of the high prevalence of patients with the 
primary outcome (52%). Sensitivity and specificity are not affected by disease 
prevalence, but negative and positive predictive value are. Consequently, if 
around half of patients have the disease (have the composite primary 
endpoint) the predictive values of a diagnostic test will not be useful. 
In studies of S100B in TBI, the diagnostic thresholds range from 0.006µg/L to 
0.2 µg/L.479,483 I identified the optimum threshold of S100B for predicting the 
composite outcome as 0.088 µg/L and then derived the diagnostic test 
characteristics at thresholds of 0.09, 0.1, 0.2 and 0.5 µg/L. The highest 
sensitivity was 58% at a threshold of 0.09 µg/L. This is well below an 
acceptable level and below the level that S100B performs at in patients with 
TBI, although similar to that found in patients in coma after recovery of 
spontaneous circulation following a cardiac arrest. In this situation, S100B has 
sensitivities ranging from 42% to 88% for diagnosing poor neurological 
outcome.484 In these studies, the threshold ranged from 0.12 to 0.76 µg/L, 
which is higher than the threshold in which S100B performed best in patients 
with seizure.485,486 At a higher threshold, fewer patients are ‘positive’ for the 
test, which increases the specificity (true negative rate). This is seen in the 




assessment of different thresholds for seizure patients, with a specificity of 
98% at a threshold of 0.5 µg/L. 
Why is a negative S100B effective for excluding intracranial haemorrhage in 
TBI patients, but not for excluding poor neurological outcomes in comatose 
post cardiac arrest patients, nor for the composite primary outcome in patients 
that had a seizure? Patients that are comatose after a cardiac arrest are likely 
to have sustained a hypoxic brain injury. However, in these patients, S100B 
was sometimes measured days after the cardiac arrest, and if the injury to the 
brain is no longer occurring, there may be no ongoing leak of S100B into the 
plasma, and previously elevated levels of S100B may have reduced. In 
contrast, the insult to the brain because of a seizure, in the absence of a 
concurrent injury, may be so minimal as not to elevate the S100B sufficiently. 
But, S100B levels were significantly higher in patients with the composite 
primary endpoint compared to without (0.22 vs 0.11 µg/L, Figure 4.3). The 
levels I report are comparable to the thresholds utilised in TBI studies 
(although not in post cardiac arrest studies), yet S100B had little prognostic 
value. The conclusion is therefore that elevated S100B has little association 
with the composite primary endpoint of seizure recurrence, admission, 
readmission and death. 
Copeptin, which occurs in identical quantities as vasopressin in the plasma, 
but is more stable, has also shown promise in predicting poor neurological 
outcomes. In patients with acute ischaemic stroke, copeptin is significantly 
different in survivors and non-survivors, and in patients with good and poor 
neurological outcomes.359,487-490 Copeptin levels were 8 to 10 and 19 to 32 
pmol/L in patients with good and poor neurological outcomes respectively, 




and 10 to 15 and 29 to 60 pmol/L in survivors and patients that died 
respectively. In patients with spontaneous basal ganglia haemorrhage and 
healthy controls, copeptin levels were 24 and 5 pmol/L respectively.491 
Furthermore, in patients with basal ganglia haemorrhage, copeptin has a 
sensitivity of 82% for one year mortality. In another study comparing patients 
that survived or died after spontaneous intracranial haemorrhage, copeptin 
was 13 pmol/L and 178 pmol/L respectively, with an AUC of 0.88 for 30-day 
mortality. I found that copeptin was significantly different in patients with 
seizure that did and did not meet the composite primary endpoint, at 77.0 
pmol/L and 27.0 pmol/L respectively (Figure 4.3). The thresholds used in 
studies of copeptin in ischaemic or haemorrhagic stroke are not reported. I 
derived the optimum threshold to maximise the test characteristics, and found 
it to be 6.26 pmol/L. Using thresholds of 6.2, 15, 50, and 100 I calculated test 
characteristics. The sensitivity for the combined endpoint was 80% at a 
threshold of 6.2 pmol/L, with a low specificity, and as the threshold is set 
higher, sensitivity reduces, and specificity rises. As seen with S100B, the 
negative predictive value is around 50% regardless of the threshold, because 
the prevalence of patients with the outcome is so high. Copeptin had no 
prognostic value for predicting the primary endpoint. This may be because of 
the four elements that composed the primary endpoint, only two were 
physiological processes that could conceivably elevate a biomarker. One was 
seizure, which is a physiological process, the other death, which is also a 
physiological process but only occurred in one patient. The other two 
components are process measures, proxy for a disease state (admission or 
readmission).  




Recommendations for further research 
This thesis has shown that although most patients return to normal functional 
activities relatively quickly, most have short term ongoing symptoms and a 
proportion have poor outcomes at one year. The reasons for ongoing disability 
are not clear but could be influenced by pre-injury factors such as previous 
injuries, years in education or previous mental health diagnoses; factors 
associated with the injury, such as the force absorbed by the body; or factors 
occurring after the injury such as follow up care. The resolution of normal 
function may be predicted by clinical signs such as the presence of loss of 
consciousness or amnesia, or by the results of tests such as neurocognitive 
tests. The degree of heterogeneity in reporting these factors is large, with 
mostly small studies that report many different outcomes, making analysis of 
multiple studies challenging. 
Outcomes after traumatic brain injury 
A consensus on the most useful patient-centred outcomes would enable high 
quality research to be performed that would also lend itself to comparison 
between research groups. Initiatives such as the Core Outcome Measures in 
Effectiveness Trials (COMET) and the International Consortium for Health 
Outcomes Measurement (ICHOM) create core outcome sets that if used in 
research or clinical practice represent value-based healthcare and a 
standardised system for measuring endpoints in research.415,492 Common data 
elements for TBI research have in fact been recommended in two different 
publications, and include the global outcome measure the Extended Glasgow 
Outcome Scale (GOSE-E), as well as specific outcome measures for several 
functional domains including psychological status, symptoms, behavioural 




symptoms and cognition.493,494 However, many of the recommended outcomes 
are difficult to interpret and communicate to patients. Further research should 
be undertaken, with patient liaison involvement, to determine outcomes that 
if they were improved after a mild TBI, would most positively impact on 
patients’ lives. A large-scale observational study measuring mild TBI core 
outcome sets could then be undertaken. Identification of interventions that 
might improve core outcomes in mild TBI is essential and these may be 
pharmaceutical, psychotherapeutic, educational or simply be the act of seeing 
a patient in clinic after the injury. 
Epidemiology of traumatic brain injury 
In the UK a new commissioning dataset for emergency care (the Emergency 
Care Data Set [ECDS]) was introduced, with the first of 200 English 
Emergency Departments submitting data centrally in September 2017. One of 
the key premises of the ECDS is that accurate presenting complaint, 
mechanism of injury and diagnostic data are recorded at a national level. This 
is the first time in the world that such a clean and lean set of categorical data 
is legally required to be submitted nationally. This gives researchers in the UK 
a unique opportunity to identify people with head injuries, understand how 
the head injury was sustained, and know the associated diagnosis. The current 
most up to date and accurate assessment of TBI epidemiology comes from the 
US and is derived from survey data, most commonly the National Hospital 
Ambulatory Medical Care Survey – Emergency Department (Figure 1.2). By 
definition this is an estimate. The Emergency Care Data Set gives UK 
researchers the opportunity to know the exact number of patients that attend 
Emergency Departments with a head injury, and the correct diagnoses. Two 




SNOMED-CT (Systematized Nomenclature of Medicine – Clinical Terms) 
coded chief complaints and 14 diagnoses would be required to identify patients 
(Table 5.1). The Emergency Care Data Set also has a detailed section on injury, 
including injury mechanism, whether the injury was sustained as a result of an 
apparent assault, and whether the injury was associated with alcohol or drugs. 
This would be of enormous importance in planning resource allocation from a 
healthcare, social and Policing perspective. Furthermore, outcomes in terms 
of use of health care, such as admission into hospital, surgery, or discharge and 
subsequent primary care access, could be measured. Analysis of this national 
data set would be an extremely cost-effective way of understanding how head 
injuries relate to brain injuries at a country level and would be unparalleled. 
Regionally this would also be invaluable in helping to plan resources required 
for head injury clinics, which in turn would contribute to improved outcomes 
for patients with TBI. 
  




SNOMED-CT code SNOMED-CT term 
Chief complaint  
82271004 Injury of head (disorder) 
417746004 Traumatic injury (disorder) 
  
Diagnosis  
371162008 Closed fracture of skull (disorder) 
371161001 Open fracture of skull (disorder) 
127302008 Minor traumatic brain injury : no LOC 
127299008 Minor traumatic brain injury : LOC less than 30s 
127300000 Minor traumatic brain injury : LOC more than 30s 
40425004 Post-concussion syndrome (more than 1 day post incident) 
262952002 Subdural hematoma 
262949005 Extradural haematoma 
262955000 Traumatic subarachnoid haemorrhage 
450418003 Traumatic intracerebral haemorrhage 
262693007 Diffuse axonal injury 
34663006 Contusion of brain 
314661000 Moderate traumatic brain injury (GCS less than 13) 
314662007 Severe traumatic brain injury (GCS less than 9) 
Table 5.1 SNOMED-CT codes and terms for traumatic brain injury 
SNOMED-CT; Systematized Nomenclature of Medicine -- Clinical Terms; 
LOC, loss of consciousness; GCS, Glasgow Coma Scale.  
 
Treatments for traumatic brain injury 
Treatments for TBI can be broadly classified as pharmaceutical, therapeutic 
(including cognitive behavioural therapy and other psychological therapies), 
information giving and education, generic follow up, and rest or exercise. 
Pharmaceutical interventions target multiple proposed pathophysiological 
pathways implicated in symptoms following mild TBI. Cholinergic agents, 
specifically donepezil, rivastigmine, and galantamine, which are 
acetylcholinesterase inhibitors, are licensed in the UK to treat Alzheimer’s 
Disease. There are some parallels between Alzheimer’s Disease and TBI, 
particularly similarities in deficiencies in cognitive domains and in cellular 
processes. Evidence from several sources suggest that TBI alters cholinergic 




function in the brain, with an initial period of hypercholinergic activity, 
followed by more sustained hypocholinergic activity.495,496 TBI frequently 
causes damage to deep structures, and particularly the hippocampal region, 
which is both high in levels of acetylcholine and responsible for short term 
memory formation.497-499 Patients with TBI can have problems laying down 
new memories, which implicates the hippocampus both as a region critical for 
forming memories and for having high concentrations of acetylcholine.500 
However in the single PubMed listed trial of donepezil in TBI, only ten patients 
were included.501 Eight of ten patients completed treatment and there was no 
improvement in memory, although clinical global improvement ratings did 
increase.  
Cerebrolysin is another compound shown to be of benefit in Alzheimer’s 
Disease, and also in stroke, and is consequently proposed for mild TBI. 
Cerebrolysin is thought to improve neuronal oxygen utilisation, reduce 
cerebral lactic acid concentration, and decrease oxygen free radical 
concentration.502 In a double-blind randomised controlled trial of conscious 
patients with TBI and intracranial haemorrhage, cerebrolysin or placebo was 
administered within 24 hours of injury.502 At 12 weeks, the cerebrolysin group 
had significantly improved overall cognitive ability and specifically drawing 
and long term memory abilities, compared to the placebo group. 
Another proposed mechanism of disease in mild TBI is disruption to 
catecholamine action in the brain.503 As noted above, patients with mild TBI 
commonly have deficits in memory, and specifically in working memory. 
Despite this, patients with mild TBI can score as highly in tests of working 
memory as healthy controls. However, functional MRI demonstrates 




significantly greater cerebral activation in patients with mild TBI being given 
working memory tasks compared with healthy controls.504 This indicates that 
patients with mild TBI have to ‘work harder’ to achieve the same scores as 
control subjects. A potential mechanism for this is disruption to catecholamine 
pathways. This was tested indirectly by trialling bromocriptine, a dopamine 
D2-receptor agonist, and placebo, both in patients with mild TBI and controls, 
i.e. in four groups.504 Prolactin and functional MRI were measured. Dopamine 
inhibits prolactin secretion, therefore a patient with an altered catecholamine 
pathway might be expected not to respond to bromocriptine in the same way 
as that of a healthy control patient. There were significant differences in 
prolactin between bromocriptine and placebo in both mild TBI patients and 
controls, but no difference between mild TBI and controls when grouped by 
bromocriptine and placebo. During tests of working memory, on placebo, 
control patients showed increased cerebral activation compared with patients 
with mild TBI. On bromocriptine, a similar pattern was seen, but in addition, 
patients with mild TBI displayed activation in regions outside of normal 
working memory circuitry, including the bilateral post-central and superior 
temporal gyri. This indicates that patients with mild TBI do have a subtle 
dysregulation of dopaminergic systems in the first four to six weeks after injury 
but that treatment with a dopamine agonist may not improve cognitive 
functioning. An alternate pathway within the catecholamine system is based 
on evidence that experimental alpha-2A antagonism produces spatial working 
memory impairment, whereas alpha-1 and beta receptor antagonism do not. 
Conversely alpha-1A agonism leads to impaired working memory. The same 
authors that conducted the study of bromocriptine also investigated 
guanfacine, an alpha-2A agonist.505 If alpha-2A antagonism leads to deficiency 




in working memory, then alpha-2A agonism should improve it. In this study, 
guanfacine was associated with increased cerebral activation in a region 
specific to working memory in the mild TBI group, indicating that guanfacine 
may be a potential pharmaceutical intervention of value in patients with mild 
TBI and deficiencies in working memory. 
N-acetyl cysteine has been shown to be neuroprotective in animal models of 
stroke and TBI.506,507 The neuroprotective effects of N-acetyl cysteine are 
thought to be mediated through anti-oxidant and anti-inflammatory effects.508 
In a single randomised controlled trial of N-acetyl cysteine versus placebo, 
administered intravenously for a week from day of injury in blast-injured US 
military personnel, patients that received N-acetyl cysteine had higher rates of 
complete resolution of symptoms by day seven, and a better chance of 
symptom resolution.509 
Several studies have reported hyperbaric oxygen therapy for the treatment of 
mild TBI. One theory behind using hyperbaric oxygen therapy for mild TBI is 
that supraphysiological levels of oxygen will reactivate metabolic or 
electrophysiological pathways in functionally retrievable neurons that are 
adjacent to dead or severely damaged neurones.510 Other mechanisms of 
action proposed include stem cell mobilization to sites of injury, immune 
modulation, and impact on fundamental neurotransmitters such as nitric 
oxide.510 However, in a randomised controlled trial there was no difference 
between 30 sessions hyperbaric oxygen and sham compression (placebo) in 
symptoms, cognitive measures or post-traumatic disorder measures in US 
military service members with mild TBI.510 In contrast, in 56 patients with 
symptoms of mild TBI for greater than one year, in a randomised crossover 




trial of 40 sessions of hyperbaric oxygen versus placebo, there was 
improvement in the cognitive function and quality of life in the treatment 
group.511 Improvements in multiple domains of neurocognitive function were 
also seen in a preliminary study of hyperbaric oxygen, with earlier 
administration after injury, younger age, military status, and increased 
number of hyperbaric oxygen administrations being associated with improved 
outcomes.512 However, hyperbaric oxygen therapy is expensive, is contra-
indicated in some patients and represents a significant logistical challenge to 
deliver. As such, implementing a hyperbaric oxygen therapy service for 
patients with mild TBI would have to include a careful selection procedure that 
would take into account which patients are most likely to benefit.  
Other pharmaceutical interventions have been trialled in moderate to severe 
TBI. A monoaminergic stabiliser called OSU6162 has effect on dopamine D2 
and D3 receptors, and 5-HT2A receptors. In patients with moderate to severe 
TBI, there was increased fMRI signs of blood oxygen level dependent signal 
changes (relative to placebo) in the right occipitotemporal cortex, the right 
brain-stem, and the right orbitofrontal cortex, but no difference in clinical 
measures.513 In a different study, succinate was infused via a microdialysis 
catheter directly into brain tissue in sedated patients with severe TBI.514 This 
resulted in a decreased lactate/pyruvate ratio which suggested better redox 
status, indicating better mitochondrial function, and lower glucose, indicating 
improved glucose utilisation. The authors concluded that direct tricarboxylic 
acid cycle supplementation with 2,3-13C2 succinate improved human traumatic 
brain injury brain chemistry. Minocycline, a semi-synthetic tetracycline which 
has been shown to have neuroprotective properties in rats, has been tested for 




safety and feasibility but not efficacy in patients with severe TBI.515 
Amantadine, an antiviral drug also used in Parkinson’s disease, administered 
for six weeks, had no benefit compared with placebo at six months in patients 
with severe TBI. Another promising pathway may be that of mast cells. Mast 
cells have been shown to play a role in blood brain barrier disruption, 
neuroinflammation and neurodegeneration. Multiple mast cell antagonists 
including hydrogen, ketotifen, palmitoylethanolamide, luteolin, masitinib, 
and intravenous immunoglobulin may be of value in attenuating the effect of 
mast cells and providing some neuroprotective function but no clinical trials 
in TBI exist at this point.516 
A final intervention in mild TBI, which although not pharmaceutical is a 
physical intervention, is selective brain cooling. This is achieved by placing a 
cooling helmet and neck piece on the patient, and can apply temperatures 
ranging from -20˚C to 54˚C. In 12 patients with sports related concussion, 
symptoms were reduced compared to controls whilst they were receiving the 
cooling, but recurred immediately after.517 Arterial spin labelling MRI revealed 
reduced cerebral blood flow immediately before cooling but increased cerebral 
blood flow after cooling. The authors postulated that this was a consequence 
of compromised neurovascular coupling in the acute phase of injury possibly 
being temporarily restored by cooling to match cerebral blood flow with surges 
in metabolic demands of the brain. 
Several studies have investigated psychological therapies as an intervention 
for mild TBI. Two studies investigate cognitive behavioural therapy. In one, 
cognitive behavioural therapy was compared with a telephone counselling 
service, initiated from four to six weeks of injury in an ‘at-risk’ population, 




defined as patients with mild TBI and high numbers of early complaints.518 At 
three and 12 months, patients that received telephone counselling reported 
fewer complaints. Furthermore, more patients that received telephone 
counselling had complete resolution of symptoms at a year than those that had 
cognitive behavioural therapy. This suggests that early follow up in at risk 
patients is effective, and that the less resource intensive intervention of 
telephone counselling may be better than cognitive behavioural therapy. 
However, cognitive behavioural therapy was beneficial in adolescents with 
mild TBI and high numbers of symptoms and sleep disruption.519 Patients that 
received cognitive behavioural therapy reported large and clinically significant 
improvements in insomnia ratings immediately after treatment, which were 
maintained at four weeks. They also reported improved sleep quality and fewer 
dysfunctional beliefs. Cognitive therapy was also beneficial in patients with 
chronic post-concussive symptoms after mild TBI compared with usual 
care.520 Those receiving cognitive therapy reported fewer cognitive and 
memory difficulties, greater use of cognitive strategies, and improved 
attention, learning and executive function. In addition to cognitive therapy, 
other reported interventions include multidisciplinary assessment and 
therapy, which resulted in no difference in symptoms or psychosocial 
functioning; a telephone delivered problem solving treatment which did result 
in reduced psychological distress but no difference in symptoms; and 
individual and group-based neuropsychological treatment with exercise 
therapy and physiotherapeutic coaching which resulted in reductions in 
symptoms and mental fatigue, and improved social functioning.521-523 




Conventionally, the advice given to patients with mild TBI was to ‘rest’. This 
could mean a break from physical activity, or cognitive rest. However, recent 
studies have shown consistently that rest, in the form of bedrest or sick leave 
(i.e. cognitive rest) does not result in improved short term or medium term 
symptoms or cognition, and may result in poorer outcomes.374,524-526 
Conversely, exercise in the form of sub-symptom threshold aerobic training or 
simple exercise therapy results in reduced symptoms and a shorter time to 
become symptom free.523,527,528 
Giving information regarding the nature of mild TBI or concussion, and what 
to expect over the coming days and weeks, reduces anxiety and stress in adult 
and parent-child populations.529,530 Furthermore, a single education session 
may not be inferior to a more resource-intensive and extensive assessment, 
education, and treatment-as-needed.531 A mobile phone app symptom diary 
with a video game theme for children with mild TBI resulted in improved post-
concussion symptoms and optimism compared with a control group.532 Follow 
up has inconsistent outcomes, with two studies finding no difference in 
symptoms or limitations in activity, and one study reporting longer time to 
return to work in a multi-disciplinary out-patient follow up compared with 
general practitioner follow up.533-535 However, a recently proposed structured 
approach to a clinic based assessment of patients with mild TBI, which 
includes a history, clinical exam, symptom inventory, neurocognitive tests, 
vestibular and oculomotor assessment, exertion assessment and psychological 
assessment, has yet to be tested.536   





In conclusion, mild traumatic brain injury represents a significant disease 
burden to individual patients and to the population. Many patients with mild 
traumatic brain injury experience both persistent deficiencies in cognition and 
persistent symptoms, which impact on their ability to perform usual activities 
including maintaining employment. Lack of standardisation of outcome 
measurement and variation in reporting in mild traumatic brain injury 
research may give rise to results that are difficult to generalise and so reduce 
the impact of any potential intervention. Few patients with traumatic brain 
injury attend the Emergency Department with a seizure. Being able to predict 
outcomes following TBI is important for information and health care planning, 
but the biomarkers S100B and copeptin add no extra value to current 
prediction tools in identifying who will go on to have a further seizure. Since 
traumatic brain injury is extremely common and as much as 90% of all 
traumatic brain injury is mild, the consequences of any minor improvement in 
outcomes for this disease would translate into sizeable societal health gains. 
Several pharmaceutical and psychological therapeutic interventions show 
promise in improving outcomes after mild TBI, but studies are small and 
rarely repeated. Large randomised controlled trials of pharmaceutical and 
cognitive therapies in patients with mild TBI should be performed.  
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Chapter 6 Appendices 
Appendix 1 
Definitions of mild traumatic brain injury 
American Congress of Rehabilitation Medicine (1993)6 
A traumatically induced disruption of brain function manifesting with at least 
one of the following criteria: 
1. Any loss of consciousness 
2. Any loss of memory of the event immediately before or after the 
accident; 
3. Any alteration in mental state at the time of the accident (e.g., feeling 
dazed, disoriented, or confused); 
4. Focal neurological deficit that may or may not be transient. 
But where the severity of the injury does not exceed the following 
• Loss of consciousness of 30 minutes or less; 
• After 30 minutes an initial GCS of 13-15; 
• Post-traumatic amnesia not greater than 24 hours 
  




European Federation of Neurological Societies (2002)7 
The EFNS definition subclassifies mild TBI into four categories, based on 
which decisions on admission and investigation can be made. All mild TBI in 
the EFNS definition have traumatic head injury or rapid acceleration, 
deceleration or shear force to the head, with GCS 13 to 15. They are categorised 
as follows: 
1. Category 0 
• GCS 15, no loss of consciousness, no post-traumatic amnesia, no 
risk factors 
• Can be considered a head injury with no TBI 
• Can be discharged home 
2. Category 1 
• GCS 15, loss of consciousness < 30 minutes, post-traumatic 
amnesia < 1 hour, no risk factors 
• CT recommended 
3. Category 2 
• GCS 15, and risk factors present 
• CT mandatory 
4. Category 3 
• GCS 13–14, loss of consciousness < 30 minutes, post-traumatic 
amnesia < 1 hour, no risk factors, with or without risk factors 
present 
Risk factors are defined as: unclear or ambiguous accident history, continued 
post-traumatic amnesia, retrograde amnesia longer than 30 min, trauma 
above the clavicles including clinical signs of skull fracture (skull base or 
depressed skull fracture), severe headache, vomiting, focal neurological 
deficit, seizure, age < 2 years, age > 60, coagulation disorders, high-energy 
accident, intoxication with alcohol/drugs. 
  




Centers for Disease Control and Prevention (2003)8 
An injury to the head as a result of blunt trauma or acceleration or deceleration 
forces that result in one or more of the following conditions: 
• Any period of observed or self-reported: 
o Transient confusion, disorientation, or impaired consciousness 
o Dysfunction of memory around the time of injury 
o Loss of consciousness lasting less than 30 minutes. 
• Observed signs of neurological or neuropsychological dysfunction, such 
as: 
o Seizures acutely following injury to the head 
o Among infants and very young children: irritability, lethargy, or 
vomiting following head injury 
o Symptoms among older children and adults such as headache, 
dizziness, irritability, fatigue or poor concentration, when 
identified soon after injury, can be used to support the diagnosis 
of mild TBI, but cannot be used to make the diagnosis in the 
absence of loss of consciousness or altered consciousness. 
Research may provide additional guidance in this area. 
  




World Health Organisation collaborating task force (2004)9,537 
Mild TBI is an acute brain injury resulting from mechanical energy to the head 
from external physical forces. Operational criteria for clinical identification 
include: 
1. One or more of the following: 
a. confusion or disorientation 
b. loss of consciousness for 30 minutes or less 
c. post-traumatic amnesia for less than 24 hours 
d. and/or other transient neurological abnormalities such as focal 
signs, seizure, and intracranial lesion not requiring surgery; and 
2. Glasgow Coma Scale score of 13 to 15 after 30 minutes post-injury or 
later upon presentation for healthcare. 
These manifestations of mild TBI must not be due to drugs, alcohol, 
medications, caused by other injuries or treatment for other injuries (e.g. 
systemic injuries, facial injuries or intubation), caused by other problems (e.g. 
psychological trauma, language barrier or coexisting medical conditions) or 
caused by penetrating craniocerebral injury 





Neurocognitive and symptom assessment tools 
Standardized Assessment of Concussion 
Orientation 
What month is it?      0/1 
What’s the date today?     0/1 
What’s the day of the week?     0/1 
What year is it?      0/1 
What time is it right now (within 1 hour)?   0/1 
Orientation test score:       /5 
 
Immediate memory 
I am going to test your memory. I will read you a list of words and when I am done, 
repeat back as many words as you can remember, in any order. 
List Trial 1 Trial 2 Trial 3 
Elbow 0/1 0/1 0/1 
Apple 0/1 0/1 0/1 
Carpet 0/1 0/1 0/1 
Saddle 0/1 0/1 0/1 
Bubble 0/1 0/1 0/1 
Total   /5   /5   /5 
Trials 2 and 3: I am going to repeat that list again. Repeat back as many words as you 
can remember in any order, even if you said the word before.  
Complete all trials regardless of score on trials 1 and 2. 1 point for each correct response. Total score 
equals sum across all 3 trials.  
Immediate memory test score:      /15 
 
Concentration 
Digits backwards: I am going to read you a string of numbers and when I am done, 
you repeat them back to me backwards, in reverse order of how I said them to you. 
For example, if I say 7-1-9 you would say 9-1-7. 
If correct go to next string length. If incorrect, read trial 2. 1 point possible for each string length. Stop 
after incorrect on both trials. 
4-9-3  6-2-9      0/1 
3-8-1-4 3-2-7-9     0/1 
6-2-9-7-1 1-5-2-8-6     0/1 
7-1-8-4-6-2 5-3-9-1-4-8     0/1 
Months in reverse order: Now tell me the months of the year in reverse order. Start 
with the last month and go backwards. So, you’ll say December, November…go 
ahead. 
1 point for entire sequence correct. 
Dec-Nov-Oct-Sept-Aug-Jul-Jun-May-Apr-Mar-Feb-Jan 0/1 
Concentration total score       /5 
 





Do you remember that list of words I read a few times earlier? Tell me as many words 
from the list as you can remember in any order. 
Circle each word correctly recalled. Total score equals number of words recalled. 
Elbow  Apple  Carpet  Saddle  Bubble 
Delayed recall total score:      /5 
 
SAC scoring summary 
Orientation        /5 
Immediate memory       /15 
Concentration        /5 
Delayed recall        /5 
SAC total score       /30 
 
Concussion Symptom Inventory 
The following symptoms graded 0-6 (0 = absent, 1 = mild, 6 = severe) 
1. Headache 
2. Nausea 
3. Balance problems/Dizziness 
4. Fatigue 
5. Drowsiness 
6. Feeling like “in a fog” 
7. Difficulty concentrating 
8. Difficulty remembering 
9. Sensitivity to light 
10. Sensitivity to noise 
11. Blurred vision 
12. Feeling slowed down  





International classification of disease codes used for identifying head or 
brain injured patients in epidemiological studies 
ICD-9 codes: 
800-80 Fracture of Skull 
800 Fracture of vault of skull 
801 Fracture of base of skull 
802 Fracture of face bones 
803 Other and unqualified skull fractures 
804 Multiple fractures involving skull or face with other bones 
850-854 Intracranial Injury, Excluding Those With Skull Fracture 
850 Concussion 
851 Cerebral laceration and contusion 
852 Subarachnoid subdural and extradural hemorrhage following injury 
853 Other and unspecified intracranial hemorrhage following injury 
854 Intracranial injury of other and unspecified nature 
  
ICD-10-CM heading codes 
S00 Superficial injury of head 
S01 Open wound of head 
S02 Fracture of skull and facial bones 
S03 Dislocation, sprain and strain of joints and ligaments of head 
S04 Injury of cranial nerves 
S05 Injury of eye and orbit 
S06 Intracranial injury 
S06.1 Traumatic cerebral oedema 
S06.2 Diffuse brain injury 
S06.3 Focal brain injury 
S06.4 Epidural haemorrhage 
S06.5 Traumatic subdural haemorrhage 
S06.6 Traumatic subarachnoid haemorrhage 
S06.7 Intracranial injury with prolonged coma 
S06.8 Other intracranial injuries 
S06.9 Intracranial injury, unspecified 
S07 Crushing injury of head 
S08 Traumatic amputation of part of head 
S09 Other and unspecified injuries of head 
T00 Superficial injuries involving multiple body regions 
T01 Open wounds involving multiple body regions 
T02 Fractures involving multiple body regions 
T03 Dislocations, sprains and strains involving multiple body regions 
T04 Crushing injuries involving multiple body regions 
T05 Traumatic amputations involving multiple body regions 
T06 Other injuries involving multiple body regions, not elsewhere classified 
T07 Unspecified multiple injuries 
T90 Sequelae of injuries of head 
  
National Health Service Centre for Clinical Coding and Classification, based on ICD-10 




18 minor HI 
19 moderate to severe HI 
 
Table 6.1 Diagnostic codes used in epidemiological studies of head 
or brain injury 
 





PRISMA 2009 Checklist 
   Page 
Title   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  122 
    
Abstract   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
N/A 
    
Introduction   
Rationale  3 Describe the rationale for the review in the context of what is already known.  122 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
123 
    
Methods   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
124 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
124 




Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched.  
125 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
126, 313 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 
if applicable, included in the meta-analysis).  
126 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
127 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
127 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
127 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  131 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
131 
 
Table 6.2 PRISMA 2009 Checklist 
 





Search strategy for systematic review and meta-analysis of return to work 
after mild traumatic brain injury 
Search date – 09/10/2017 
# Database Search 
Platform 
Search term 
1 Medline  HDAS (tbi).ti,ab  
2 Medline  HDAS (mtbi).ti,ab  
3 Medline  HDAS (mild tbi).ti,ab  
4 Medline  HDAS ("mild tbi").ti,ab  
5 Medline  HDAS (minor tbi).ti,ab  
6 Medline  HDAS ("minor tbi").ti,ab  
7 Medline  HDAS (mild traumatic brain injury).ti,ab  
8 Medline  HDAS ("mild traumatic brain injury").ti,ab  
9 Medline  HDAS (minor traumatic brain injury).ti,ab  
10 Medline  HDAS ("minor traumatic brain injury").ti,ab  
11 Medline  HDAS (mild head injury).ti,ab  
12 Medline  HDAS ("mild head injury").ti,ab  
13 Medline  HDAS (minor head injury).ti,ab  
14 Medline  HDAS ("minor head injury").ti,ab  
15 Medline  HDAS (mild head trauma).ti,ab  
16 Medline  HDAS ("mild head trauma").ti,ab  
17 Medline  HDAS (minor head trauma).ti,ab  
18 Medline  HDAS ("minor head trauma").ti,ab  
19 Medline  HDAS (minor brain trauma).ti,ab  
20 Medline  HDAS ("minor brain trauma").ti,ab  
21 Medline  HDAS (concussion).ti,ab  
22 Medline  HDAS (concus*).ti,ab  
23 Medline  HDAS exp "BRAIN CONCUSSION"/  
24 Medline  HDAS exp "BRAIN INJURIES"/ OR exp "CRANIOCEREBRAL 
TRAUMA"/  
25 Medline  HDAS (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 
11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 
OR 20 OR 21 OR 22)  
26 Medline  HDAS (23 OR 24)  




27 Medline  HDAS exp "RETURN TO WORK"/  
28 Medline  HDAS ("return to work").ti,ab  
29 Medline  HDAS (27 OR 28)  
30 Medline  HDAS (25 AND 28)  
31 Medline  HDAS (26 AND 27)  
32 Medline  HDAS (30 OR 31)  
33 EMBASE HDAS (tbi).ti,ab 
34 EMBASE HDAS (mtbi).ti,ab 
35 EMBASE HDAS (mild tbi).ti,ab 
36 EMBASE HDAS ("mild tbi").ti,ab 
37 EMBASE HDAS (minor tbi).ti,ab 
38 EMBASE HDAS ("minor tbi").ti,ab 
39 EMBASE HDAS (mild traumatic brain injury).ti,ab 
40 EMBASE HDAS ("mild traumatic brain injury").ti,ab 
41 EMBASE HDAS (minor traumatic brain injury).ti,ab 
42 EMBASE HDAS ("minor traumatic brain injury").ti,ab 
43 EMBASE HDAS (mild head injury).ti,ab 
44 EMBASE HDAS ("mild head injury").ti,ab 
45 EMBASE HDAS (minor head injury).ti,ab 
46 EMBASE HDAS ("minor head injury").ti,ab 
47 EMBASE HDAS (mild head trauma).ti,ab 
48 EMBASE HDAS ("mild head trauma").ti,ab 
49 EMBASE HDAS (minor head trauma).ti,ab 
50 EMBASE HDAS ("minor head trauma").ti,ab 
51 EMBASE HDAS (minor brain trauma).ti,ab 
52 EMBASE HDAS ("minor brain trauma").ti,ab 
53 EMBASE HDAS (concussion).ti,ab 
54 EMBASE HDAS (concus*).ti,ab 
64 EMBASE HDAS (33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 
OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 
50 OR 51 OR 52 OR 53 OR 54) 
55 EMBASE HDAS exp "BRAIN INJURY"/ OR exp "BRAIN CONCUSSION"/ 
56 EMBASE HDAS exp "TRAUMATIC BRAIN INJURY"/ 
57 EMBASE HDAS exp "POSTCONCUSSION SYNDROME"/ 
58 EMBASE HDAS (55 OR 56 OR 57) 
59 EMBASE HDAS exp "RETURN TO WORK"/ 




60 EMBASE HDAS exp "WORK RESUMPTION"/ 
61 EMBASE HDAS ("return to work").ti,ab 
62 EMBASE HDAS (59 OR 60) 
63 EMBASE HDAS (58 AND 62) 
65 EMBASE HDAS (61 AND 64) 
66 PsycINFO HDAS (tbi).ti,ab 
67 PsycINFO HDAS (mtbi).ti,ab 
68 PsycINFO HDAS (mild tbi).ti,ab 
69 PsycINFO HDAS ("mild tbi").ti,ab 
70 PsycINFO HDAS (minor tbi).ti,ab 
71 PsycINFO HDAS ("minor tbi").ti,ab 
72 PsycINFO HDAS (mild traumatic brain injury).ti,ab 
73 PsycINFO HDAS ("mild traumatic brain injury").ti,ab 
74 PsycINFO HDAS (minor traumatic brain injury).ti,ab 
75 PsycINFO HDAS ("minor traumatic brain injury").ti,ab 
76 PsycINFO HDAS (mild head injury).ti,ab 
77 PsycINFO HDAS ("mild head injury").ti,ab 
78 PsycINFO HDAS (minor head injury).ti,ab 
79 PsycINFO HDAS ("minor head injury").ti,ab 
80 PsycINFO HDAS (mild head trauma).ti,ab 
81 PsycINFO HDAS ("mild head trauma").ti,ab 
82 PsycINFO HDAS (minor head trauma).ti,ab 
83 PsycINFO HDAS ("minor head trauma").ti,ab 
84 PsycINFO HDAS (minor brain trauma).ti,ab 
85 PsycINFO HDAS ("minor brain trauma").ti,ab 
86 PsycINFO HDAS (concussion).ti,ab 
87 PsycINFO HDAS (concus*).ti,ab 
91 PsycINFO HDAS (66 OR 67 OR 68 OR 69 OR 70 OR 71 OR 72 OR 73 OR 74 
OR 75 OR 76 OR 77 OR 78 OR 79 OR 80 OR 81 OR 82 OR 
83 OR 84 OR 85 OR 86 OR 87) 
88 PsycINFO HDAS exp "BRAIN CONCUSSION"/ OR exp "TRAUMATIC BRAIN 
INJURY"/ OR exp "HEAD INJURIES"/ 
89 PsycINFO HDAS exp REEMPLOYMENT/ 
90 PsycINFO HDAS ("return to work").ti,ab 
92 PsycINFO HDAS (88 AND 89) 
93 PsycINFO HDAS (91 AND 90) 




94 PubMed HDAS (tbi).ti,ab 
95 PubMed HDAS (mtbi).ti,ab 
96 PubMed HDAS (mild tbi).ti,ab 
97 PubMed HDAS ("mild tbi").ti,ab 
98 PubMed HDAS (minor tbi).ti,ab 
99 PubMed HDAS ("minor tbi").ti,ab 
100 PubMed HDAS (mild traumatic brain injury).ti,ab 
101 PubMed HDAS ("mild traumatic brain injury").ti,ab 
102 PubMed HDAS (minor traumatic brain injury).ti,ab 
103 PubMed HDAS ("minor traumatic brain injury").ti,ab 
104 PubMed HDAS (mild head injury).ti,ab 
105 PubMed HDAS ("mild head injury").ti,ab 
106 PubMed HDAS (minor head injury).ti,ab 
107 PubMed HDAS ("minor head injury").ti,ab 
108 PubMed HDAS (mild head trauma).ti,ab 
109 PubMed HDAS ("mild head trauma").ti,ab 
110 PubMed HDAS (minor head trauma).ti,ab 
111 PubMed HDAS ("minor head trauma").ti,ab 
112 PubMed HDAS (minor brain trauma).ti,ab 
113 PubMed HDAS ("minor brain trauma").ti,ab 
114 PubMed HDAS (concussion).ti,ab 
115 PubMed HDAS (concus*).ti,ab 
116 PubMed HDAS ("return to work").ti,ab 
117 PubMed HDAS (94 OR 95 OR 96 OR 97 OR 98 OR 99 OR 100 OR 101 OR 
102 OR 103 OR 104 OR 105 OR 106 OR 107 OR 108 OR 
109 OR 110 OR 111 OR 112 OR 113 OR 114 OR 115) 
118 PubMed HDAS (116 AND 117) 
1 PubMed PubMed concussion[MeSH Terms] 
2 PubMed PubMed mild traumatic brain injury[MeSH Terms] 
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#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 
or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 






































































#27 and #31 






1 Trip database ((("mild traumatic brain injury") OR (concussion)) AND 
("return to work")) 
1 Clinicaltrials.gov Mild traumatic brain injury  
2 Clinicaltrials.gov Return to work 
1 European Clinical Trials 
Registry (EU-CTR) 
Mild traumatic brain injury 
2 European Clinical Trials 
Registry (EU-CTR) 
Concussion 
3 European Clinical Trials 
Registry (EU-CTR) 
Return to work 
1 ISRCTN Condition: mild traumatic brain injury 
2 ISRCTN Condition: concussion 
1 Australia and New 
Zealand Clinical Trials 
Registry (ANZCTR) 
Mild traumatic brain injury 
2 Australia and New 
Zealand Clinical Trials 
Registry (ANZCTR) 
Concussion 
1 Clinical Trials Registry 
of India (CTRI) 
Mild traumatic brain injury 
2 Clinical Trials Registry 
of India (CTRI) 
Concussion 
1 China Clinical Trials 
Registry (ChiCTR) 
Mild traumatic brain injury 
2 China Clinical Trials 
Registry (ChiCTR) 
Concussion 
1 Brazilian Clinical Trials 
Registry (ReBec) 
Mild traumatic brain injury 
2 Brazilian Clinical Trials 
Registry (ReBec) 
Concussion 
1 Pan-African Clinical 
Trials Registry (PACTR) 
Mild traumatic brain injury 
2 Pan-African Clinical 
Trials Registry (PACTR) 
Concussion 
 
Table 6.3 Search strategy for systematic review and meta-analysis 
of return to work after mild traumatic brain injury 
  





Data abstraction dictionary for systematic review and meta-analysis of return to 
work following mild traumatic brain injury 
Name of data point Description of data point Data points 
UI Unique identifier for this 
review 
numerical 
Au_F First Author text 
Journal Journal text 
Year Year numerical 
St_tr Study or trial 1=study, 2=trial 
Pr_Rt Prospective or 
retrospective 
1=prospective, 2=retrospective 
RTW_ave/prop RTW is reported as 
average or as proportion 
at pre-defined time point 
1=average, 2=proportion 
No_pt Number of patients in 
study 
numerical 
No_F/U Number of patients 
followed up 
numerical 
Prop_F/U Percentage followed up 
out of included 
numerical 
No_gp_1 Number of patients in 
group 1 (if applicable) 
numerical 
No_gp_2 Number of patients in 
group 2 (if applicable) 
numerical 
No_gp_3 Number of patients in 
group 3 (if applicable) 
numerical 
No_gp_4 Number of patients in 
group 4 (if applicable) 
numerical 
Nm_gp_1 Name of group 1 text 
Nm_gp_2 Name of group 2 text 
Nm_gp_3 Name of group 3 text 
Nm_gp_4 Name of group 4 text 
Setting Setting text 
Mean_age Mean age numerical 
Age_SD Standard deviation of age numerical 
Med_age Median age if reported numerical 
Age_IQR Interquartile range of age numerical 
Age_youngest Youngest included numerical 
Age_oldest Oldest included numerical 
Sex_male Sex – proportion male numerical 
Ed_secondary Proportion up to 
secondary 
numerical 
Ed_years Mean years education numerical 
Def_mTBI Definition of mild TBI 1=American Academy of 
Neurology; 2=World Health 
Organisation Collaborating Task 




Force on MTBI; 3=Center for 
Disease Control and Prevention; 
4=American Congress of 
Rehabilitation Medicine; 
5=European Federation of 
Neurological Societies; 6=clinical 
diagnosis 
PTA_pr Proportion post traumatic 
amnesia 
numerical 
PTA_dur Duration post traumatic 
amnesia (hours usually) 
numerical 
LOC_pr Loss of consciousness 
proportion 
numerical 
Inj_sev_pr Injury Severity (blood on 
CT) proportion 
numerical 
RTW_duties Narrative description of 
level of duties patients 
RTW to work at, if 
reported 
text 
RTW_mean_time Mean time to RTW (if 
reported) 
numerical 
RTW_median_time Median time to RTW (if 
reported) 
numerical 
Pre_d_t_1 Pre-defined time point 1 text 
Pre_d_t_2 Pre-defined time point 2 text 
Pre_d_t_3 Pre-defined time point 3 text 
Pre_d_t_4 Pre-defined time point 4 text 
Prop_RTW_t_1 Proportion of cohort that 
RTW at time point 1 
numerical 
Prop_RTW_t_2 Proportion of cohort that 
RTW at time point 2 
numerical 
Prop_RTW_t_3 Proportion of cohort that 
RTW at time point 3 
numerical 
Prop_RTW_t_4 Proportion of cohort that 
RTW at time point 4 
numerical 
Pred_v Predictor/independent 
variable(s) if study, 
intervention if trial 
text 
Outcome_v Outcome/dependent 
variable(s) if study, 
control if trial 
text 
Effect_est Effect estimates (RR/OR) 1=RR, 2=OR 
Selection_MH_drugs_TB
I 
Excluded patients if MH, 
drugs/alcohol, prev TBI 
1=Y, 2=N 
Selection_rep Representativeness of the 
exposed cohort 
1=truly representative of the 
average mild TBI* ; 2=somewhat 
representative of the average 
mild TBI*; 3=selected group of 
users e.g. nurses, volunteers; 
4=no description of the 
derivation of the cohort 




Selection_sel Selection of the non-
exposed cohort 
1=drawn from the same 
community as the exposed 
cohort*; 2=drawn from a 
different source; 3=no 
description of the derivation of 
the non-exposed cohort 
Selection_asc Ascertainment of 
exposure 
1=secure record (e.g. surgical 
records)*; 2=structured 
interview*; 3=written self-
report; 4=no description 
Selection_dem Demonstration that 
outcome of interest was 
not present at start of 
study 
1=yes*; 2=no 
Comparability_com Comparability of cohorts 
based on the design or 
analysis 
1=study controls for mild TBI*, 
2=study controls for any 
additional factor* (this criterion 
could be modified to indicate 
specific control for a second 
important factor) 
Outcome_ass Assessment of outcome 1=independent blind 
assessment*; 2=record linkage*; 
3=self-report; 4=no description 
Outcome_f/u_t Was follow-up long 
enough for outcomes to 
occur 
1=yes*; 2=no 
Outcome_f/u_adeq Adequacy of follow up of 
cohorts 
1=complete follow up - all 
subjects accounted for*; 
2=subjects lost to follow up 
unlikely to introduce bias - lost 
<20% follow up, or description 
provided of those lost)*; 
3=follow up rate <50% and no 
description of those lost; 4=no 
statement 
Pop_empl_pre-mTBI Was the sample 
population employed 
prior to the injury? 
1=all workers, 2=employed 
including 
student/homemaker/other 








Table 6.4 Data abstraction dictionary for systematic review and 
meta-analysis of return to work following mild traumatic brain 
injury 
  





Post hoc power calculation data 
 
Variable Obs. W’ V’ z p 
Baseline NC function 178 0.91774 12.129 5.121 0.00001 
Follow up NC function 101 0.96211 3.476 2.464 0.00687 
Baseline #Sx 178 0.96909 4.557 3.112 0.00093 
Follow up #Sx 101 0.96782 2.953 2.141 0.01612 
Table 6.5 Normality of neurocognitive and total number of 
symptoms data 
Tested using the Shapiro-Francia test for normality in which the null hypothesis is that the 
data is normally distributed. NC, neurocognitive; #Sx, number of symptoms, Obs, number of 
observations; W’, Shapiro-Francia test result, V’, index of departure from normality in which 
a median value of V’ is 1 for samples from normal populations; z, z-statistic, estimate divided 
by its standard error. 
 
Variable Obs. p (skewness) p (kurtosis) Chi2 p (Chi2) 
Baseline NC function 178 0.0000 0.0001 37.28 0.0000 
Follow up NC function 101 0.0015 0.1892 10.14 0.0063 
Baseline #Sx 178 0.0178 0.0000 19.35 0.0001 
Follow up #Sx 101 0.0114 0.0489 8.99 0.0112 
Table 6.6 Skewness/kurtosis tests for normality of neurocognitive 
and total number of symptoms data 
Significant p values indicate the source of non-normality. The Chi2 and associated p values is 
also a test of normality, testing the null hypothesis that the data is normally distributed, but is 
less favoured than the Shapiro-Francia test. 
 
Variable Obs. W’ V’ z p 
Change in NC function 99 0.96843 2.849 2.068 0.01931 
Change in #Sx 98 0.97531 2.209 1.565 0.05883 
Table 6.7 Normality of change in neurocognitive and total number 
of symptoms data 
Tested using the Shapiro-Francia test for normality in which the null hypothesis is that the 
data is normally distributed. NC, neurocognitive; #Sx, number of symptoms, Obs, number of 
observations; W’, Shapiro-Francia test result, V’, index of departure from normality in which 
a median value of V’ is 1 for samples from normal populations; z, z-statistic, estimate divided 
by its standard error. 
 
Variable Obs. p (skewness) p (kurtosis) Chi2 p (Chi2) 
Change in NC function 99 0.1510 0.0644 5.35 0.0689 
Change in #Sx 98 0.8094 0.0303 4.77 0.0922 
Table 6.8 Skewness/kurtosis tests for normality of change in 
neurocognitive and total number of symptoms data 
Significant p values indicate the source of non-normality. The Chi2 and associated p values is 
also a test of normality, testing the null hypothesis that the data is normally distributed, but is 
less favoured than the Shapiro-Francia test.  





Baseline data in UK and French groups 
Variable UK France Overall 
Total 97 (22%) 346 (78%) 443 
    
Eligibility    
Seizure prior to arrival in ED 91 (83%) 327 (84%) 418 (94%) 
Seizure in ED 19 (17%) 61 (16%) 79 (18%) 
Male Sex 59 (61%) 188 (54%) 247 (56%) 
Age 40.5 (14.9) 45.9 (19.2) 44.7 (18.5) 
Previous seizures 66 (68%) 200 (58%) 266 (60%) 
    
Previous diagnoses    
Epilepsy 39 (40%) 201 (58%) 240 (54%) 
Alcohol abuse 25 (26%) 39 (11%) 64 (14%) 
Stroke 12 (12%) 26 (8%) 38 (9%) 
Other neurological path. 7 (7%) 16 (5%) 23 (5%) 
Substance misuse 6 (6%) 11 (3%) 17 (4%) 
Meningitis 4 (4%) 10 (3%) 14 (3%) 
    
Regular prescriptions    
Anti-epileptic drugs 31 (32%) 167 (48%) 198 (45%) 
Benzodiazepines 5 (5%) 64 (18%) 69 (16%) 
    
Symptoms in ED    
Headache 28 (29%) 86 (25%) 114 (26%) 
Confusion 16 (16%) 29 (8%) 45 (10%) 
Photophobia 6 (6%) 10 (3%) 16 (4%) 
Meningism 6 (6%) 1 (0%) 7 (2%) 
Focal neurological deficit 5 (5%) 9 (3%) 14 (3%) 
    
Seizure characteristics    
Generalized Tonic-clonic 82 (85%) 252 (73%) 334 (75%) 
Complex Partial 9 (9%) 36 (10%) 45 (10%) 
Absence 3 (3%) 31 (9%) 34 (8%) 
Other seizure 2 (2%) 29 (8%) 31 (7%) 
Simple Partial 1 (1%) 28 (8%) 29 (7%) 
Provoked/ Acute sympt. 31 (32%) 125 (36%) 156 (35%) 
Witnessed 73 (75%) 242 (70%) 315 (71%) 
    
Therapy in ED    
Benzodiazepine 8 (8%) 241 (70%) 249 (56%) 
Antiepileptic drug 3 (3%) 123 (36%) 126 (28%) 
    
Physiological    
Heart rate (beats per minute) 92 (20) 89 (18) 90 (19) 
Systolic blood pressure (mmHg) 129 (23) 130 (20) 129 (21) 
Diastolic blood pressure (mmHg) 76 (15) 78 (14) 78 (15) 




Temperature (°C) 36.5 (0.7) 36.7 (0.5) 36.7 (0.6) 
Peripheral saturation oxygen 97 (2) 97.2 (2.3) 97 (2) 
GCS 13-15 85 (87.6%) 329 (95.1%) 414 (93.2%) 
GCS 9-12 5 (5.2%) 6 (1.7%) 11 (2.5%) 
GCS 3-8 3 (3.1%) 3 (0.9%) 6 (1.4%) 
    
Laboratory    
White blood cell count (x103) 8.7 
(6.5 to 12.3) 
10.3 
(7.3 to 14.5) 
9.7 
(12 to 6.7) 
Glucose (mmol/L) 6.6 (5.2 to 8) 6.2 (5.2 to 7.1) 6 (8.1 to 5.2) 
Sodium (mEq/L) 140 
(138 to 142) 
138 
(136 to 140) 
139 
(138 to 137) 
Calcium (mmol/L) 1.2 (1.2 to 1.3) 2.4 (2.3 to 2.5) 2.3 (2.2 to 1.3) 
Lactate (mmol/L) 2.5 (1.6 to 4.7) 1.6 (1.1 to 2.7) 1.8 (3.3 to 1.2) 
S100B (µg/L) 0.08 
(0.06 to 0.19) 
0.08 
(0.06 to 0.16) 
0.09 
(0.17 to 0.07) 
Copeptin (pmol/L) 27.3 
(9.1 to 60.3) 
26.1 
(9.5 to 70.8) 
19.8 
(54.6 to 8.7) 
Table 6.9 Baseline date in UK and French groups 
